

Lawrence S.C. Czer, M.D., FAHA, FACC, FACP, FCCP

**Cedars-Sinai Heart Institute
127 S. San Vicente Blvd
Los Angeles, CA 90048
(310) 423-3851**

EDUCATION

- 1969 - 73 Bachelor of Science (Physics), University of California, Los Angeles.
(GPA, 3.96/4.00)
- 1973 - 77 Doctor of Medicine, University of California, Los Angeles,
School of Medicine. (GPA, 3.6/4.0)
- 1977 - 80 Internship and Residency in Medicine, UCLA - San Fernando Valley
Medical Program, Sepulveda Veterans Administration and Olive View
County Hospitals, Sepulveda, CA
- 1980 - 82 Fellowship in Cardiology, Cedars-Sinai Medical Center, Los Angeles, CA
(Director, H.J.C. Swan, M.D., Ph.D.)
- 1982 - 83 Research fellowship in Surgical Cardiology, Cedars-Sinai Medical Center,
Los Angeles, CA (Jack Matloff, M.D., Richard J. Gray, M.D., and H.J.C.
Swan, M.D., Ph.D.)

BOARD CERTIFICATION

- 1978 National Board of Medical Examiners (183773)
(Part I: 710; 98.5 percentile. Part II: 655; 94th percentile)
- 1980 American Board of Internal Medicine (075973; September 9, 1980)
- 1983 Subspecialty Board of Cardiovascular Diseases (075973; November 9, 1983)
- 1987 Certificate of Special Competency in Cardiac Pacing (000264; North American
Society for Pacing and Electrophysiology)
- 2010 Advanced Heart Failure and Transplant Cardiology (075973; November 8, 2010)

PROFESSIONAL EXPERIENCE

- 2015 – present Professor (in Residence), Department of Medicine, UCLA School of
Medicine (effective July 1, 2015; step VI).

- 2012 - 2015 Professor (in Residence), Department of Medicine, UCLA School of Medicine (effective July 1, 2012; Step V).
- 2009 - present Professor of Medicine, Cedars-Sinai Medical Center, Cedars-Sinai Heart Institute, Professorial Series (effective July 1, 2009).
- 2009 - 2012 Professor (in Residence), Department of Medicine, UCLA School of Medicine (effective July 1, 2009; Step IV).
- 2008 – present Associate Medical Director, Mechanical Circulatory Support Program
- 2006 - 2009 Professor (in Residence), Department of Medicine, UCLA School of Medicine (effective July 1, 2006; Step III).
- 2002 - 2010 Director, Surgical Cardiology and Transplant Cardiology, Cedars-Sinai Medical Center.
- 1990 - present Medical Director of Heart Transplantation Program, Cedars-Sinai Medical Center.
- 2000 - 2006 Professor (in Residence), Department of Medicine, UCLA School of Medicine (effective July 1, 2000; Step II).
- 1999 - 2006 Medical Director, 6-ICU, Cedars-Sinai Medical Center.
- 1997 - 2000 Professor (in Residence), Department of Medicine, UCLA School of Medicine (effective July 1, 1997; Step I).
- 1991 - 1997 Associate Professor (in Residence), Department of Medicine, UCLA School of Medicine (effective July 1, 1991; Step I).
- 1988 - 1990 Acting Medical Director of Heart Transplantation Program, Cedars-Sinai Medical Center.
- 1985 - 1991 Assistant Professor (in Residence), Department of Medicine, UCLA School of Medicine (Appointed December 1, 1985, Step 2)
- 1983 - present Attending Physician, Cardiac Surgery Intensive Care Unit, Cedars-Sinai Medical Center, Los Angeles, CA. Clinical rounds with medical students, surgical residents, and cardiology fellows.
- 1983 - present Surgical Cardiologist, Department of Thoracic and Cardiovascular Surgery, Cedars-Sinai Medical Center, Los Angeles, CA
- 1983 - present Full-time Staff Cardiologist, Division of Cardiology, Cedars-Sinai Medical Center, Los Angeles, CA

OTHER PROFESSIONAL EXPERIENCE

2002 - present	Co-Director, Cardiac Surgery Database, Cedars-Sinai Medical Center
1990 - 2010	Director, Heart Transplant Database, Cedars-Sinai Medical Center
1985 - 1994	Co-Director of Intraoperative Echocardiography and Color Doppler Imaging Program, Cedars-Sinai Medical Center
1983 - 1989	Associate Director, Cardiac Surgery Database, Cedars-Sinai Medical Center, Los Angeles, CA

PROFESSIONAL ACTIVITIES

COMMITTEES

2014 – present	Member, Institutional Review Board, Stem Cell Review Organization (SCRO) and Cancer, Cedars-Sinai Medical Center
2012 – 2013	Member, MedCAP (Medical Committee on Appointments and Promotions), UCLA School of Medicine
2001 - 2012	Member, Transplant Committee, Cedars-Sinai Medical Center
1999 - 2012	Member, Critical Care Committee, Cedars-Sinai Medical Center.
1991 - 2011	Chair, Quarterly Heart Transplant Morbidity and Mortality Committee, Cedars-Sinai Medical Center.
1982 - 20210	Member, Cardiology Fellowship Selection Committee, Cedars-Sinai Medical Center.
2000 - 2002	Member, Transfusion Committee, Cedars-Sinai Medical Center
2000 - 2001	Member, Cardiac Transplant Utilization Committee, Cedars-Sinai Medical Center
1994 - 1996	Chairman, Cardiac Transplant MST Committee, Cedars-Sinai Medical Center.
1990 - 2000	Member, Transplant QI Committee, Cedars-Sinai Medical Center.
1986 - 2000	Member, Institutional Review Board, Cedars-Sinai Medical Center.

PROFESSIONAL ASSOCIATIONS AND SCHOLARLY SOCIETIES

2015 – present	Fellow, American Heart Association
----------------	------------------------------------

2004 - present	Member, Board of Advisors, One Legacy
2004 - 2010	Member, Thoracic Organ Review Board for UNOS Region 5
2004 - present	Alternate voting representative of Cedars-Sinai Medical Center Transplant Programs for UNOS Region 5
1994 - present	Member, American Society of Echocardiography
1990 - present	Member, International Society for Heart Transplantation
1989 - 1995	Member and Chairman, Western Hemisphere Committee, International Society of Intraoperative Cardiovascular Ultrasound
1988 - present	Fellow, American College of Physicians
1988 - 1994	Member, New York Academy of Sciences
1988 - 1995	Founding Member, Council on Geriatric Cardiology, American College of Cardiology
1987 - 1994	Member, American Association for the Advancement of Science
1987 - 2010	Member, North American Society of Pacing and Electrophysiology
1986 - present	Fellow, American College of Chest Physicians
1985 - present	Fellow, American College of Cardiology
1984 - 1994	Member, American Federation for Clinical Research

EDITORIAL SERVICES

2014 – present	Guest editor, <u>Journal of American College of Cardiology</u>
1995 - 2013	Reviewer, <u>Journal of Thoracic and Cardiovascular Surgery</u>
1990 - 1993	Editorial board, <u>Transplantation Science</u>
1989 - 2012	Reviewer, <u>Echocardiography</u>
1988 - 2012	Reviewer, <u>Journal of American College of Cardiology</u>
1988 - 2012	Reviewer, <u>Chest</u>
1987 - 2012	Reviewer, <u>Circulation</u>

1985 - 1987 Reviewer, Catheterization and Cardiovascular Diagnosis

HONORS AND SPECIAL AWARDS

1971 - 1972 Milton J. Phillips Scholarship, University of California

1972 Sigma Pi Sigma (Physics Honor Society)

1973 Phi Beta Kappa

1973 Kinsey Award, Dept. of Physics (UCLA) for highest level of achievement
in graduating class in physics

1973 Summa cum laude, Certificate of honors at graduation

1973 - 1974 Health Professions Scholarship, University of California

1977 Alpha Omega Alpha

1978 Intern of the year

2001 *Chest* 2001 Nominee, Governors Community Service Awards Program

2002 Strathmore's Who's Who

2003 Chairman, California, Physician Advisory Board for U.S. Congressional
House Majority Leader.

2006 Physician Command Leader, Move-In of Saperstein Critical Care Tower
(January 25).

PATENTS

- 2007 Methods and Solutions for Tissue Preservation (Kamlot, Trento, Czer, Pass). PCT/US patent (application # 11/575,900 filed 3-23-07). Provisional patent (application # 60/630,118 filed 11-22-04). Patent Application 2008/0286745 A1 published 11-20-08. Patent application 14/530,006 filed on 10-31-14.
- 2007 Electronic Device for Detecting Cardiac Rejection in Heart Transplant Recipients. Provisional patent (application # 60/885,510 filed 1-18-07). Permanent patent PCT/US08/51301 filed 1-17-08. Patent Application 2010/0016684 A1 published 1-21-10. Patent granted US 8,523,780 B2 on 9-3-13.
- 2008 Apparatus for Continuous Cold Perfusion of Explanted Donor Heart to Improve Heart Preservation. Provisional Patent applied for (June 2008).

PROGRAMMATIC

- 2008 Joint Commission approval of Ventricular Assist Device Program at Cedars-Sinai Medical Center, December 10 and 11.
- Approval of Heart Transplant Program at Cedars-Sinai Medical Center as National Center of Excellence for Kaiser Permanente Medical Group
- 2010 UNOS Review of Heart Transplant Program at Cedars-Sinai Medical Center, May 2010. Clinical score 100%, Administrative score 99%.
- 2013 Joint Commission approval of Ventricular Assist Device Program at Cedars-Sinai Medical Center, June 10-11. No findings.

MENTOR FOR UCLA IN-RESIDENCE FACULTY

Eric Vasiliauskas, M.D. February 1999 - 2005
Brian Kan, M.D. February 2000 - 2001

Ph.D. CANDIDATES (UCLA SCHOOL OF NURSING) SUPERVISED IN HEART TRANSPLANT REAEARCH

Lynn Doering, R.N. May 1992 - June 1994
Bernice Coleman, R.N. June 1992 - July 1999

PHYSICIANS TRAINED IN HEART TRANSPLANT RESEARCH AND CLINICAL HEART TRANSPLANTATION

Denis Tixier, M.D. January 1991 - December 1992. Creteil, France.
Peter Barath, M.D. July 1991 - December 1994. Los Angeles, California.
Dan Admon, M.D. December 1991 - March 1994. Jerusalem, Israel.
Mario Valenza, M.D. March 1993 - March 1994. Palermo, Italy.
Dov Freimark, M.D. July 1993 - June 1994. Tel Hashomer, Israel.
Ivan Aleksic, M.D. June 1993 - December 1994. Gottingen, Germany.
George Diamond, M.D. July 1994 - December 1994. Los Angeles, California.
Hanneke Takkenberg, M.D. August 1994 - February 1996. Amsterdam, Netherlands.
Uri Elkayam, M.D. January 1996 - February 1996. Los Angeles, California.
Adrianus Quartel, M.D. March 1996 - August 1997. Amsterdam, Netherlands.
Yigal Kassif, M.D. July 1997 - October 1998. Tel Hashomer, Israel.
Sorel Goland, M.D. December 2004 - August 2007. Rehovot, Israel.
Andrea Ruzza, M.D. September 2008 – June 2015. Rome, Italy.
Roberta Vespignani, M.D. September 2008 - October 2011. Rome, Italy.
Roh Yanagida, M.D., Ph.D. October 2008 - October 2011. Philadelphia, Pennsylvania.
Anita Phan, M.D. July 2009 - June 2010. Los Angeles, California.
Ryan Morrissey, M.D. July 2010 - June 2011. Los Angeles, California.
Pavel Goykhman, M.D. July 2010 - June 2011. Los Angeles, California.
Evan Kransdorf, M.D., Ph.D. July 2011 - June 2012. Durham, North Carolina.
Pranav Kansara, M.D. July 2011 - June 2012. Buffalo, New York.
Manuel Caceres, M.D. July 2011 – June 2012. Cleveland, Ohio.
Hilit Hassidim, M.D. Sept 2011 - November 2011. Jerusalem, Israel.
Robert Morlend, M.D. July 2012 – June 2013. Atlanta, Georgia.
Dael Geft, M.D. July 2012 – June 2013. Los Angeles, California.
Shyamasundar Balasubramanya, M.D. July 2012 – June 2013. Chicago, Illinois.
Chhaya Aggarwal, M.D. July 2013 – June 2014. Little Rock, Arkansas.
Natasha Lipson Altman, M.D. July 2013 – June 2014. New York, New York.
Michael Sasevich, M.D. July 2013 – June 2014. San Diego, California.
Kai Ihnken, M.D. Sept 2013 – July 2015. Fairfax, Virginia.
Jared Herr, M.D. July 2014 – June 2015. Los Angeles, California.
Kambiz Ghafourian, M.D. July 2014 – June 2015. Washington, D.C.
Armin Kiankhooy, M.D. July 2014 – June 2015. Charlottesville, Virginia.
Diane Tran, M.D. July 2015 – June 2016. Honolulu, Hawaii.

Rajeev Mohan, M.D.	July 2015 – June 2016. San Diego, California.
Jonathan Neyer, M.D.	July 2015 – June 2016. Los Angeles, California.
Paul Perry, M.D.	July 2015 – June 2016. Davis, California.
Robert Cole, M.D.	July 2016 – June 2017. Los Angeles, California.
Daniel Westerdahl, M.D.	July 2016 – June 2017. Portland, Oregon.
Nicholas Furiasse, M.D.	July 2016 – June 2017. Chicago, Illinois.
Ajay Vaidya, M.D.	July 2017 – present.
Yu Xie, M.D.	July 2017 – present.
Gupreet Sodhi, M.D.	July 2017 – present.

VISITING SCIENTISTS - HEART TRANSPLANT RESEARCH LABORATORY

Lynn Wang, M.D., Ph.D. August 1996 - December 1996. China
Yong-Hwan Kim, M.D., Ph.D. June 2001 - January 2003. Korea

POSTDOCTORAL RESEARCHERS SUPERVISED IN HEART TRANSPLANT RESEARCH

Bernice Coleman, R.N., Ph.D. December 2000 – December 2012.

LABORATORY SCIENTISTS SUPERVISED - HEART TRANSPLANT RESEARCH

Chuek-Kee Chan, Ph.D. February - August 1993
Charles Hong-Kai Wang, M.D. July 1997 - July 2001
Hai-Mei Wang, D.D.S. March 1995 - June 1999; and October 2004 - July 2008

SURGICAL RESIDENTS SUPERVISED IN HEART TRANSPLANT RESEARCH LABORATORY

Angela Wong, M.D. June 1999 - June 2000
Andreas Kamlot, M.D. June 2000 - June 2001
Harmik Soukiasian, M.D. June 2001 - June 2002
Heidi Reich, M.D. June 2013 – June 2016

PHYSICIANS ASSISTANTS AND NURSE PRACTITIONERS SUPERVISED IN CLINICAL HEART TRANSPLANTATION AND HEART TRANSPLANT RESEARCH

Carmen A. Queral, P.A.-C. March 1993 - December 2000
Bernice Coleman, RN, NP, PhD June 2005 – December 2012

NURSE PRACTITIONER CANDIDATES (UCLA SCHOOL OF NURSING) SUPERVISED IN ADVANCED HEART FAILURE AND CLINICAL HEART TRANSPLANTATION

Lisa Tritico October 1997 - December 1997
Pamela Miller January 2004 - March 2004
Heather Sanders April 2004 - June 2004

**UNDERGRADUATE AND MEDICAL STUDENTS SUPERVISED IN HEART TRANSPLANT
RESEARCH LABORATORY**

Greg Albert	July 1991 - August 1991; New York Medical College.
Rex Amador	July 1992 - June 1994; University of California, Los Angeles.
Kourosh Eghbali	June 1995 - December 1995; University of California, Davis, School of Medicine.
Andrea Trento	July 1995 - September 1995; Yale University. Subsequently, University of California, Los Angeles, School of Medicine.
Mabelle Cohen	August 1994 - July 1998; Brandeis University. Subsequently, Chicago Medical School, Chicago, Illinois.
Thomas Kleisli	November 2000 - March 2001, and June 2001 – June 2002; University of California, Irvine, School of Medicine.
Robert Tabrizi	June 2001 - June 2002.
Zhanna Feldsher	July 2001 - March 2004.
Roemer van Wijk	April 2004 - July 2004; Erasmus University Medical Center, Rotterdam, Netherlands.
Aram John Raissi	July 2004 - September 2004; Boston University.
Jason Lee	Nov 2004 - July 2008; University of California, Los Angeles.
Chris Capelli	June 2005 - September 2005; Loyola Marymount University.
Kaveh Zivari	February 2006 - May 2009; University of California, Los Angeles. Subsequently, University of California, Davis, School of Medicine.
Raffi Salibian	January 2007 - March 2007; Virginia Commonwealth University.
Sarah Kim	June 2007 - July 2007; Johns Hopkins University, Baltimore.
Matthew Rafiei	May 2009 - Nov 2010; University of California, Los Angeles.
Robby Pixton	November 2009 - July 2010; University of California, Berkeley.
Alexandra Rudolph	Dec 2009 - Aug 2010; University of California, Los Angeles.
Saba Badar	Dec 2009 - Aug 2010; Cornell University, New York City.
Morcos Awad	Dec 2009 – July 2014; July – Aug 2015; University of California, Los Angeles. Subsequently, Midwestern University Arizona College of Osteopathic Medicine.
Kavi Patel	March 2011 - Aug 2011; University of California, Los Angeles.
Shea Gallagher	June 2011 - Aug 2012; University of San Diego, San Diego. Subsequently, University of California, Irvine, School of Medicine.
Hannah Morris	July 2011 - Sept 2011; University of California, San Diego.
Saman Setareh-Shenas	June 2012 – Sept 2012; Sackler School of Medicine, Tel Aviv.
Camelia Soliman	August 2012 – July 2014; University of California, San Diego. Subsequently, University of Virginia School of Medicine.
Sarah Saba Golshani	January 2013 – July 2014; University of California, Los Angeles.
Joshua Pinzas	June 2013 – August 2014; University of Santa Clara.
Michael Goltche	July 2013 – July 2014; University of California, Los Angeles.
Kelsey Rihbany	July 2013 – June 2015.
Maximilian Kovary	July 2014 – August 2014; University of California, San Diego.
Margaret Hou	August 2014 – August 2016.
Tomik Vertanous	July 2015 – August 2015. University of Southern California.
Jacob Valk	July 2015 – August 2015. Sackler School of Medicine, Tel Aviv.

Victor Ruan July 2016 – August 2016. SUNY, New York.

UCLA COURSE - PHY SCI 596 - TUT 25 (721-992-225) INDIVIDUAL STUDIES – GRAD STUDENT

Mabelle Cohen January 1996 - June 1996 (Winter and Spring 1996)

UCLA COURSE - PHY SCI 598 - TUT 20 (721-996-220) RESEARCH & PREP THESIS

Mabelle Cohen January 1997 - June 1997 (Winter and Spring 1997)

UCLA COURSE - MED 99 - TUT 6 (264-297-206) STUDENT RESEARCH PROGRAM

Kaveh Zivari September 2006 - December 2006 (Fall 2006)

UCLA COURSE - SURG 199 - TUT 1 (355-894-201) DIRECTED RESEARCH

Kaveh Zivari March 2007 - June 2007 (Spring 2007)

UCLA COURSE - MED 199 - TUT 3 (264-895-203) DIRECTED RESEARCH

Kaveh Zivari July 2007 - September 2007 (Summer 2007)

UCLA COURSE - MED 199 - TUT 6 (264-895-206) DIRECTED RESEARCH

Kaveh Zivari September 2007 - December 2007 (Fall 2007)

UCLA COURSE - MED 199 - TUT 19 (264-895-219) DIRECTED RESEARCH

Kaveh Zivari March 2008 - June 2008 (Spring 2008)

Saman Setareh-Shenas March 2008 - June 2008 (Spring 2008)

UCLA COURSE - MED 199 - TUT 23 (264-895-223) DIRECTED RESEARCH

Sarah Saba Golshani January 2013 – March 2013 (Winter 2013)

UCLA COURSE - MED 199 - TUT 4 (264-895-204) DIRECTED RESEARCH

Sarah Saba Golshani April 2013 – June 2013 (Spring 2013)

UCLA COURSE - MED 199 - TUT 10 (264-895-210) DIRECTED RESEARCH

Sarah Saba Golshani June 2013 – Jul 2013 (Summer 2013 Session A)

UCLA COURSE - MED 199 - TUT 5 (264-895-205) DIRECTED RESEARCH

Sarah Saba Golshani Jul 2013 – Aug 2013 (Summer 2013 Session C)

Michael Nissan Goltche Jul 2013 – Aug 2013 (Summer 2013 Session C)

Lawrence S.C. Czer, M.D.
Aug 2017

11

UCLA COURSE - MED 199 - TUT 39 (203-935-850) DIRECTED RESEARCH

Michael Nissan Goltche Jan 2014 – Mar 2014 (Winter 2014)

BIOLOGY COURSE

Lighthouse Christian Academy High School September 1999 - July 2002

PUBLICATIONS/BIBLIOGRAPHY

RESEARCH PAPERS - PEER REVIEWED

1. **Czer LSC**, Shoemaker WC. Optimal hematocrit value in critically ill postoperative patients. *Surg Gynec Obstet* 1978; 147: 363-368.
2. Shoemaker WC, Chang P, **Czer L**, Bland R, Shabot MM, State D. Cardiorespiratory monitoring in postoperative patients: I. Prediction of outcome and severity of illness. *Crit Care Med* 1979; 7: 237-242.
3. Shoemaker WC, Chang P, Bland R, **Czer L**, Shabot MM, Clifton J. Cardiorespiratory monitoring in postoperative patients: II. Quantitative therapeutic indices as guides to therapy. *Crit Care Med* 1979; 7: 243-249.
4. Shoemaker WC, **Czer LSC**. Evaluation of the biologic importance of various hemodynamic and oxygen transport variables: Which variables should be monitored in postoperative shock? *Crit Care Med* 1979; 7: 424-429.
5. Shoemaker WC, Appel P, **Czer LSC**, Bland R, Schwartz S, Hopkins JA. Pathogenesis of respiratory failure (ARDS) after hemorrhage and trauma: I. Cardiorespiratory patterns preceding the development of ARDS. *Crit Care Med* 1980; 8: 504-512.
6. **Czer LSC**, Appel P, Shoemaker WC. Pathogenesis of respiratory failure (ARDS) after hemorrhage and trauma: II. Cardiorespiratory patterns after development of ARDS. *Crit Care Med* 1980; 8: 513-518.
7. **Czer LSC**, Shoemaker WC. Myocardial performance in critically ill patients: Response to whole blood transfusion as a prognostic measure. *Crit Care Med* 1980; 8: 710-715.
8. Bateman TM, Gray RJ, **Czer LSC**, Levy RL, Stewart ME, DeRobertis MA, Brown DE, Matloff JM, Swan HJC, Berman DS. Regional distribution of pulmonary blood volume: an index of pulmonary capillary wedge pressure determined from blood pool scintigraphy. *Am J Cardiol* 1983; 51: 1404-1408.
9. **Czer L**, Hamer A, Murphy F, Bussell J, Chaux A, Bateman T, Matloff J, Gray RJ. Transient hemodynamic dysfunction after myocardial revascularization. Temperature dependence. *J Thorac Cardiovasc Surg* 1983; 86: 226-234.
10. Bateman TM, Gray RJ, Raymond MJ, Chaux A, **Czer LSC**, Matloff JM. Arrhythmias and conduction disturbances following cardiac operation for the removal of left atrial myxomas. *J Thorac Cardiovasc Surg* 1983; 86: 601-607.

RESEARCH PAPERS - PEER REVIEWED (cont.)

11. Bateman TM, **Czer LSC**, Gray RJ, Maddahi J, Raymond MJ, Geft IJ, Ganz W, Shah PK, Berman DS. Transient pathologic Q waves during acute ischemic events: An electrocardiographic correlate of stunned but viable myocardium. *Am Heart J* 1983; 106: 1421-1426.
12. **Czer LSC**, Gray RJ, DeRobertis MA, Bateman TM, Stewart ME, Chaux A, Matloff JM. Mitral valve replacement: Impact of coronary artery disease and determinants of prognosis following revascularization. *Circulation* 1984; 70 (Suppl I): I-198 to I-207.
13. Chaux A, **Czer LSC**, Matloff JM, DeRobertis MA, Stewart ME, Bateman TM, Kass RM, Lee ME, Gray RJ. The St. Jude Medical bileaflet valve prosthesis. A five-year experience. *J Thorac Cardiovasc Surg* 1984; 88: 706-717.
14. Bateman TM, **Czer LSC**, Gray RJ, Kass RM, Raymond MJ, Garcia EV, Chaux A, Matloff JM, Berman DS. Detection of occult pericardial hemorrhage early after open-heart surgery using technetium-99m red blood cell radionuclide ventriculography. *Am Heart J* 1984; 108: 1198-1206.
15. Bateman TM, Weiss MH, **Czer LSC**, Conklin CM, Kass RM, Stewart ME, Matloff JM, Gray RJ. Fascicular conduction disturbances and ischemic heart disease: Adverse prognosis despite coronary revascularization. *J Am Coll Cardiol* 1985; 5: 632-639.
16. **Czer LSC**, Weiss M, Bateman TM, Pfaff JM, DeRobertis M, Eigler N, Vas R, Matloff JM, Gray RJ. Fibrinolytic therapy of St. Jude valve thrombosis under guidance of digital cinefluoroscopy. *J Am Coll Cardiol* 1985; 5: 1244-1249.
17. Gray RJ, Bateman TM, **Czer LSC**, Conklin CM, Matloff JM. Esmolol: a new ultrashort-acting beta-adrenergic blocking agent for rapid control of heart rate in postoperative supraventricular tachyarrhythmias. *J Am Coll Cardiol* 1985; 5: 1451-1456.
18. Bateman TM, **Czer LSC**, Kass RM, Raymond MJ, Chaux A, Matloff JM, Berman DS, Gray RJ. Cardiac causes of shock early after open-heart surgery: etiologic classification by radionuclide ventriculography. *Circulation* 1985; 71: 1153-1161.
19. Gray RJ, Bateman TM, **Czer LSC**, Conklin C, Matloff JM. Use of esmolol in hypertension after cardiac surgery. *Am J Cardiol* 1985; 56: 49F-56F.
20. **Czer LSC**, Matloff JM, Chaux A, DeRobertis M, Yoganathan A, Gray RJ. A six year experience with the St. Jude Medical valve: hemodynamic performance, surgical results, biocompatibility, and follow-up. *J Am Coll Cardiol* 1985; 6: 904-912.
21. **Czer LSC**, Gray RJ, Bateman TM, DeRobertis M, Resser K, Chaux A, Matloff JM. Hemodynamic differentiation of pathologic and physiologic stenosis in mitral porcine bioprostheses. *J Am Coll Cardiol* 1986; 7: 284-294.

RESEARCH PAPERS - PEER REVIEWED (cont.)

22. Tsai TP, Matloff JM, Gray RJ, Chaux A, Kass RM, Lee ME, **Czer LSC**. Cardiac surgery in the octogenarian. *J Thorac Cardiovasc Surg* 1986; 91: 924-928.
23. Tsai TP, Matloff J, Chaux A, Kass RM, Lee ME, **Czer LSC**, DeRobertis MA, Gray RJ. Combined valve and coronary artery bypass procedures in septuagenarians and octogenarians: results in 120 patients. *Ann Thorac Surg* 1986; 42: 681-684.
24. Harold JG, Bateman TM, **Czer LSC**, Chaux A, Matloff JM, Gray RJ. Mitral valve replacement early after myocardial infarction: attendant high risk of left ventricular rupture. *J Am Coll Cardiol* 1987; 9: 277-282.
25. Gray RJ, Bateman TM, **Czer LSC**, Conklin C, Matloff JM. Comparison of esmolol and nitroprusside for the treatment of acute postcardiac surgical hypertension. *Am J Cardiol* 1987; 59: 887-891.
26. **Czer LSC**, Matloff JM, Chaux A, DeRobertis M, Gray RJ. Comparative clinical experience with porcine bioprosthetic and St. Jude valve replacement. *Chest* 1987; 91: 503-514.
27. **Czer LSC**, Bateman TM, Gray R, Raymond M, Stewart ME, Lee S, Goldfinger D, Chaux A, Matloff JM. Treatment of severe platelet dysfunction and hemorrhage after cardiopulmonary bypass: Reduction in blood product usage with desmopressin. *J Am Coll Cardiol* 1987; 9: 1139-1147.
28. **Czer LSC**, Matloff JM, Chaux A, DeRobertis M, Stewart ME, Gray RJ. The St. Jude valve: analysis of thromboembolism, warfarin-related hemorrhage, and survival. *Am Heart J* 1987; 114: 389-397.
29. Maurer G, **Czer LSC**, Chaux A, Bolger AF, DeRobertis M, Resser K, Kass RM, Lee ME, Matloff JM. Intraoperative Doppler color flow mapping for assessment of valve repair for mitral regurgitation. *Am J Cardiol* 1987; 60: 330-337.
30. Maurer G, **Czer LSC**, Chaux A, Matloff JM. Intraoperative color flow Doppler for evaluating valvuloplasty and correction of congenital heart disease. *Am J Cardiac Imaging* 1987; 1: 234-241.
31. **Czer LSC**, Maurer G, Bolger AF, DeRobertis M, Resser KJ, Kass RM, Lee ME, Blanche C, Chaux A, Gray RJ, Matloff JM. Intraoperative evaluation of mitral regurgitation by Doppler color flow mapping. *Circulation* 1987; 76 (Suppl III): III-108 to III-116.
32. Gray RJ, **Czer LSC**, Chaux A, Sethna D, DeRobertis M, Raymond M, Matloff JM. Harken caged-disc mitral valve replacement 1969 - 1975: Analysis of late mortality, thromboembolism, and valve failure. *Texas Heart Institute Journal* 1987; 14: 411-417.

RESEARCH PAPERS - PEER REVIEWED (cont.)

33. **Czer LSC**, Gray RJ, Stewart ME, DeRobertis M, Chaux A, Matloff JM. Reduction in sudden late death by concomitant revascularization with aortic valve replacement. *J Thorac Cardiovasc Surg* 1988 Mar; 95: 390-401. PMID: 3343849
34. Khan S, **Czer LS**, Gray RJ, Matloff J. Use of the valvular resistance in the separation of normal and stenotic Hancock mitral valves. *J Card Surg* 1988; 3: 241-246. PMID: 2980023
35. **Czer LSC**. Doppler assessment of prosthetic valves. *International Journal of Cardiac Imaging* 1989; 4: 9-10. PMID: 2746021
36. Maurer G, **Czer LSC**. Intraoperative color Doppler assessment of mitral and tricuspid valvuloplasty. *International Journal of Cardiac Imaging* 1989; 4: 11-13. PMID: 2746011
37. **Czer LSC**, Maurer G, Bolger A, DeRobertis M, Kleinman J, Gray RJ, Chaux A, Matloff JM. Tricuspid valve repair: operative and follow-up evaluation by Doppler color flow mapping. *J Thorac Cardiovasc Surg* 1989; 98: 101-111. PMID: 2739416
38. Maurer G, **Czer LSC**, Shah PK, Chaux A. Assessment by Doppler color flow mapping of ventricular septal defect after acute myocardial infarction. *Am J Cardiol* 1989 Sep 15; 64: 668-671. PMID: 2782259
39. Kleinman JP, **Czer LS**, DeRobertis M, Chaux A, Maurer G. A quantitative comparison of transesophageal and epicardial color Doppler echocardiography in the intraoperative assessment of mitral regurgitation. *Am J Cardiol* 1989; 64: 1168-1172. PMID: 2816769
40. **Czer LSC**. Mediastinal bleeding after cardiac surgery: etiologies, diagnostic considerations, and blood conservation methods. *J Cardiothoracic Anesthesia* 1989 Dec; 3: 760-775. PMID: 2521037
41. Khan SS, Nessim S, Gray R, **Czer LS**, Chaux A, Matloff J. Increased mortality of women in coronary artery bypass surgery: evidence for referral bias. *Ann Int Med* 1990 Apr; 112: 561-567. PMID: 2327676
42. **Czer LSC**, Maurer G. Intraoperative echocardiography in mitral and tricuspid valve repair. *Echocardiography* 1990 May; 7: 305-322. PMID: 10149231
43. **Czer LS**, Chaux A, Matloff JM, DeRobertis MA, Nessim SA, Scarlata D, Khan SS, Kass RM, Tsai TP, Blanche C, Gray RJ. Ten year experience with the St. Jude Medical valve for primary valve replacement. *J Thorac Cardiovasc Surg* 1990; 100: 44-55. PMID: 2366564
44. Baumgartner H, Khan S, DeRobertis M, **Czer L**, Maurer G. Discrepancies between Doppler and catheter gradients in aortic prosthetic valves in vitro: a manifestation of localized gradients and pressure recovery. *Circ* 1990 Oct; 82: 1467-1475. PMID: 2401075
45. Blanche C, Segalowitz J, **Czer LSC**, Wong S, Matloff JM. Excimer laser angioplasty during aortocoronary bypass grafting. *Ann Thorac Surg* 1991; 51: 670-2. PMID: 2012432

RESEARCH PAPERS - PEER REVIEWED (cont.)

46. Principal Investigators: Goldberg ME, Halpern N, Krakoff L, et al. Coinvestigators: **Czer LSC**. Efficacy and safety of intravenous nicardipine in the control of postoperative hypertension. *Chest* 1991; 99: 393-398.
47. **Czer LSC**, Fishbein M, Blanche C, Trento A. Accelerated rejection in cardiac transplantation. *Transplantation Science* 1991; 1:11-13.
48. Maurer G, Siegel RJ, **Czer LSC**. The use of color flow mapping for intra-operative assessment of valve repair. *Circulation* 1991 Sep; 84 (3 Suppl I): I-250-I-258. PMID: 1884493
49. Baumgartner H, Khan S, DeRobertis M, **Czer L**, Maurer G. Color Doppler regurgitant characteristics of normal mechanical mitral valve prostheses in vitro. *Circulation* 1992 Jan; 85: 323-332. PMID: 1728464
50. Baumgartner H, Khan S, DeRobertis M, **Czer L**, Maurer G. Effect of prosthetic aortic valve design on the Doppler-catheter gradient correlation: an in vitro study of normal St. Jude, Medtronic-Hall, Starr-Edwards and Hancock valves. *J Am Coll Cardiol* 1992 Feb; 19: 324-332. PMID: 1531058
51. Blanche C, **Czer LSC**, Trento A, Fishbein MC, Doan D, Jordan S, Utley C, Barath P, Matloff JM. Bradyarrhythmias requiring pacemaker implantation after orthotopic heart transplantation: association with rejection. *J Heart and Lung Transplantation* 1992 May-Jun; 11: 446-452. PMID: 1610853
52. Baumgartner H, Khan SS, DeRobertis M, **Czer LS**, Maurer G. Doppler assessment of prosthetic valve orifice area: an in vitro study. *Circulation* 1992 Jun; 85: 2275-2283. PMID: 1591841
53. Blanche C, Khan SS, Matloff JM, Chaux A, DeRobertis MA, **Czer LSC**, Kass RM, Tsai T-P. Results of early repair of ventricular septal defect after an acute myocardial infarction. *J Thorac Cardiovasc Surg* 1992 Oct; 104: 961-965. PMID: 1405696
54. Qiao J-H, Ruan X-M, Trento A, **Czer LSC**, Blanche C, Fishbein MC. Expression of cell adhesion molecules in human cardiac allograft rejection. *J Heart and Lung Transplantation* 1992 Sep-Oct; 11: 920-925. PMID: 1384703
55. **Czer LSC**, Maurer G, Trento A, DeRobertis M, Nessim S, Blanche C, Kass RM, Chaux A, Matloff J. Comparative efficacy of ring and suture annuloplasty for ischemic mitral regurgitation. *Circulation* 1992 Nov; 86 (5 Suppl II): II-46 to II-52. PMID: 1424033
56. Ruan X-M, Qiao J-H, Trento A, **Czer LS**, Blanche C, Fishbein M. Cytokine expression and endothelial cell and lymphocyte activation in human cardiac allograft rejection: an immunohistochemical study of endomyocardial biopsy samples. *J Heart and Lung Transplantation* 1992 Nov-Dec; 11: 1110-1116. PMID: 1360814

RESEARCH PAPERS - PEER REVIEWED (cont.)

57. Tixier D, Tuso P, **Czer L**, Yasunaga C, Tyan D, Fishbein M, Admon D, Barath P, Blanche C, Cramer D, Makowka L, Trento A. Characterization of antiendothelial cell and antiheart antibodies following heart transplantation. *Transplantation Proceedings* 1993 Feb; 25: 931-934. PMID: 8442271
58. Jordan SC, **Czer L**, Toyoda M, Galfayan K, Doan D, Fishbein M, Blanche C, Trento A. Serum cytokine levels in heart allograft recipients: correlation with findings on endomyocardial biopsy. *J Heart Lung Transplant* 1993 Mar-Apr; 12: 333-337. PMID: 8476907
59. Goldfinger D, Capon S, **Czer L**, Leibfreid J, Trento A, Ross D, Waters P, Klapper E, Pepkowitz S. Safety and efficacy of preoperative donation of blood for autologous use by patients with end-stage heart or lung disease who are awaiting organ transplantation. *Transfusion* 1993 Apr; 33: 336-340. PMID: 8480355
60. Tyan DB, Li VA, **Czer L**, Trento A, Jordan SC. Intravenous immunoglobulin suppression of HLA alloantibody in highly sensitized transplant candidates and transplantation with a histoincompatible organ. *Transplantation* 1994 Feb 27; 57: 553-562. PMID: 8116041
61. Blanche C, **Czer LSC**, Valenza M, Trento A. Alternative technique for orthotopic heart transplantation. *Ann Thorac Surg* 1994; 57: 765-767.
62. Blanche C, Valenza M, **Czer LSC**, Trento A. Heart transplantation in corrected transposition of the great arteries. *J Heart and Lung Transplantation* 1994 Jul-Aug; 13: 631-634. PMID: 7947879
63. Blanche C, Valenza M, **Czer LSC**, Barath P, Admon D, Harasty D, Utley C, Trento A. Combined heart and kidney transplantation with allografts from the same donor. *Ann Thorac Surg* 1994 Oct; 58: 1135-1138. PMID: 7944765
64. Blanche C, Valenza M, Aleksic I, **Czer LSC**, Trento A. Technical considerations of a new technique for orthotopic heart transplantation: total excision of recipient's atria with bicaval and pulmonary venous anastomoses. *J of Cardiovascular Surgery (Torino)* 1994 Jul-Aug; 35: 283-287. PMID: 7929537
65. Blanche C, Valenza M, **Czer LS**, Barath P, Admon D, Harasty D, Utley C, Freimark D, Aleksic I, Matloff J, Trento A. Orthotopic heart transplantation with bicaval and pulmonary venous anastomoses. *Ann Thorac Surg* 1994 Nov; 58: 1505-1509. PMID: 7979683
66. Fishbein MC, Bell G, Lones MA, **Czer LSC**, Miller JM, Harasty D, Trento A. Grade 2 cellular heart rejection: Does it exist? *J Heart and Lung Transplantation* 1994 Nov-Dec; 13: 1051-1057. PMID: 7865512
67. Freimark D, **Czer LSC**, Admon D, Aleksic I, Valenza M, Barath P, Harasty D, Queral C, Azen CG, Blanche C, Trento A. Donors with a history of cocaine use: effect on survival and rejection frequency after heart transplantation. *J Heart and Lung Transplantation* 1994 Nov-Dec; 13: 1138-1144. PMID: 7865522

RESEARCH PAPERS - PEER REVIEWED (cont.)

68. Blanche C, Freimark D, Valenza M, **Czer LSC**, Trento A. Heart transplantation for Q fever endocarditis. *Ann Thorac Surg* 1994 Dec; 58: 1768-1769. PMID: 7979759
69. Khan S, Chaux A, Matloff J, Blanche C, DeRobertis M, Kass R, Tsai TP, Trento A, Nessim S, Gray R, **Czer L**. The St. Jude Medical valve: experience with 1000 cases. *J Thoracic and Cardiovasc Surg* 1994; 108: 1010-1020.
70. Lones MA, **Czer LSC**, Trento A, Harasty D, Miller JM, Fishbein MC. Clinical-pathologic features of humoral rejection in cardiac allografts: a study in 81 consecutive patients. *J Heart and Lung Transplantation* 1995 Jan-Feb; 14: 151-162. PMID: 7727464
71. Toyoda M, Zhang XM, Sun Z, **Czer L**, Trento A, Jordan SC. Use of polymerase chain reaction to rapidly detect cytomegalovirus DNA in peripheral blood leukocytes of transplant recipients. *Transplant Proc* 1995 Feb; 27: 1272-1273. PMID: 7878879
72. Blanche C, Hwang C, Valenza M, Kass RM, **Czer LSC**, Mandel WJ, Trento A. Wolff-Parkinson-White syndrome in a cardiac allograft. *Ann Thorac Surg* 1995 Mar; 59: 744-746. PMID: 7887725
73. Freimark D, Silverman JM, Aleksic I, Crues JV, Blanche C, Trento A, Admon D, Queral CA, Harasty DA, **Czer LSC**. Atrial emptying with orthotopic heart transplantation using bicaval and pulmonary venous anastomoses: a magnetic resonance imaging study. *J Am Coll Cardiol* 1995 Mar 15; 25: 932-936. PMID: 7884100
74. Luthringer DJ, Yamashita JT, **Czer LSC**, Trento A, Fishbein MC. Nature and significance of epicardial lymphoid infiltrates in cardiac allografts. *J Heart and Lung Transplantation* 1995 May-Jun; 14: 537-543. PMID: 7654737
75. Freimark D, **Czer LSC**, Aleksic I, Barthold C, Admon D, Trento A, Blanche C, Valenza M, Siegel RJ. Improved left atrial transport and function with orthotopic heart transplantation by bicaval and pulmonary venous anastomoses. *Am Heart J* 1995 Jul; 130: 121-126. PMID: 7611101
76. Valenza M, **Czer LSC**, Pan S-H, Aleksic I, Freimark D, Harasty DA, Admon D, Barath P, Blanche C, Trento A. Combined antiviral and immunoglobulin therapy as prophylaxis against cytomegalovirus infection after heart transplantation. *J Heart and Lung Transplantation* 1995 Jul-Aug; 14: 659-665. PMID: 7578172
77. Blanche C, Tsai T-P, **Czer LSC**, Valenza M, Aleksic I, Trento A. Superior vena cava stenosis after orthotopic heart transplantation: complication of an alternative surgical technique. *Cardiovascular Surgery* 1995 Oct; 3: 549-552. PMID: 8574542
78. Blanche C, **Czer LSC**, Fishbein MC, Takkenberg JJM, Trento A. Permanent pacemaker for rejection episodes after heart transplantation: a poor prognostic sign. *Ann Thorac Surg*. 1995 Nov; 60: 1263-1266. PMID: 8526610

RESEARCH PAPERS - PEER REVIEWED (cont.)

79. Blanche C, Aleksic I, Takkenberg JJ, **Czer LS**, Fishbein MC, Trento A. Heart transplant for Chagas' cardiomyopathy. *Ann Thorac Surg* 1995 Nov; 60: 1406-1409. PMID: 8719467
80. Klapper E, Pepkowitz SH, **Czer L**, Inducil C, Scott L, Goldfinger D. Confirmation of the safety of autologous blood donation by patients awaiting heart or lung transplantation: a controlled study utilizing hemodynamic monitoring. *J Thorac Cardiovasc Surg* 1995 Dec; 110: 1594-1599. PMID: 8523868
81. Freimark D, **Czer LSC**, Aleksic I, Ruan XM, Admon D, Blanche C, Trento A, Fishbein MC. Pathogenesis of Quilty lesion in cardiac allografts: relationship to reduced endocardial cyclosporine A. *J Heart Lung Transpl* 1995; 14: 1197-1203. PMID: 8719467
82. Toyoda M, Galfayan K, Wachs K, **Czer L**, Jordan SC. Immunologic monitoring of OKT3 induction therapy in cardiac allograft recipients. *Clin Transplant* 1995 Dec; 9: 472-480. PMID: 8645891
83. Aleksic I, **Czer LSC**, Admon D, Blanche C, Takkenberg JJM, Zisk J, Fishbein MC, Fermelia D, Trento A. Survival of acute intestinal infarction after cardiac transplantation. *Thoracic and Cardiovascular Surgeon* 1995 Dec; 43: 352-354. PMID: 8775861
84. Blanche C, Aleksic I, **Czer LSC**, Freimark D, Takkenberg JJM, Trento A. Heart transplantation after repair of post-infarction ventricular septal defect. *J of Cardiovascular Surgery* 1995 Dec; 36: 551-554. PMID: 8632023
85. Freimark D, Aleksic I, Trento A, Takkenberg JJM, Valenza M, Admon D, Blanche C, Queral CA, Azen CG, **Czer LSC**. Hearts from donors with chronic alcohol use: a possible risk factor for death after heart transplantation. *J Heart and Lung Transplantation* 1996 Feb; 15: 150-159. PMID: 8672518
86. Trento A, **Czer LSC**, Blanche C. Surgical techniques for cardiac transplantation. *Seminars in Thoracic and Cardiovascular Surgery* 1996 Apr; 8: 126-132. PMID: 8672565
87. Aleksic I, Ren M, **Czer LSC**, Freimark D, Dalichau H, Blanche C, Trento A, Barath P. Liposome-mediated transfer of genes containing HLA-class II alpha chain into cultured embryonic chick cardiac myocytes and cos 7 cells. *Thoracic and Cardiovascular Surgeon* 1996 Apr; 44: 81-85. PMID: 8782333
88. Tixier DB, **Czer LSC**, Fishbein MC, Blanche C, Admon D, Amador R, Albert GD, Trento A. Isolated coronary artery transplantation in pigs: a new model to study transplantation arteriosclerosis and humoral rejection. *J Heart and Lung Transplantation* 1996 Sept; 15: 919-927. PMID: 8889988
89. Aleksic I, **Czer LSC**, Freimark D, Takkenberg JJM, Dalichau H, Valenza M, Blanche C, Queral CA, Nessim S, Trento A. Resting hemodynamics after total versus standard orthotopic heart transplantation. *Thorac Cardiovasc Surg* 1996 Aug; 44:193-198. PMID: 8896162.

RESEARCH PAPERS - PEER REVIEWED (cont.)

90. Doering LV, Dracup K, Moser DK, **Czer LSC**, Peter CT. Hemodynamic adaptation to orthostatic stress after orthotopic heart transplantation. *Heart and Lung* 1996 Sep-Oct; 25: 339-351. PMID: 8886810
91. Blanche C, Takkenberg JJM, Nessim S, Cohen M, **Czer LSC**, Matloff JM, Trento A. Heart transplantation in patients 65 years of age and older: a comparative analysis of 40 patients. *Ann Thoracic Surgery* 1996 Nov; 62: 1442-1447. PMID: 8893581
92. Blanche C, Matloff JM, Denton TA, **Czer LSC**, Fishbein MC, Takkenberg JJM, Trento A. Heart transplantation in patients 70 years of age and older: initial experience. *Ann Thoracic Surg* 1996 Dec; 62: 1731 - 1736. PMID: 8957378
93. **Czer LSC**, Maurer G, Bolger AF, DeRobertis M, Chaux A, Matloff JM. Revascularization alone or combined with suture annuloplasty for ischemic mitral regurgitation: evaluation by color Doppler echocardiography. *Tex Heart Inst J* 1996; 23: 270-278. PMID: 8969026
94. Aleksic I, **Czer LSC**, Freimark D, Dalichau H, Takkenberg JJM, Blanche C, Nessim S, Nusser P, Trento A. Heart transplantation in patients with diabetic end-organ damage before transplantation. *Thorac Cardiovasc Surg* 1996 Dec; 44: 282-288. PMID: 9021904
95. Trento A, Takkenberg JM, **Czer LSC**, Blanche C, Nessim S, Cohen MH, Kass R, Raissi S, Matloff JM. Clinical experience with one hundred consecutive patients undergoing orthotopic heart transplantation with bicaval and pulmonary venous anastomoses. *J Thoracic & Cardiovascular Surgery* 1996 Dec; 112: 1496 - 1503. PMID: 8975841
96. Toyoda M, Carlos JB, Galera OA, Galfayan K, Zhang X, Sun Z, **Czer LSC**, Jordan SC. Correlation of cytomegalovirus DNA levels with response to antiviral therapy in cardiac and renal allograft recipients. *Transplantation* 1997 Apr 15; 63: 957-963. PMID: 9112347
97. Barone JM, Fishbein MC, **Czer LSC**, Blanche C, Trento A, Luthringer DJ. Absence of endocardial lymphoid infiltrates (Quilty lesions) in nonheart transplant patients treated with cyclosporine. *J Heart Lung Transplant* 1997 Jun; 16: 600-603. PMID: 9229289
98. Aleksic I, Freimark D, Blanche C, **Czer LSC**, Takkenberg JJM, Dalichau H, Nessim S, Trento A. Resting hemodynamics after total versus standard orthotopic heart transplantation in patients with high preoperative pulmonary vascular resistance. *Eur J Cardiothorac Surg* 1997 Jun; 11: 1037-1044. PMID: 9237584
99. Toyoda M, Galfayan K, Galera OA, Petrosian A, **Czer LSC**, Jordan SC. Cytomegalovirus infection induces anti-endothelial cell antibodies in cardiac and renal allograft recipients. *Transpl Immunol* 1997 Jun; 5:104-111. PMID: 9269032
100. Aleksic I, Freimark D, Blanche C, **Czer LSC**, Dalichau H, Valenza M, Takkenberg JJM, Trento A. The duration of administration of monoclonal antibody OKT3 for induction

RESEARCH PAPERS - PEER REVIEWED (cont.)

- immunosuppression after heart transplantation. *Thoracic and Cardiovascular Surgeon* 1997 Aug; 45: 190-195. PMID: 9323821
101. Takkenberg JJM, Wang H-M, Trento A, Popov A, Freimark D, Eghbali K, Wang CHK, Blanche C, **Czer LSC**. The effect of chronic alcohol use on the heart before and after transplantation in an experimental model in the rat. *J Heart Lung Transplant* 1997 Sep; 16: 939-945. PMID: 9322145
 102. Coffman KL, Valenza M, **Czer LSC**, Freimark D, Aleksic I, Harasty D, Qeral C, Admon D, Barath P, Blanche C, Trento A. An update on transplantation in the geriatric heart transplant patient. *Psychosomatics* 1997 Sep-Oct; 38: 487-496. PMID: 9314718
 103. Ikeda T, **Czer L**, Trento A, Hwang C, Ong JJC, Hough D, Fishbein MC, Mandel WJ, Karagueuzian HS, Chen P-S. Induction of meandering functional reentrant wavefront in isolated human atrial tissues. *Circulation* 1997 Nov; 96: 3013-3020. PMID: 9386170
 104. Blanche C, Nessim S, Quartel A, Takkenberg JJM, Aleksic I, Cohen M, **Czer LSC**, Trento A. Heart transplantation with bicaval and pulmonary venous anastomoses. A hemodynamic analysis of the first 117 patients. *J of Cardiovasc Surg (Torino)* 1997 Dec; 38: 561-566. PMID: 9461258
 105. Aleksic I, Ren M, Popov A, Freimark D, Blanche C, **Czer L**, Trento A, Barath P. In vivo liposome-mediated transfection of HLA-DR alpha gene into pig hearts. *Eur J Cardiothorac Surg* 1997 Nov; 12: 792-797. PMID: 9458153
 106. Kim DT, Kwan Y, Lee JJ, Ikeda T, Uchida T, Kamjoo K, Kim Y-H, Ong JJC, Athill CA, Wu T-J, **Czer L**, Karagueuzian HS, Chen P-S. Patterns of spiral tip motion in cardiac tissues. *Chaos* 1998 Mar; 8: 137-148. PMID: 12779717
 107. Jordan SC, Tyan D, **Czer L**, Toyoda M. Immunomodulatory actions of intravenous immunoglobulin (IVIG): potential applications in solid organ transplant recipients. *Pediatr Transplantation* 1998 May; 2: 92-105. PMID: 10082441
 108. Wu T-J, Ong JJC, Hwang C, Lee JJ, Fishbein MC, **Czer L**, Trento A, Blanche C, Kass RM, Mandel WJ, Karagueuzian HS, Chen P-S. Characteristics of wave fronts during ventricular fibrillation in human hearts with dilated cardiomyopathy: role of increased fibrosis in the generation of reentry. *J Am Coll Card* 1998; 32: 187-196. PMID: 9669269
 109. Jordan SC, Quartel AW, **Czer LS**, Admon D, Chen G, Fishbein MC, Schwieger J, Steiner RW, Davis C, Tyan DB. Post transplant therapy using high-dose human immunoglobulin (intravenous gammaglobulin) to control acute humoral rejection in renal and cardiac allograft recipients and potential mechanisms of action. *Transplantation* 1998 Sep 27; 66: 800-805. PMID: 9771846

RESEARCH PAPERS - PEER REVIEWED (cont.)

110. Blanche C, Takkenberg JJM, Quartel A, Nessim S, Cohen M, **Czer LSC**, Matloff JM, Trento A. Long-term results of cardiac transplantation in patients older than 65 years. *J of Am International Health Council* 1998; 1: 27-28.
111. Fredrich R, Toyoda M, **Czer LSC**, Galfayan K, Galera O, Trento A, Freimark D, Young S, Jordan SC. The clinical significance of antibodies to human vascular endothelial cells after cardiac transplantation. *Transplantation* 1999 Feb; 67: 385-391. PMID: 10030283
112. Wang CK, Zuo XJ, Carpenter D, Jordan S, Nicolaidou E, Toyoda M, **Czer LS**, Wang H, Trento A. Prolongation of cardiac allograft survival with intracoronary viral interleukin-10 gene transfer. *Transplant Proc* 1999 Feb-Mar; 31: 951-952. PMID: 10083421
113. Hwang C, Karagueuzian HS, **Czer L**, Chen PS. Reentrant wavefronts in human ventricular tissue. *J Cardiovasc Electrophysiol* 1999 Mar; 10: 419. PMID: 10210507
114. Wu T-J, Yashima M, Doshi R, Kim Y-H, Athill CA, Ong JJC, **Czer L**, Trento A, Blanche C, Kass RM, Garfinkel A, Weiss JN, Fishbein MC, Karagueuzian HS, Chen P-S. Relation between the cellular repolarization characteristics and critical mass for human ventricular fibrillation. *J Cardiovasc Electrophysiol* 1999 Aug; 10: 1077-1086. PMID: 10466488
115. Doering LV, Dracup K, Moser DK, **Czer LSC**, Peter CT. Evidence of time-dependent autonomic reinnervation after heart transplantation. *Nursing Research* 1999 Nov-Dec; 48:308-316. PMID: 10571498
116. Cao J-M, Fishbein MC, Han JB, Lai WW, Lai AC, Wu T-J, **Czer L**, Wolf PL, Denton TA, Shintaku IP, Chen P-S, Chen LS. Relationship between regional ventricular hyperinnervation and ventricular arrhythmia. *Circulation* 2000 Apr; 101: 1960-1969. PMID: 10779463
117. Principal investigators: Colucci WS, Elkayam U, Horton DP, Abraham WT, Bourge RC, Johnson AD, Wagoner LE, Givertz MM, Liang C, Neibaur M, Haught WH, LeJemtel TH. Co-invest: **Czer LSC** et. al. Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. *N Engl J Med* 2000; 343: 246-253.
118. Blanche C, Blanche DA, Kearney B, Sandhu M, **Czer LSC**, Kamlot A, Hickey A, Trento A. Heart transplantation in patients seventy years of age and older: a comparative analysis of outcome. *J Thorac Cardiovasc Surg* 2001 Mar; 121: 532-541. PMID: 11241089
119. Khan SS, Trento A, DeRobertis M, Kass RM, Sandhu M, **Czer LSC**, Blanche C, Raissi S, Fontana GP, Cheng W, Chaux A, Matloff JM. Twenty-year comparison of tissue and mechanical valve replacement. *J Thorac Cardiovasc Surg* 2001 Aug; 122: 257-269. PMID: 11479498
120. Blanche C, Kamlot A, Blanche DA, Kearney B, Wong AV, **Czer LSC**, Trento A. Combined heart-kidney transplantation with single-donor allografts. *J Thorac Cardiovasc Surg* 2001 Sep; 122: 495-500. PMID: 11547301

RESEARCH PAPERS - PEER REVIEWED (cont.)

121. Blanche C, Kamlot A, Blanche DA, Kearney B, Magliato KE, **Czer LS**, Trento A. Heart transplantation with donors fifty years of age and older. *J Thorac Cardiovasc Surg* 2002 Apr; 123: 810-815. PMID: 11986611
122. Magliato KM, Kleisli T, Soukiasian HJ, Tabrizi R, Coleman B, Hickey A, **Czer LSC**, Blanche C, Cheng W, Fontana GP, Kass RM, Raissi SS, Trento A. Biventricular support in patients with profound cardiogenic shock: a single center experience. *Am Soc for Artif Int Organs Journal* 2003 Jul-Aug; 49: 475-479. PMID: 12918594
123. Aleksic I, Freimark D, Blanche C, **Czer LSC**, Trento A. Does orthotopic heart transplantation offer improved hemodynamics during cellular rejection events? *Transplantation Proceedings* 2003 Jun; 35: 1532-1535. PMID: 12826213
124. Kobal S, **Czer LSC**, Czer PC, Feldsher Z, Hamilton R, Siegel RJ. Making an impossible mission possible. *Chest* 2004 Jan; 125: 293-296. PMID: 14718454
125. Takkenberg JJM, **Czer LSC**, Fishbein MC, Luthringer DJ, Quartel AW, Mirocha J, Queral CA, Blanche C, Trento A. Eosinophilic myocarditis in patients awaiting heart transplantation. *Crit Care Med* 2004 Mar; 32: 714-721. PMID: 15090952
126. Soukiasian HJ, **Czer LSC**, Avital I, Aoki T, Kim Y-H, Umehara Y, Pass J, Tabrizi R, Magliato K, Fontana GP, Cheng W, Demetriou AA, Trento A. A novel subpopulation of bone marrow-derived myocardial stem cells: potential autologous cell therapy in myocardial infarction. *J Heart Lung Transplant* 2004 Jul; 23: 873-880. PMID: 15261183
127. Soukiasian HJ, **Czer LSC**, Wang H-M, Luthringer D, Wang C, Kamlot A, Quartel A, Trento A. Inhibition of graft coronary arteriosclerosis after heart transplantation. *American Surgeon* 2004 Oct; 70: 833-840. PMID: 15529833
128. Aleksic A, Freimark D, Blanche C, **Czer LS**, Trento A. Hemodynamics during humoral rejection events with total versus standard orthotopic heart transplantation. *Ann Thorac Cardiovasc Surg* 2004 Oct; 10: 285-289. PMID: 15563263
129. Kim DT, Luthringer DJ, Lai AC, Suh G, **Czer L**, Chen LS, Chen P-S, Fishbein MC. Sympathetic nerve sprouting after orthotopic heart transplantation. *J Heart and Lung Transplant* 2004 Dec; 23: 1349-1358. PMID: 15607663
130. Soukiasian HJ, Raissi SS, Kleisli T, Lefor AT, Fontana GP, **Czer LSC**, Trento A. Total circulatory arrest for the replacement of the descending thoraco-abdominal aorta. *Arch Surg* 2005 Apr; 140: 394-398. PMID: 15837891
131. Kim Y-H, **Czer LSC**, Soukiasian HJ, DeRobertis M, Magliato KE, Blanche C, Raissi SS, James Mirocha, Siegel RJ, Kass RM, Trento A. Ischemic mitral regurgitation: revascularization alone versus revascularization and mitral valve repair. *Ann Thorac Surg* 2005 Jun; 79: 1895-1901. PMID: 15919280

RESEARCH PAPERS - PEER REVIEWED (cont.)

132. Lee MS, Kapoor N, Jamal F, **Czer L**, Aragon J, Forrester J, Kar S, Dohad S, Kass R, Eigler N, Trento A, Shah PK, Makkar RR. Comparison of coronary artery bypass surgery with percutaneous coronary intervention with drug-eluting stents for unprotected left main coronary artery disease. *J Am Coll Cardiol* 2006 Feb; 47: 864-870. PMID: 16487857
133. Puliyananda DP, Amet N, Dhawan A, Hilo L, Radha RK, Bunnapradist S, **Czer L**, Martin P, Jordan S, Toyoda M. Isolated heart and liver transplant recipients are at low risk for polyomavirus BKV nephropathy. *Clin Transplant* 2006; 20: 289-294. PMID: 16824143
134. Goland S, **Czer LSC**, De Robertis M, Mirocha J, Kass RM, Fontana G, Cheng W, Trento A. Risk factors associated with mortality and re-operation in 252 patients after aortic valve replacement for congenitally bicuspid aortic valve disease. *Ann Thorac Surg* 2007 Mar; 83: 931-7. PMID: 17307436
135. Goland S, **Czer LS**, Kass RM, De Robertis M, Mirocha J, Coleman B, Capelli C, Raissi S, Cheng W, Fontana G, Trento A. Pre-existing pulmonary hypertension in patients with end-stage heart failure: impact on clinical outcome and hemodynamic follow-up after orthotopic heart transplantation. *J Heart and Lung Transplant* 2007 Apr; 26:312-8 (Epub 2007 Mar 2). PMID: 17403470
136. Goland S, Trento A, Iida K, **Czer LS**, De Robertis M, Naqvi TZ, Tolstrup K, Akima T, Luo H, Siegel RJ. Assessment of aortic stenosis by three-dimensional echocardiography: an accurate and novel approach. *Heart* 2007 Jul; 93:801-7(Epub May 8). PMID: 17488766
137. Lee MS, Jamal F, Kedia G, Chang G, Kapoor N, Forrester J, **Czer L**, Zimmer R, De Robertis M, Trento A, Makkar RR. Comparison of bypass surgery with drug-eluting stents for diabetic patients with multivessel disease. *Int J Cardiol* 2007 Dec; 123: 34-42 (Epub 2007 Feb 12). PMID: 17292983
138. Goland S, Schwarz ER, Siegel RJ, **Czer LSC**. Pregnancy-associated spontaneous coronary artery dissection. *Am J Obstet Gynec* 2007 Dec; 197: e11-3. PMID: 18060935
139. Goland S, Trento A, **Czer LSC**, Eshaghian S, Tolstrup K, Naqvi TZ, De Robertis MA, Mirocha J, Iida K, Siegel RJ. Thoracic aortic atherosclerosis in patients with degenerative aortic stenosis with and without coexisting coronary artery disease. *Ann Thoracic Surg* 2008 Jan; 85: 113-9. PMID: 18154793
140. Goland S, **Czer LSC**, Luthringer D, Siegel RJ. A case of arrhythmogenic right ventricular cardiomyopathy. *Can J Cardiol* 2008 Jan; 24: 61-62. PMID: 18209772
141. Sulemanjee NZ, Merla R, Lick SD, Aunon SM, Taylor M, Manson M, **Czer LS**, Schwarz ER. The first year post heart transplantation: use of immunosuppressive drugs and early complications. *J Cardiovasc Pharmacol and Ther* 2008 Mar; 13: 13-31. PMID: 18287587

RESEARCH PAPERS - PEER REVIEWED (cont.)

142. Goland S, **Czer LS**, Kass RM, Siegel RJ, Mirocha J, De Robertis MA, Lee J, Raissi S, Cheng W, Fontana G, Trento A. Use of cardiac allografts with mild and moderate left ventricular hypertrophy can be safely used in heart transplantation to expand the donor pool. *J Am Coll Cardiol* 2008 Mar 25; 51: 1214-1220. PMID: 18355661
143. White AJ, Kedia G, Mirocha JM, Lee MS, Forrester JS, Morales WC, Dohad S, Kar S, **Czer LS**, Fontana GP, Trento A, Shah PK, Makkar RR. Comparison of coronary artery bypass surgery and percutaneous drug-eluting stent implantation for treatment of left main coronary artery stenosis. *JACC Cardiovasc Interv* 2008 Jun; 1: 236-245. PMID: 19463306
144. Goland S, **Czer LS**, Siegel RJ, Tabak S, Jordan S, Luthringer D, Mirocha J, Coleman B, Kass RM, Trento A. Intravenous immunoglobulin treatment for acute fulminant inflammatory cardiomyopathy: series of six patients and review of the literature. *Can J Cardiol* 2008 Jul; 24: 571-574. PMID: 18612500
145. Simsir SA, Fontana GP, **Czer LS**, Schwarz ER. Heart allograft transplanted twice. *Eur J Cardiothorac Surg* 2008 Oct; 34: 918-919. Epub 2008 Aug 3. PMID: 18678506
146. Goland S, **Czer LSC**, Coleman B, De Robertis MA, Mirocha J, Zivari K, Schwarz ER, Kass RM, Trento A. Induction therapy with Thymoglobulin after heart transplantation: impact of therapy duration on lymphocyte depletion and recovery, rejection, and CMV infection rates. *J Heart and Lung Transplant* 2008 Oct; 27: 1115-1121. PMID: 18926403
147. Kobashigawa J, Mehra M, West L, Kerman R, George J, Rose M, Zeevi A, Reinsmoen N, Patel J, Reed EF; Consensus Conference Participants (including **Czer LS**). Report from a consensus conference on the sensitized patient awaiting heart transplantation. *J Heart and Lung Transplant* 2009 Mar; 28: 213-25. PMID: 19285611
148. Trento A, Goland S, De Robertis MA, **Czer LS**. Counterpoint: Efficacy of adding mitral valve restrictive annuloplasty to coronary artery bypass grafting in patients with moderate ischemic mitral valve regurgitation. *J Thorac Cardiovasc Surg* 2009 Aug; 138: 286-288.
149. Goland S, Luthringer D, Shirvani V, Trento A, **Czer LSC**. An unusual case of allograft neutrophilic myocarditis mimicking acute myocardial infarction in a post-heart transplant patient. *J Heart and Lung Transplant* 2009 Aug; 28: 843-846. PMID: 19632583
150. Fieno DS, **Czer LS**, Schwarz ER, Simsir S. Left ventricular assist device placement in a patient with end stage heart failure and human immunodeficiency virus. *Interact Cardiovasc Thorac Surg* 2009 Nov; 9: 919-920. (Epub 2009 Aug 25). PMID: 19706718
151. Goland S, Modi K, Bitar F, Janmohamed M, Mirocha JM, **Czer LS**, Illum S, Hatamizadeh P, Elkayam U. Clinical profile and predictors of complications in peripartum cardiomyopathy. *J Card Fail* 2009 Oct; 15: 645-650. (Epub 2009 Jul 16). PMID: 19786252

RESEARCH PAPERS - PEER REVIEWED (cont.)

152. Goland S, **Czer LS**, Siegel RJ, De Robertis MA, Mirocha J, Zivari K, Kass RM, Raissi S, Fontana G, Cheng W, Trento A. Coronary revascularization alone or with mitral valve repair: outcomes in patients with moderate ischemic mitral regurgitation. *Tex Heart Inst J* 2009 Oct; 36: 416-424. PMID: 19876417
153. Simsir SA, Schwarz ER, **Czer LS**, Hamburg SI. Heart transplantation using bivalirudin as anticoagulant. *Interact Cardiovasc Thorac Surg* 2010 Jan; 10: 150-151 (Epub 2009 Oct 1).
154. Ronco F, Simsir S, **Czer L**, Luo H, Siegel RJ. Incidental finding by two-dimensional echocardiography of a mycotic pseudoaneurysm of the ascending aorta after orthotopic heart transplantation. *J Am Soc Echocardiogr* 2010 May; 23: 580.e1-3 (Epub 2009 Oct 31). PMID: 19880279
155. Unes Kunju S, Naim HJ, **Czer L**, Simsir S, Schwarz ER. Acute cellular transplant rejection following laparoscopic adjustable gastric banding in a morbidly obese patient post heart transplantation. *J Cardiovasc Med (Hagerstown)* 2010 Sep; 11: 695-699. PMID: 19910801
156. Cheng W, Fontana GP, De Robertis MA, Mirocha J, **Czer LS**, Kass RM, Trento A. Is robotic mitral valve repair a reproducible approach? *J Thorac Cardiovasc Surg* 2010 Mar; 139: 628-633 (Epub 2009 Dec 28). PMID: 20038479
157. Phan A, Ishak WW, Shen BJ, Fuess J, Philip K, Bresee C, **Czer L**, Schwarz ER. Persistent sexual dysfunction impairs quality of life after cardiac transplantation. *J Sex Med* 2010 Aug; 7: 2765-2773 (Epub 2010 May 19). PMID: 20497304
158. Schwarz ER, **Czer LS**, Simsir SA, Kass RM, Trento A. Amiodarone-induced QT prolongation in a newly transplanted heart associated with recurrent ventricular fibrillation. *Cardiovasc J Afr* 2010 Mar-Apr; 21: 109-112. PMID: 20532436
159. Wang H, Goland S, Burton K, **Czer LS**, Schwarz ER, Trento A. An agonist of liver X receptor slows valvular disease in a hypercholesterolemia mouse model. *J Heart Valve Dis* 2010 Sep; 19: 653-664. PMID: 21053746
160. Ruzza A, Vespignani R, **Czer LS**, De Robertis M, Wu GN, Trento A. Heterotopic heart transplantation in rats: improved anesthetic and surgical technique. *Transplantation Proceedings* 2010 Nov; 42: 3828-3832. PMID: 21094865
161. Daneshvar DA, **Czer LS**, Phan A, Trento A, Schwarz ER. Heart transplantation in the elderly: why cardiac transplantation does not need to be limited to younger patients but can be safely performed in patients above 65 years of age. *Ann Transplant* 2010 Dec; 15: 110-119. PMID: 21183885
162. Yanagida R, Kass R, **Czer L**, Khoynzhad A. Endovascular repair of arterio-bronchial fistula of the outflow graft of HeartMate II left ventricular assist device. *J Thorac Cardiovasc Surg* 2011 Sept; 142: 710-711 (Epub 2011 Jan 25). PMID: 21272896

RESEARCH PAPERS - PEER REVIEWED (cont.)

163. Kobashigawa J, Crespo-Leiro MG, Ensminger SM, Reichenspurner H, Angelini A, Berry G, Burke M, **Czer L**, Hiemann N, Kfoury AG, Mancini D, Mohacsi P, Patel J, Pereira N, Platt JL, Reed EF, Reinsmoen N, Rodriguez ER, Rose ML, Russell SD, Starling R, Suciufoca N, Tallaj J, Taylor DO, Van Bakel A, West L, Zeevi A, Zuckermann A. Report from a consensus conference on antibody-mediated rejection in heart transplantation. *J Heart Lung Transplant* 2011 Mar; 30: 252-269. PMID: 21300295
164. Morrissey RP, Rana JS, Luthringer DJ, Cheng V, **Czer LS**, Philip K, Kass R, Schwarz ER. Case of fulminant giant-cell myocarditis associated with polymyositis, treated with biventricular assist device and subsequent heart transplantation. *Heart & Lung* 2011 Jul-Aug; 40: 340-345 (Epub 2011 Mar 21). PMID: 21419487
165. Goland S, Siegel RJ, Burton K, De Robertis MA, Rafique A, Schwarz E, Zivari K, Mirocha J, Trento A, **Czer LS**. Changes in left and right ventricular function of donor hearts during the first year after heart transplantation. *Heart* 2011 Oct; 97: 1681-1686 (Epub 2011 May 17). PMID: 21586422
166. Morrissey RP, **Czer L**, Shah PK. Chronic heart failure: current evidence, challenges to therapy, and future directions. *Am J Cardiovasc Drugs* 2011 Jun; 11: 153-171. PMID: 21619379
167. Morrissey RP, Aronow HU, **Czer LS**. Vehicle safety features, especially airbags, may account for the recent decline in heart donors. *J Heart Lung Transplant* 2011 Sep; 30: 1068-1070 (Epub 2011 May 28). PMID: 21620733
168. **Czer LS**, Ruzza A, Vespignani R, Rafiei M, Pixton JR, Awad M, De Robertis M, Wong AV, Trento A. Prophylaxis of cytomegalovirus disease in mismatched patients after heart transplantation using combined antiviral and immunoglobulin therapy. *Transplantation Proceedings* 2011 Jun; 43: 1887-1892. PMID: 21693295
169. Thompson K, Dhesi P, Nguyen D, **Czer L**, Moriguchi J, Schwarz ER. Evaluation of the HeartMate II left ventricular assist device in obese heart failure patients: Effects on weight loss. *Ann Transplant* 2011 June; 16: 63-67. PMID: 21716188
170. Rana RK, Ghandehari S, Falk JA, Sinsir S, Ghaly AS, Cheng W, Cohen JL, Peng A, **Czer LS**, Schwarz ER, Chaux GE. Successful combined heart-bilateral lung-kidney transplantation from a same donor to treat severe hypertrophic cardiomyopathy with secondary pulmonary hypertension and renal failure: case report and review of the literature. *Transplantation Proceedings* 2011 Sept; 43: 2820 – 2826. PMID: 21911172
171. Schwarz ER, Philip KJ, Sinsir SA, **Czer L**, Trento A, Finder SG, Cleenewerck LA. Maximal care considerations when treating patients with end-stage heart failure: ethical and procedural quandaries in management of the very sick. *J Relig Health* 2011 Dec; 50: 872-879 (Epub 2010 Feb 27). PMID: 20191322

RESEARCH PAPERS - PEER REVIEWED (cont.)

172. Yanagida R, **Czer LSC**, Reinsmoen NL, Cao K, Rafiei M, De Robertis MA, Mirocha J, Kass RM, Kobashigawa J, Trento A. Impact of virtual cross match on waiting times for heart transplantation. *Ann Thorac Surg* 2011 Dec; 92: 2104-2111. PMID: 22115224
173. Daneshvar D, **Czer LSC**, Phan A, Schwarz ER, De Robertis M, Mirocha J, Rafiei M, Pixton JR, Kass RM, Trento A. Heart transplantation in patients aged 70 years and older: a two-decade experience. *Transplantation Proceedings* 2011 Dec; 43: 3851-3856. PMID: 22172859
174. **Czer LSC**, Cohen MH, Gallagher SP, Czer LA, Soukiasian HJ, Rafiei M, Pixton JR, Awad M, Trento A. Exercise performance comparison of bicaval and biatrial orthotopic heart transplant recipients. *Transplantation Proceedings* 2011 Dec; 43: 3857-3862. PMID: 22172860
175. **Czer LSC**, Wong AV, Soukiasian HJ, Gallagher S, De Robertis M, Trento A. Prolonged cold ischemic times and less donor-recipient histocompatibility accelerate graft vascular disease. *Transplantation Proceedings* 2011 Dec; 43: 3863-3868. PMID: 22172861
176. **Czer LSC**, Ruzza A, Vespignani R, Jordan S, De Robertis MA, Mirocha J, Gallagher SP, Patel K, Schwarz ER, Kass RM, Trento A. Survival and allograft rejection rates after combined heart and kidney transplantation in comparison with heart transplantation alone. *Transplantation Proceedings* 2011 Dec; 43: 3869-3876. PMID: 2217286
177. Makkar RR, Smith RR, Cheng K, Malliaras K, Thomson LE, Berman D, **Czer LS**, Marban L, Mendizabal A, Johnston PV, Russell SD, Schuleri KH, Lardo AC, Gerstenblith G, Marban E. Intracoronary cardiosphere-derived cells for heart regeneration after myocardial infarction (CADUCEUS): a prospective, randomised phase 1 trial. *Lancet* 2012 Mar; 379: 895-904 (Epub 2012 Feb 14). PMID: 22336189
178. Vespignani R, Ruzza A, **Czer LSC**, Berci G, Trento A. High definition optical system for microsurgical heterotopic heart transplantation in rats. *Transplantation Proceedings* 2012 Jun; 44: 1404-1406. PMID: 22664024
179. Suviolahti E, Petrosyan A, Mirocha J, Ge S, Karasyov A, Thomas D, Galera O, Lim W, Jimenez A, **Czer LSC**, Chaux G, De Leon J, Pao A, Jordan SC, Toyoda M. Significant reduction of ATP production in PHA-activated CD4+ cells in 1-day-old blood from transplant patients. *Transplantation* 2012 Dec 27; 94: 1243-1249. PMID: 23135604
180. White AJ, Smith RR, Matsushita S, Chakravarty T, **Czer LS**, Burton K, Schwarz ER, Davis DR, Wang Q, Reinsmoen NL, Forrester JS, Marban ER, Makkar R. Intrinsic cardiac origin of cardiosphere-derived cells. *Eur Heart J* 2013 Jan; 34: 68-75 (Epub 2011 June 9). PMID: 21659438
181. **Czer LSC**, Goland S, Soukiasian HJ, Gallagher S, De Robertis MA, Mirocha J, Siegel R, Kass RM, Trento A. Aortic valve replacement or heart transplantation in patients with

RESEARCH PAPERS - PEER REVIEWED (cont.)

- aortic stenosis and severe left ventricular dysfunction. *Transplantation Proceedings* 2013 Jan-Feb; 45: 364-368 (Epub 2012 Sep 19). PMID: 23267804
182. Ruzza A, Vespignani R, Khoynezhad A, Berci G, Robertis MD, Trento A, **Czer LSC**. Concomitant dual intravascular and subcutaneous microsurgical implantation of xenograft tissue in a rodent model for evaluation of structural degeneration. *Transplantation Proceedings* 2013 Mar; 45: 735-740 (Epub 2012 Sep 6). PMID: 23267809
183. Caceres M, **Czer LSC**, Esmailian F, Ramzy D, Moriguchi J. Bariatric surgery in severe obesity and end-stage heart failure with mechanical circulatory support as a bridge to successful heart transplantation: a case report. *Transplantation Proceedings* 2013 Mar; 45: 798-799. PMID: 23498822
184. Caceres M, Cheng W, De Robertis MA, Mirocha J, **Czer L**, Esmailian F, Khoynezhad A, Ramzy D, Kass R, Trento A. Survival and quality of life for nonagenarians after cardiac surgery. *Ann Thorac Surg* 2013 May; 95: 1598-1602 (Epub 2013 Apr 6). PMID: 23566648
185. Yanagida R, **Czer LS**, Ruzza A, Schwarz ER, Simsir SA, Jordan SC, Trento A. Use of ventricular assist device as bridge to simultaneous heart and kidney transplantation in patients with cardiac and renal failure. *Transplantation Proceedings* 2013 Jul-Aug; 45: 2378-2383. PMID: 23953551
186. Perkel D, **Czer LS**, Morrissey RP, Ruzza A, Rafiei M, Awad M, Patel J, Kobashigawa JA. Heart transplantation for end-stage heart failure due to cardiac sarcoidosis. *Transplantation Proceedings* 2013 Jul-Aug; 45: 2384-2386. PMID: 23953552
187. **Czer LS**, Phan A, Ruzza A, Rafiei M, Setareh-Shenas S, Caceres M, Awad M, Soliman C, Mirocha J, De Robertis M, Kass RM, Trento A. Antithymocyte globulin induction therapy adjusted for immunologic risk after heart transplantation. *Transplantation Proceedings* 2013 Jul-Aug; 45: 2393-2398. PMID: 23953554
188. Ruzza A, **Czer LSC**, Trento A, Esmailian F. Combined heart and kidney transplantation: what is the appropriate surgical sequence? *Interactive CardioVascular and Thoracic Surgery* 2013 Aug; 17: 416-418 (Epub 2013 Apr 24). PMID: 23615433
189. Lin J, Cheng W, **Czer LS**, De Robertis MA, Mirocha J, Ruzza A, Kass RM, Khoynezhad A, Ramzy D, Esmailian F, Trento A. Coronary artery bypass graft surgery using the radial artery as a secondary conduit improves patient survival. *JAHA* 2013 Aug 22; 2: e000266. PMID: 23969224
190. Kransdorf EP, **Czer LS**, Luthringer DJ, Patel JK, Montgomery SP, Velleca A, Mirocha J, Zakowski PC, Zabner R, Gaultier CR, Qvarnstrom Y, Benedict T, Steurer F, Bosserman E, Paddock CD, Rafiei M, Kobashigawa JA. Heart transplantation for Chagas cardiomyopathy in the United States. *Am J Transplant* 2013 Dec; 13: 3262-3268 (Epub 2013 Oct 28). PMID: 24165397

RESEARCH PAPERS - PEER REVIEWED (cont.)

191. Caceres M, **Czer LS**, Esmailian F, Luthringer D, Ramzy D, Moriguchi J. Staged approach to mechanical circulatory support and recovered allograft function after transplantation rejection with cardiogenic shock. *Texas Heart Institute Journal* 2013 Dec; 40: 596-599. (Editorial commentary 600-601). PMID: 24391334
192. Kansara P, **Czer L**, Awad M, Arabia F, Mirocha J, De Robertis M, Moriguchi J, Ramzy D, Kass RM, Esmailian F, Trento A, Kobashigawa J. Heart transplantation with and without prior sternotomy: analysis of the United Network for Organ Sharing database. *Transplantation Proceedings* 2014 Jan-Feb; 46: 249-255. PMID: 24507061
193. Azarbal B, Arbit B, Ramaraj R, Kittleson M, Young A, **Czer L**, Rafiei M, Currier J, Makkar R, Kobashigawa J. Clinical and angiographic outcomes with everolimus eluting stents for the treatment of cardiac allograft vasculopathy. *J Interv Cardiol* 2014 Feb; 27: 73-79 (Epub 2013 Sep 30). PMID: 24118198
194. Cheng K, Malliaras K, Smith RR, Shen D, Sun B, Blusztajn A, Xie Y, Ibrahim A, Aminzadeh MA, Liu W, Li TS, De Robertis MA, Marban L, **Czer LS**, Trento A, Marban E. Human cardiosphere-derived cells from advanced heart failure patients exhibit augmented functional potency in myocardial repair. *JACC Heart Fail* 2014 Feb; 2: 49-61. PMID: 24511463
195. Reinsmoen NL, Lai CH, Mirocha J, Cao K, Ong G, Naim M, Wang Q, Haas M, Rafiei M, **Czer L**, Patel J, Kobashigawa J. Increased negative impact of donor HLA-specific together with non-HLA-specific antibodies on graft outcome. *Transplantation* 2014 Mar 15; 97: 595-601 (Epub 2013 Oct 24). PMID: 24162250
196. Caceres M, Ma Y, Rankin JS, Saha-Chaudhuri P, Englum BR, Gammie JS, Suri RM, Thourani VH, Esmailian F, **Czer LS**, Puskas JD, Svennson LG. Mortality characteristics of aortic root surgery in North America. *Eur J Cardiothorac Surg* 2014 Nov; 46: 887-893 (Epub 2014 Mar 17). PMID: 24639452
197. Kobashigawa J, Zuckermann A, Macdonald P, LePrince P, Esmailian F, Luu M, Mancini D, Patel J, Razi R, Reichenspurner H, Russell S, Segovia J, Smedira N, Stehlik J, Wagner F; Consensus Conference participants (including **Czer LS**). Report from a consensus conference on primary graft dysfunction after cardiac transplantation. *J Heart Lung Transplant*. 2014 Apr; 33: 327-340 (Epub 2014 Mar 5). PMID: 24661451
198. Caceres M, Esmailian F, Moriguchi JD, Arabia FA, **Czer LS**. Mechanical circulatory support in cardiogenic shock following an acute myocardial infarction: a systematic review. *J Card Surg* 2014 Sept; 29: 743-751 (Epub 2014 Aug 1). PMID: 25080837
199. Lee CC, Luthringer DJ, **Czer LSC**. Dobutamine-induced fever and isolated eosinophilic myocarditis in a 66-year-old male awaiting heart transplantation: a case report. *Transplantation Proceedings* 2014 Sept; 46: 2464-2466. PMID: 25242803

RESEARCH PAPERS - PEER REVIEWED (cont.)

200. Awad M, Ruzza A, Mirocha J, Setareh-Shenas S, Pixton JR, Soliman C, **Czer LSC**. Prevalence of hypertension in The Gambia and Sierra Leone, western Africa: a cross-sectional study. *Cardiovasc J Afr* 2014 Nov-Dec; 25: 269-278 (Epub 2014 Sept 29). PMID: 25333811
201. Rafiei M, Kittleson M, Patel J, Osborne A, Chang D, **Czer L**, Reinsmoen N, Esmailian F, Kobashigawa J. Anti-thymocyte gammaglobulin may prevent antibody production after heart transplantation. *Transplantation Proceedings* 2014 Dec; 46: 3570-3574. PMID: 25498091
202. Yanagida R, **Czer LSC**, Mirocha J, Rafiei M, Esmailian F, Moriguchi J, Kobashigawa JA, Trento A. Left ventricular assist device in patients with body mass index greater than 30 as bridge to weight loss and heart transplant candidacy. *Transplantation Proceedings* 2014 Dec; 46: 3575-3579. PMID: 25498092
203. Awad M, Ruzza A, Soliman C, Pinzas J, Marban E, Trento A, **Czer LSC**. Endomyocardial biopsy technique for orthotopic heart transplantation and cardiac stem cell harvesting. *Transplantation Proceedings* 2014 Dec; 46: 3580-3584. PMID: 25498093
204. Ruzza A, **Czer LS**, Ihnken KA, Sasevich M, Trento A, Ramzy D, Esmailian F, Moriguchi J, Kobashigawa J, Arabia F. Combined heart-kidney transplantation after total artificial heart insertion. *Transplantation Proceedings* 2015 Jan-Feb; 47: 210-212 (Epub 2015 Jan 14). PMID: 25596961
205. Awad M, **Czer LSC**, Mirocha J, Ruzza A, Rafiei M, Reich H, De Robertis M, Rihbany K, Pinzas J, Ramzy D, Arabia F, Trento A, Kobashigawa J, Esmailian F. Prior sternotomy increases the mortality and morbidity of adult heart transplantation. *Transplantation Proceedings* 2015 Mar; 47: 485-497. PMID: 25769596
206. Kobashigawa J, Patel J, Azarbal B, Kittleson M, Chang D, **Czer L**, Daun T, Luu M, Trento A, Cheng R, Esmailian F. Randomized pilot trial of gene expression profiling versus heart biopsy in the first year after heart transplant: early invasive attenuation through gene expression trial (EIMAGE). *Circ Heart Fail* 2015 May; 8: 557-564 (Epub 2015 Feb 19). PMID: 25697852
207. Elboudwarej O, Patel JK, Liou F, Rafiei M, Osborne A, Chai W, Kittleson M, **Czer L**, Stern L, Esmailian F, Kobashigawa J. Risk of deep vein thrombosis and pulmonary embolism after heart transplantation: clinical outcomes comparing upper extremity deep vein thrombosis and lower extremity deep vein thrombosis. *Clin Transplant* 2015 Jul; 29: 629-635 (Epub 2015 Jun 16). PMID: 25982188
208. Doering LV, McGuire A, Eastwood JA, Chen B, Bodan RC, **Czer LS**, Irwin MR. Cognitive behavioral therapy for depression improves pain and perceived control in

RESEARCH PAPERS - PEER REVIEWED (cont.)

- cardiac surgery patients. *Eur J Cardiovasc Nurs* 2016 Oct; 15: 417-424 (Epub 2015 June 26). PMID: 26115954
209. Awad M, **Czer LS**, Soliman C, Mirocha J, Ruzza A, Pinzas J, Rihbany K, Chang D, Moriguchi J, Ramzy D, Esmailian F, Kobashigawa J, Arabia F. Prevalence of warfarin genotype polymorphisms in patients with mechanical circulatory support. *ASAIO J* 2015 Jul-Aug; 61: 391-396. PMID: 26125664
210. Reich H, **Czer L**, Bannykh S, De Robertis M, Wolin E, Amersi F, Moriguchi J, Kobashigawa J, Arabia F. Total artificial heart bridge to transplantation for a patient with occult intracardiac malignancy: case report. *Transplantation Proceedings* 2015 Sept; 47: 2291-2294. PMID: 26361702
211. Reich HJ, Chan JL, **Czer LS**, Mirocha J, Annamalai AA, Cheng W, Jordan SC, Chaux G, Ramzy D. Combined lung-kidney transplantation: an analysis of the UNOS/OPTN database. *Am Surgeon* 2015 Oct; 81: 1047-1052. PMID: 26463306
212. Reich H, Ramzy D, **Czer L**, Esmailian F, Moriguchi J, Ihnken K, Yusufali T, D'Attellis N, Arabia F, Annamalai A. Hemodynamic consequences of laparoscopy for patients on mechanical circulatory support. *J Laparoendoscopic & Advanced Surgical Techniques* 2015 Dec; 25: 999-1004 (Epub 2015 Nov 2). PMID: 26523797
213. Reich HJ, Awad M, Ruzza A, DeRobertis MA, Ramzy D, Nissen N, Colquhoun S, Esmailian F, Trento A, Kobashigawa J, **Czer LS**. Combined heart and liver transplantation: the Cedars-Sinai experience. *Transplantation Proceedings* 2015 Nov; 47: 2722 - 2726. PMID: 26680081
214. Reich HJ, Shah A, Azarbal B, Kobashigawa J, Moriguchi J, **Czer L**, Esmailian F. Microaxial flow left ventricular assist device as a bridge to transplantation after LVAD malfunction. *Tex Heart Inst J* 2015 Dec; 42: 572-574. PMID: 26664315
215. Azarbal B, Cheng R, Vanichsarn C, Patel JK, **Czer LS**, Chang DH, Kittleson MM, Kobashigawa JA. Induction therapy with antithymocyte globulin in patients undergoing cardiac transplantation is associated with decreased coronary plaque progression as assessed by intravascular ultrasound. *Circ Heart Failure* 2016 Jan; 9: e002252. PMID: 26747860
216. Vertanous T, **Czer LS**, De Robertis M, Kiankhooy A, Kobashigawa J, Esmailian F, Trento A. Leading efforts to increase organ donation through professionalization of organ procurement organizations and establishment of organ and tissue registries. *Transplantation Proceedings* 2016 Jan-Feb; 48: 10-14. PMID: 26915835
217. Awad M, **Czer LS**, De Robertis MA, Mirocha J, Ruzza A, Rafiei M, Reich H, Trento A, Moriguchi J, Kobashigawa J, Esmailian F, Arabia F, Ramzy D. Adult heart

RESEARCH PAPERS - PEER REVIEWED (cont.)

- transplantation following ventricular assist device implantation: early and late outcomes. *Transplantation Proceedings* 2016 Jan-Feb; 48: 158-166. PMID: 26915862
218. Ruzza A, **Czer LS**, De Robertis M, Luthringer D, Moriguchi J, Kobashigawa J, Trento A, Arabia F. Total artificial heart as bridge to heart transplantation in Chagas cardiomyopathy: case report. *Transplantation Proceedings* 2016 Jan-Feb; 48: 279-281. PMID: 26915885
219. Kobashigawa J, Teuteberg J, Colvin M, Edwards L, Daun T, Luu M, Patel J, Vega JD, Meyer D; forum participants (including **Czer LS**). Proceedings of the AST heart allocation meeting at the American Transplant Congress, Philadelphia, Pennsylvania, May 4, 2015. *Clin Transplant* 2016 May; 30: 641-648 (Epub 2016 Mar 22). PMID: 27000519
220. Kransdorf EP, Fishbein MC, **Czer LS**, Patel JK, Velleca A, Tazelaar HD, Roy RR, Steidley DE, Kobashigawa JA, Luthringer DJ. Pathology of chronic Chagas cardiomyopathy in the United States: a detailed review of 13 cardiectomy cases. *Am J Clin Pathol* 2016 Aug; 146: 191-198 (Epub 2016 July 17). PMID: 27425387
221. Awad M, **Czer LS**, Mirocha J, Ruzza A, De Robertis M, Rafiei M, Reich H, Sasevich M, Rihbany K, Kass R, Kobashigawa J, Arabia F, Trento A, Esmailian F, Ramzy D. Similar mortality and morbidity of orthotopic heart transplantation for patients 70 years of age and older in comparison with younger patients. *Transplantation Proceedings* 2016 Oct; 48(8):2782-2791. PMID 27788818
222. Awad M, **Czer LS**, Hou M, Golshani SS, Goltche M, De Robertis M, Kittleson M, Patel J, Azarbal B, Kransdorf E, Esmailian F, Trento A, Kobashigawa JA. Early denervation and later reinnervation of the heart following cardiac transplantation: a review. *JAHA* 2016 Nov 1; 5 PMID 27802930
223. Volod O, Lam LD, Lin G, Kam C, Kolyouthapong K, Mac J, Mirocha J, Ambrose PJ, **Czer LS**, Arabia FA. Role of thromboelastography platelet mapping and international normalized ratio in defining “normocoagulability” during anticoagulation for mechanical circulatory support devices: a pilot retrospective study. *ASAIO J* 2017 Jan-Feb; 63(1): 24-31(Epub 2016 Sep 20). PMID 27660902
224. Ruan V, **Czer LS**, Awad M, Kittleson M, Patel J, Arabia F, Esmailian F, Ramzy D, Chung J, De Robertis M, Trento A, Kobashigawa JA. Use of anti-thymocyte globulin for induction therapy in cardiac transplantation: a review. *Transplantation Proceedings* 2017 Mar; 49(2): 253-259. PMID: 28219580
225. Awad M, **Czer LS**, Esmailian F, Jordan S, De Robertis M, Mirocha J, Patel J, Chang DH, Kittleson M, Ramzy D, Arabia F, Chung JS, Cohen JL, Trento A, Kobashigawa JA. Combined heart and kidney transplantation: a 23-year experience. *Transplantation Proceedings* 2017 Mar; 49(2):348-353. Doi: 10.1016/j.transproceed.2016.11.040. PMID: 28219597

RESEARCH PAPERS - PEER REVIEWED (cont.)

226. Chan JL, Kobashigawa JA, Reich HJ, Ramzy D, Thottam MM, Yu Z, Aintablian TL, Liou F, Patel JK, Kittleson MM, **Czer LS**, Trento A, Esmailian F. Intermediate outcomes with ex-vivo allograft perfusion for heart transplantation. *J Heart Lung Transplant* 2017 Mar; 36(3): 258-263 (Epub 2016 Aug 20). PMID: 27646064
227. Cheng R, Ramzy D, Azarbal B, Esmailian F, **Czer LS**, Kobashigawa JA, Moriguchi JD. Device strategies for patients in INTERMACS profiles 1 and 2 cardiogenic shock: double bridge with extracorporeal membrane oxygenation and initial implant of more durable devices. *Artif Organs* 2017 Mar; 41(3): 224-232 (Epub 2016 Sep 23). PMID 27658844
228. Chan JL, Kobashigawa JA, Aintablian TL, Li Y, Perry PA, Patel JK, Kittleson MM, **Czer LS**, Zarrini P, Velleca A, Rush J, Arabia FA, Trento A, Esmailian F. Vasoplegia after heart transplantation: outcomes at 1 year. *Interact Cardiovasc Thorac Surg* 2017 Apr 27 (Epub ahead of print). PMID: 28459983.
229. Kobashigawa J, Khush K, Colvin M, Acker M, Van Bakel A, Eisen H, Naka Y, Patel J, Baran DA, Daun T, Luu M, Olymbios M, Rogers J, Jeevanandam V, Esmailian F, Pagani FD, Lima B, Stehlik J; conference participants (including **Czer LS**). Report from the American Society of Transplantation conference on donor heart selection in adult cardiac transplantation in the United States. *Am J Transpl* 2017 May 16; doi: 10.1111/ajt.14354 (Epub ahead of print). PMID 28510318
230. Reich HJ, Morgan J, Arabia F, **Czer L**, Moriguchi J, Ramzy D, Esmailian F, Lam L, Dunhill J, Volod O. Comparative analysis of von Willebrand factor profiles after implantation of left ventricular assist device and total artificial heart. *Journal of Thrombosis and Haemostasis* 2017 Aug; 15: 1620-1624 (Epub 2017 Jul 5) doi: 10.1111/jth.13753 PMID: 28586149.

RESEARCH PAPERS - PEER REVIEWED (in press)

1. Ruzza A, Arabia F, Czer LSC, Esmailian F, Ramzy D, Cheng W, Trento A. Left ventricular remodeling for post-infarction left ventricular aneurysm: a review of the surgical techniques. Texas Heart Institute Journal 2017.

RESEARCH PAPERS - NOT PEER REVIEWED

1. **Czer LSC**, Bateman TM, Gray RJ, Matloff JM. Mitral valve replacement and associated coronary artery disease. *Cardiology Board Review* 1985; 2: 99-110.
2. Bateman TM, **Czer LSC**, Gray RJ, Berman DS, Matloff JM. Value of radionuclide ventriculography for differentiating the causes of cardiac shock early after open-heart surgery. *Cardiology Board Review* 1986; 3: 77-82.
3. Maurer G, **Czer LSC**, Chaux A. Intraoperative Doppler color flow mapping for assessment of valve repair for mitral regurgitation. *Am Coll Cardiol Learning Center Highlights* 1989; 4: 1-6.
4. Baumgartner H, **Czer L**, DeRobertis M, Khan S, Maurer G. Doppler gradients across prosthetic heart valves: limitations and pitfalls. *Am Coll Cardiol Learning Center Highlights* 1992; 7: 1-7.
5. Baumgartner H, **Czer L**, DeRobertis M, Khan S, Maurer G. Normal regurgitation in mechanical valve prostheses: impact on Doppler studies. *Am Coll Cardiol Learning Center Highlights* 1992; 8: 1-6.
6. Baumgartner H, Khan S, DeRobertis M, **Czer L**, Maurer G. Doppler characteristics of normal heart valve prostheses - new insights. *Cardio* 1992; December: 20 - 26.
7. Blanche C, Takkenberg JJM, Quartel A, Nessim S, Cohen M, **Czer LSC**, Matloff JM, Trento A. Long-term results of cardiac transplantation in patients older than 65 years. *J Am Internat Health Council* 1998; 1: 27-28.
8. **Czer LSC**. Cytomegalovirus infection in heart transplantation. *Advances in Heart & Heart Surgery*. June 2011.

REVIEWS

1. **Czer LSC**, Capon SM. Clinical experience in disorders of hemostasis. In: Schmitt BD, Salzman EW, eds: Treatment of disorders of diuresis and hemostasis: Desmopressin. Drug Investigation 1990; 2 (Supp 5): 32-44.

EDITORIALS

1. **Czer LSC**, Matloff JM. Combined valvular and coronary surgery. Chest 1986; 90: 312-314.

LETTERS TO THE EDITOR

1. **Czer LSC**, Gray R, Matloff JM. Postoperative temperatures and ventricular function. J Thorac Cardiovasc Surg 1985; 90: 632-633.
2. **Czer LSC**. Warfarin-related hemorrhage after valve replacement. Am Heart J 1988; 116: 1649-1650.
3. **Czer LS**, Kass RM, Trento A. Why should we repair ischemic mitral regurgitation? (Reply). Ann Thorac Surg 2006; 81: 785-786.
4. Ruzza A, **Czer LSC**. Is gender-specific survival in patients undergoing radial artery grafting influenced by hormone levels? J Thorac Cardiovasc Surg 2013 Jun; 145: 1687-1688.
5. Ruzza A, Trento A, **Czer LSC**. Are different mechanical circulatory support devices important factors maximizing patient survival after heart transplant? Ann Thorac Surg 2013 Oct; 96: 1530-1531.
6. Makkar RR, Smith RR, **Czer LS**, Russell SD, Gerstenblith G, Marban E. Letter regarding article "Cell therapy for heart failure: a comprehensive overview of experimental and clinical studies, current challenges, and future directions". Circ Res 2014 Nov 7; 115 (11): e32.
7. **Czer LSC**, Patel J. Response to letter regarding article "Heart transplantation for end-stage heart failure due to cardiac sarcoidosis". Transplantation Proceedings 2015 Jul-Aug; 47: 2077.

CHAPTERS

1. **Czer LSC**, Matloff J, Gray R, Bateman, T, Chaux A. Mitral valve replacement with coronary artery disease. In: Duran C, Angell WW, Johnson AD, Oury JH, eds. Recent Progress in Mitral Valve Disease. London: Butterworths, 1984; Chapter 24, 304-319.
2. Matloff JM, Chaux, **Czer LSC**, DeRobertis M, Gray RJ. A four year experience with the St. Jude mitral valve prosthesis. In: Ionescu MI, Cohn LH, eds. Mitral Valve Disease. Diagnosis and Treatment. London: Butterworths, 1985: Chapter 18, 233-242.
3. Gray RJ, **Czer LSC**, Chaux A, Bateman TM, DeRobertis M, Matloff JM. Double valve replacement. In: Matloff JM, ed. Cardiac Valve Replacement: Current Status. Boston: Martinus Nijhoff Publishing, 1985; Chapter 13, 99-109.
4. Matloff JM, **Czer LSC**. Cardiac valve replacement in the presence of coronary atherosclerosis. In: Matloff JM, ed. Cardiac Valve Replacement: Current Status. Boston: Martinus Nijhoff Publishing, 1985; Chapter 14, 111-122.
5. Gray RJ, Chaux A, **Czer LSC**, DeRobertis M, Matloff JM. A 60-month experience with the St. Jude Medical prosthesis at Cedars-Sinai Medical Center. In: Matloff JM, ed: Cardiac Valve Replacement: Current Status. Boston: Martinus Nijhoff Publishing, 1985; Chapter 23, 189-193.
6. Gray RJ, Bateman TM, **Czer LSC**, Conklin CM, Matloff JM. Therapeutic role of esmolol in hypertension after cardiac surgery. In: Kaplan JA, ed. Esmolol and the Adrenergic Response to Perioperative Stimuli. New York: Biomedical; Information Corp, 1986:45-52.
7. Chaux A, Matloff JM, **Czer LSC**, DeRobertis MA, Gray RJ. Clinical Results with the St. Jude Medical Valve. In: Starek PJK, ed. Heart Valve Replacement and Reconstruction. Chicago: Year Book Medical Publishers, Inc, 1987; Chapter 15, 191-200.
8. **Czer LSC**, Matloff JM, Chaux A, DeRobertis MA, Stewart ME, Gray RJ. An eight-year experience with the St. Jude valve. In: Rabago G and Cooley D, eds. Heart Valve Replacement: Current Status and Future Trends. Mount Kisco, New York: Futura Publishing Co, Inc., 1987; Chapter 12, 153-166.
9. Gray RJ, **Czer LSC**, Matloff JM. Hydrodynamics of cardiac valve prostheses: Is excellence necessary? In: Indications for Valve Replacement by Age Group, Duran CG, Reul GJ Jr, ed. Boston: Cluwer Academic Publishers, 1988, 231-244.
10. Maurer G, **Czer LSC**. Intraoperative color Doppler for assessment of valvular and congenital heart disease. In: Pohost G, ed. New Concepts in Cardiac Imaging 1989. Chicago: Year Book Medical Publishers, 1989: Vol. 5, Chapter 2, 25-36.
11. **Czer LSC**. Echocardiographic and Doppler evaluation of prosthetic heart valves. In: Maurer G and Mohl W, eds. Echocardiography and Doppler in Cardiac Surgery. Igaku-Shoin Medical Publishers, New York, 1989; Chapter 7, 109-120.

CHAPTERS (cont.)

12. Maurer G, **Czer LSC**. Intraoperative color Doppler assessment of mitral and tricuspid valve repair. In: Maurer G and Mohl W, eds. Echocardiography and Doppler in Cardiac Surgery. Igaku-Shoin Medical Publishers, New York, 1989; Chapter 14, 243-258.
13. Maurer G, **Czer LSC**. Intraoperative Doppler color flow mapping. In: Nanda NC, ed. Textbook of Color Doppler Echocardiography. Lea & Febiger, Philadelphia, 1989; Chapter 24, 258-270.
14. **Czer LSC**. Mediastinal bleeding, blood conservation techniques, and transfusion practices. In: Gray RJ and Matloff JM, eds. Medical Management of the Cardiac Surgical Patient. Williams and Wilkins, Baltimore, 1990; Chapter 17, 187-207.
15. Khan S, **Czer LSC**. Antithrombotic Therapy after Cardiac Surgery. In: Gray RJ and Matloff JM, eds. Medical Management of the Cardiac Surgical patient. Williams and Wilkins, Baltimore, 1990; Chapter 19, 221-232.
16. Khan SS, **Czer LSC**. Follow-up after valve replacement. In: Gray RJ and Matloff JM, eds. Medical management of the Cardiac Surgical Patient. Williams and Wilkins, Baltimore, 1990; Chapter 32, 334-352.
17. Maurer G, **Czer LSC**. Intraoperative Doppler color flow mapping for assessment of valvuloplasty and repair of congenital heart disease. In: Schapira JN and Harold JG, eds. Two-dimensional Echocardiography and Cardiac Doppler, 2nd edition, Williams and Wilkins, Baltimore, 1990; Chapter 8, 157-171.
18. Katz J, **Czer LSC**. Evaluation of prosthetic heart valves. In: Schapira JN and Harold JG, eds. Two-dimensional Echocardiography and Cardiac Doppler, 2nd edition. Williams and Wilkins, Baltimore 1990; Chapter 11, 250-280.
19. **Czer LSC**, Maurer G. Epicardial echocardiography and Doppler color flow mapping in the adult patient. In: De Bruijn N.P. and Clements F.M., eds. Intraoperative Use of Echocardiography. A Society of Cardiovascular Anesthesiologists Monograph. J.B. Lippincott, Philadelphia, 1991; Chapter 9, 157-181.
20. Maurer G and **Czer LSC**. Intraoperative evaluation of mitral regurgitation and assessment of mitral valve repair surgery by Doppler color-flow mapping. Cardiothoracic and Vascular Anesthesia Update. WB Saunders Co, Philadelphia, 1991; Vol. 2, Chapter 6, pp 1-9.
21. **Czer LSC**, Maurer G. Conventional and color Doppler intraoperative echocardiography. In: Nanda NC, ed. Doppler Echocardiography, 2nd edition. Lea and Febiger, Philadelphia, 1993; Chapter 37, pp 427-442.

CHAPTERS (cont.)

22. **Czer LSC**, Siegel RJ, Maurer G, Ritter SB. Transesophageal and epicardial color-flow Doppler echocardiography: surgical repair of valvular, ischemic, and congenital heart disease. In: Kaplan JA, ed. Cardiac Anesthesia, third edition. WB Saunders Co., Philadelphia, 1993; Chapter 12, pp. 386-421.
23. Lau YK, **Czer LSC**. Transesophageal color Doppler echocardiography in surgical repair of valvular and ischemic heart disease. In: Maurer G, ed. Transesophageal Echocardiography. McGraw-Hill Publishers, New York 1994; Chapter 13, pp 235-255.
24. Khan SS, **Czer L**. Management of the postoperative cardiac surgery patient. In: Parillo JE and Bone RC, ed. Critical Care Medicine: Principles of Diagnosis and Management. Mosby-Year Book Inc., St. Louis, 1995; Chapter 33, pp 577-597.
25. Khan SS, Denton TA, **Czer LSC**. Management of the Postoperative Cardiac Surgery Patient. In: Parillo JE and Dellinger RP, ed. Critical Care Medicine: Principles of Diagnosis and Management, Second Edition. WB Saunders Company, New York 2001; Chapter 33, pp 684-701.

BOOKS, MONOGRAPHS, SUPPLEMENTS, AND SPECIAL ISSUES

1. Maurer G, Mohl W, **Czer LSC**, eds. Intraoperative Echocardiography. Echocardiography 1990; 7:177-367.

ABSTRACTS

1. Shoemaker WC, Bland R, **Czer, L.** What are the physiological monitoring goals for critically ill postoperative patients? *Crit Care Med* 1978; 6: 116.
2. Shoemaker WC, Appel P, **Czer LSC**, Bland R, Schwartz S, Hopkins JA. Physiologic pattern of adult respiratory distress syndrome following hemorrhagic and traumatic shock. *Federation Proceedings* 1980; 39: 365.
3. Shoemaker WC, Appel P, **Czer LSC**, Bland R, Schwartz S, Hopkins JA. Pathogenic significance of physiologic patterns in patients with trauma and hemorrhage prior to development of respiratory failure. *Crit Care Med* 1980; 8: 245.
4. Shoemaker WC, Appel P, **Czer LSC**, Bland R. Cardiorespiratory patterns in surviving and nonsurviving patients with ARDS from trauma and hemorrhage. *Crit Care Med* 1980; 8: 245.
5. **Czer L**, Hamer A, Murphy F, Gray R, Bussell J, Mandel WJ, Swan HJC, Matloff J. Atrial pacing after coronary bypass surgery: Effect of temperature. *Clin Res* 1982; 30: 5A.
6. Hamer A, Murphy F, **Czer L**, Gray R, Bussell J, Peter T, Chaux A, Matloff J, Mandel WJ. Supraventricular electrophysiology and catecholamine levels after coronary artery surgery: Relevance to atrial arrhythmias. *Clin Res* 1982; 30: 11A.
7. Bateman T, Gray R, Raymond M, Chaux A, **Czer L**, Matloff J. Acute and chronic arrhythmias and conduction disturbances complicating cardiac operation for the removal of left atrial myxomas. *Chest* 1983; 84: 346.
8. **Czer L**, Gray R, Bateman T, Chaux A, Matloff J. Determinants of survival following mitral valve replacement and coronary revascularization. *Circulation* 1983; 68 (Suppl III): III-319.
9. Bateman T, Conklin C, Weiss M, **Czer L**, Stewart M, Kass R, Matloff J, Gray R. Determinants of early mortality after perioperative myocardial infarction. *Clin Res* 1984; 32: 2A.
10. Bateman T, Conklin C, Weiss M, **Czer L**, Stewart M, Kass R, Matloff J, Gray R. Adverse perioperative outcome in patients with fascicular conduction disturbances: high risk subgroups. *Clin Res* 1984; 32: 2A.
11. Bateman T, **Czer LSC**, Raymond M, Chaux A, Lee M, Matloff J, Berman D, Gray R. Tc-99m RBC wall motion scintigraphy: New utility for detecting occult hemorrhage early after open-heart surgery. *Clin Res* 1984; 32: 2A.
12. Bateman T, Raymond M, **Czer L**, Chaux A, Kass R, Matloff J, Berman D, Gray R. Stenosis severity: Comparative assessment by Tl-201 scintigraphy, angiography, and intracoronary pressure gradients. *Clin Res* 1984; 32: 3A.

ABSTRACTS (cont.)

13. **Czer L**, Bateman T, Chaux A, DeRobertis M, Stewart M, Matloff J, Gray R. High risk subgroups following double valve replacement. Clin Res 1984; 32: 3A.
14. **Czer L**, Chaux A, DeRobertis M, Bateman T, Stewart M, Matloff J, Gray R. A five-year experience with the St. Jude valve. Clin Res 1984; 32: 4A.
15. Bateman T, Conklin C, Weiss M, **Czer L**, Stewart M, Kass R, Matloff J, Gray R. Enhanced perioperative mortality in patients with fascicular conduction disturbances: high risk subgroups. J Am Coll Cardiol 1984; 3: 480.
16. **Czer L**, Chaux A, DeRobertis M, Bateman T, Stewart M, Matloff J, Gray R. The St. Jude valve: A five-year experience. J Am Coll Cardiol 1984; 3: 486.
17. Bateman T, Raymond M, **Czer L**, Chaux A, Kass R, Matloff J, Berman D, Gray R. Stenosis severity: Analysis using Tl-201 scintigraphy and intracoronary pressure gradients. J Am Coll Cardiol 1984; 3: 606.
18. **Czer L**, Weiss M, Bateman T, Pfaff JM, Eigler N, Vas R, Nivatpumin T, Chaux A, Matloff J, Gray R. Streptokinase dissolution of St. Jude valve thrombosis under guidance of digital-enhanced cinefluoroscopy. Chest 1984; 86: 315.
19. Gray RJ, Bateman TM, **Czer LSC**, Conklin CM, Matloff JM. Esmolol - a new ultra short acting beta blocking agent for rapid control of heart rate in postoperative supraventricular tachyarrhythmias. Chest 1984; 86: 320.
20. Weiss M, Pfaff JM, **Czer L**, Vas R, Eigler N, Bateman T, Nivatpumin T, Gray R, Forrester J. Computer enhanced cinefluoroscopy of prosthetic valves: A new non-invasive technique. Circulation 1984; 70 (Suppl II): II-30.
21. Gray R, Bateman T, **Czer L**, Conklin C, Matloff J. Esmolol - a new ultra short acting beta blocking agent for rapid control of heart rate in postoperative supraventricular tachyarrhythmias. Circulation 1984; 70 (Suppl II): II-385.
22. Harold JG, Bateman TM, **Czer LSC**, Chaux A, Matloff JM, Gray RJ. Left ventricular posterior wall rupture complicating mitral valve replacement: relationship to recent infarction. J Am Coll Cardiol 1985; 5: 392.
23. **Czer L**, Gray R, Bateman T, DeRobertis M, Chaux A, Matloff J. Mitral bioprostheses - improved hemodynamic differentiation of pathologic from physiologic stenosis. J Am Coll Cardiol 1985; 5: 459.
24. **Czer L**, Bateman, T, Gray R, Raymond M, Chaux A, Matloff J. DDAVP improves platelet function in patients with prolonged bleeding time and hemorrhage after cardiopulmonary bypass. Chest 1985; 88 (July Special Issue): 36S.

ABSTRACTS (cont.)

25. Tsai TP, Chaux A, Kass R, Lee M, Gray R, **Czer L**, Matloff J. Bypass surgery in septuagenarians and octogenarians. *Chest* 1985; 88 (July Special Issue): 47S.
26. Bateman T, Kass R, Garcia E, Raymond M, Wong C, Gray R, **Czer L**, Matloff J, Berman D. Evaluation of pericardial bleeding by Tc-99m RBC gated equilibrium cardiac scintigraphy. *Chest* 1985; 88 (July Special Issue): 59S.
27. Matloff JM, **Czer LSC**, Chaux A, Gray RJ. Influence of coronary artery disease on results of cardiac valve replacement. *J Cardiovasc Surg* 1985; 26 (Suppl to No. 5): 93.
28. **Czer L**, Bateman T, Gray R, Raymond M, Chaux A, Matloff J, Stewart M. Prospective trial of DDAVP in treatment of severe platelet dysfunction and hemorrhage after cardiopulmonary bypass. *Circulation* 1985; 72 (Suppl III): III-130.
29. Maurer G, **Czer L**, DeRobertis M, Kass R, Lee M, Chaux A, Gray R, Matloff J. Intraoperative Doppler color flow mapping in valvular and congenital heart disease. *Circulation* 1985; 72 (Suppl III): III-206.
30. Ehrich M, Bateman T, Gray R, **Czer L**, Raymond M, Moll J, Matloff JM. Demonstration of pressure gradients in normal coronaries during physiologic flow augmentation. *Clin Res* 1986; 34: 295A.
31. Maurer G, **Czer L**, DeRobertis M, Chaux A, Kass R, Lee M, Matloff J. Color Doppler flow mapping for intraoperative assessment of valvuloplasty and repair of congenital heart disease. *J Am Coll Cardiol* 1986; 7: 2A.
32. Bateman TM, Gray RJ, **Czer LSC**, Raymond MJ, Conklin CM, Maddahi J, Charuzi Y, Lee ME, Matloff JM, Berman DS. Severely depressed left ventricular function: Role of rest-redistribution thallium-201 imaging to predict improvement after coronary bypass. *J Am Coll Cardiol* 1986; 7: 23A.
33. **Czer L**, Maurer G, DeRobertis M, Kass R, Lee M, Chaux A, Matloff J. Utility of intraoperative color Doppler flow imaging after surgical correction of valvular regurgitation. *J Am Coll Cardiol* 1986; 7: 160A.
34. **Czer L**, Bateman T, Gray R, DeRobertis M, Kass R, Chaux A, Matloff J. Impact of coronary artery disease and myocardial revascularization on results of aortic valve replacement. *J Am Coll Cardiol* 1986; 7: 161A.
35. Gray RJ, Bateman TM, **Czer LSC**, Conklin CM, Matloff JM. Esmolol for hypertension early after cardiac surgery. *J Am Coll Cardiol* 1986; 7: 178A.
36. Bateman TM, Gray RJ, **Czer LSC**, Raymond MJ, Conklin CM, Maddahi J, Charuzi Y, Lee ME, Matloff JM, Berman DS. The severely depressed left ventricle in ischemic heart disease: rest-redistribution Tl-201 imaging predicts improvement after revascularization. *J Nucl Med* 1986; 27: 933.

ABSTRACTS (cont.)

37. Tsai TP, Chaux A, Kass R, Lee M, **Czer L**, Conklin C, Gray R, Matloff J. Using internal mammary artery as bypass conduit in septuagenarians - early experience with 66 patients. *Chest* 1986; 89 (June suppl): 464S.
38. Buch M, Tsai TP, **Czer L**, Maurer G, Matloff J. Using color-coded Doppler flow mapping intraoperatively to assess the diagnosis and repair of two patients with post-infarction septal defects. *Chest* 1986; 89 (June Suppl): 464S.
39. Tsai TP, Matloff J, Chaux A, Kass R, Lee M, **Czer L**, Gray R. Combined valve procedure and bypass surgery in septuagenarians and octogenarians - results in 119 patients. *Chest* 1986; 89 (June Suppl): 467S.
40. Maurer G, **Czer L**, Bolger A, DeRobertis M, Blanche C, Ferry D, Fink B, Chaux A. Intraoperative color Doppler flow mapping for repair of congenital heart disease. *Circulation* 1986; 74 (Suppl II): II-37.
41. **Czer LSC**, Maurer G, DeRobertis M, Bolger AF, Kass RM, Lee ME, Blanche C, Chaux A, Matloff JM. Intraoperative evaluation of mitral regurgitation: superiority of Doppler color flow mapping. *Circulation* 1986; 74 (Suppl II): II-394.
42. **Czer LSC**, Bateman TM, Gray RJ, DeRobertis MA, Chaux A, Matloff JM. Reduction in sudden late death by concomitant revascularization after aortic valve replacement. *Clin Res* 1987; 35: 272A.
43. **Czer LSC**, Maurer G, DeRobertis MA, Bolger AF, Gray RJ, Matloff JM. Intraoperative detection and quantitation of mitral regurgitation by Doppler color flow mapping. *Clin Res* 1987; 35: 272A.
44. **Czer LSC**, Maurer G, Lin S-L, Resser K, Bolger A, Matloff JM. Mitral regurgitant jet size by Doppler color flow mapping: influence of afterload. *Clin Res* 1987; 35: 272A.
45. Gray RJ. **Czer L**, Raymond M, Mead C, Matloff JM. High incidence of abnormal findings on multiday transtelephonic ECG monitoring after hospital discharge. *Clin Res* 1987; 35: 282A.
46. Tsai TP, Chaux A, Kass R, Lee M, **Czer L**, Gray R, Matloff J. Experience of using internal mammary artery as bypass conduit in 152 septuagenarians. *Chest* 1987; 92 (August suppl): 55S.
47. Honma H, **Czer L**, Ostrzega E, Sethna D, Don Michael A, Charuzi Y. Role of stress thallium-201 tomography and cine-CT in noninvasive evaluation of coronary artery bypass patients. *Circulation* 1987; 76 (Suppl IV): IV-5.
48. Khan S, **Czer LSC**, Gray RJ, DeRobertis M, Chaux A, Matloff JM. The Gorlin formula revisited: impact of the diastolic filling period on the pressure-flow relationship. *Circulation* 1987; 76 (Suppl IV): IV-90.

ABSTRACTS (cont.)

49. **Czer LSC**, Maurer G, Bolger A, DeRobertis M, Gray RJ, Chaux A, Matloff J. Ischemic mitral regurgitation: comparative evaluation of revascularization vs. repair by Doppler color flow mapping. *Circulation* 1987; 76 (Suppl IV): IV-389.
50. **Czer LSC**, Maurer G, Lin S-L, DeRobertis M, Resser K, Chaux A, Matloff J. Left ventricular afterload: an important determinant of mitral regurgitant jet size by Doppler color flow mapping. *Circulation* 1987; 76 (Suppl IV): IV-449.
51. Lin S-L, **Czer L**, Lai W-Y, Bolger A, Maurer G. Afterload dependence of tricuspid regurgitation severity: color Doppler evaluation. *Circulation* 1987; 76 (Suppl IV): IV-449.
52. Kapur KK, Nanda NC, Fan P-H, Bolger A, **Czer L**, Maurer G. Color Doppler evaluation of acute ventricular septal rupture. *Circulation* 1987; 76 (Suppl IV): IV-527.
53. Khan S, **Czer L**, Gray R, DeRobertis M, Matloff J. A comparison of the Gorlin area and the valve resistance in separating normal from stenotic Hancock mitral valves. *Clin Res* 1988; 36: 109A.
54. Khan S, **Czer L**, Gray R, DeRobertis M, Matloff J. Flow dependent behavior of the Gorlin constant in Hancock mitral valves in vivo. *Clin Res* 1988; 36: 109A.
55. **Czer L**, Maurer G, Khan S, DeRobertis M, Resser K, Chaux A, Matloff JM. Reparative surgery for tricuspid regurgitation: operative and follow-up evaluation by Doppler color flow mapping. *J Am Coll Cardiol* 1988; 11: 3A.
56. Bolger A, **Czer LS**, Friedman A, Kleinman J, DeRobertis M, Chaux A, Maurer G. Intraoperative transesophageal color Doppler imaging: advantages and limitations. *J Am Coll Cardiol* 1988; 11: 217A.
57. Conklin CM, Gray RJ, **Czer LS**, Khan S. Esmolol: an effective adjunct to digoxin for the treatment of rapid atrial fibrillation after cardiac surgery. *Clin Res* 1988; 36: 269A.
58. Gray RJ, **Czer LSC**, Raymond MJ, Mead CN, Matloff JM. Arrhythmia management at home: transtelephonic ECG monitoring after hospitalization. *Clin Res* 1988; 36: 280A.
59. Khan S, **Czer L**, Gray R, DeRobertis M, Matloff J. Flow dependent behavior of the Gorlin constant in Hancock mitral valves. *Clin Res* 1988; 36: 289A.
60. Blanche C, **Czer L**, Chaux A, DeRobertis M, Kass R, Tsai T, Gray R, Matloff J. Long-term results of tricuspid valve surgery. *Chest* 1988; 94 (July suppl): 22S.
61. Khan S, Cheng R, **Czer L**, Gray R, Chaux A, Matloff J. A comparison of the Gorlin, Cannon, Angel, and Hakki equations for the determination of pathologic stenosis in porcine xenografts. *J Am Coll Cardiol* 1989; 13: 123A.

ABSTRACTS (cont.)

62. Kleinman J, **Czer L**, DeRobertis M, Maurer G. Prosthetic mitral regurgitation: improved sensitivity of detection using transesophageal color Doppler. *International Journal of Cardiac Imaging* 1989; 4: 75.
63. Kleinman J, **Czer L**, DeRobertis MA, Chaux A, Maurer G. Transesophageal versus epicardial color Doppler to assess mitral regurgitation in candidates for valve repair or replacement. *International Journal of Cardiac Imaging* 1989; 4: 75.
64. Wong WS, **Czer L**, Blanche C, Grundfest W, Maurer G. Epicardial coronary echo guidance of intraoperative laser angioplasty. *Circulation* 1989; 80 (Suppl II): II-564.
65. Khan SS, Gray R, **Czer LS**, Raymond M, Chaux A, Matloff J. Excess mortality of women undergoing coronary bypass surgery: evidence for referral bias. *Circulation* 1989; 80 (Suppl II): II-627.
66. Khan SS, Nessim S, Gray R, **Czer L**, Tsai P, Matloff J. Long term prognosis of octogenarians undergoing coronary artery bypass surgery. *J Am Coll Cardiol* 1990; 15: 116A.
67. Baumgartner H, Khan S, DeRobertis M, **Czer L**, Maurer G. In vitro comparison of Doppler and catheter derived gradients in St. Jude and Hancock valves. *J Am Coll Cardiol* 1990; 15: 138A.
68. Khan S, Baumgartner H, DeRobertis M, **Czer L**, Maurer G. Flow dependence of Doppler velocities in normal St. Jude valves. *J Am Coll Cardiol* 1990; 15: 140A.
69. Baumgartner H, Khan S, DeRobertis M, **Czer L**, Maurer G. Pressure recovery - a cause of discrepancy between Doppler and catheter gradients in St. Jude valves. *J Am Coll Cardiol* 1990; 15: 153A.
70. **Czer L**. Valve repair surgery: impact of anatomical information on surgical decision-making. *Echocardiography* 1990; 7: 345.
71. Wong WS, **Czer LSC**, Blanche C, Grundfest WS, Maurer G. Epicardial coronary echo guidance of intraoperative excimer laser angioplasty. *Echocardiography* 1990; 7: 367.
72. Tsai TP, Nessim S, Chaux A, Kass RM, Blanche C, Trento A, Khan S, Gray RJ, **Czer L**, Matloff JM. Aortic valve replacement in 75 octogenarians. *Chest* 1990; 98 (Aug Suppl): 40S.
73. Baumgartner H, Khan SS, DeRobertis MA, **Czer LSC**, Maurer G. Doppler assessment of prosthetic valve orifice area: an in vitro study. *Circulation* 1990; 82 (Suppl III): III-16.
74. Baumgartner H, Khan S, DeRobertis M, **Czer L**, Maurer G. Importance of prosthetic valve design on the relationship between Doppler and catheter gradients in vitro. *Circulation* 1990; 82 (Suppl III): III-17.

ABSTRACTS (cont.)

75. Khan SS, Gray RJ, Nessim SA, **Czer LSC**, Chaux A, Matloff JM. Predicting outcome after coronary artery bypass surgery: a multivariate analysis. *Circulation* 1990; 82 (Suppl III): III-294.
76. Jordan S, Trento A, Toyoda M, **Czer LSC**, Galfayan K, Doan D, Blanche C, Fishbein M, Matloff J. Analysis of serum cytokine levels in heart transplant recipients: correlation with stage of allograft rejection (AR). *Clinical Research* 1991; 39: 47A.
77. Baumgartner H, Khan SS, DeRobertis MA, **Czer LSC**, Maurer G. Color Doppler regurgitant characteristics of mechanical valves in vitro. *J Am Coll Cardiol* 1991; 17: 156A.
78. Qiao J-H, Ruan X-M, Trento A, **Czer LSC**, Blanche C, Fishbein MC. Endothelial-leukocyte adhesion molecules are expressed in endocardial infiltrates (Quilty effect) of cardiac allografts. *Circulation* 1991; 84 (Suppl II): II-440.
79. **Czer LSC**, Maurer G, DeRobertis M, Nessim S, Trento A, Blanche C, Raissi S, Kass RM, Chaux A, Matloff JM. Comparative efficacy of ring versus suture annuloplasty for ischemic mitral regurgitation. *Circulation* 1991; 84 (Suppl II): II-577.
80. Tixier D, **Czer LSC**, Barath P, Tuso P, Blanche C, Fishbein M, Cramer D, Trento A. Demonstration and quantification of cytotoxic anti-endothelial cell antibodies during humoral rejection after cardiac transplantation. *J Heart and Lung Transplantation* 1992; 11: 208.
81. Koyyana R, Toyoda M, Wachs K, Trento A, **Czer L**, Fishbein M, Young S, Jordan SC. Significance of antibodies to human vascular endothelial cells in cardiac allograft recipients. *J Heart and Lung Transplantation* 1992; 11(Jan/Feb suppl): 215.
82. **Czer L**, Nessim S, Hodgson K, Barath P, Trento A, Matloff JM, Bateman T, Berman DS. Rest-redistribution thallium scintigraphy in ischemic cardiomyopathy: prediction of survival and improved left ventricular function after revascularization. *J Am Coll Cardiol* 1992; 19: 171A.
83. Ameli S, Kaul S, Arora C, Castro L, Mirea A, **Czer L**, Shah PK. Transient increase in circulating endothelin following cardiac transplantation: relationship to cyclosporine and plasma catecholamines. *Clin Res* 1992; 40: 234A.
84. Pan S-H, **Czer LSC**, Shane R, Rosenthal R. Improved oral cyclosporine absorption with Liqui-E in the early post-transplant period. *Pharmacotherapy* 1992; 12: 256.
85. Tsai TP, Chaux A, Kass R, Blanche C, Trento A, Khan S, Gray R, **Czer L**, Matloff J. Experience of cardiac surgery in 436 octogenarians. *Chest* 1992; 102 (August suppl): 69S.

ABSTRACTS (cont.)

86. Leong HC, Schmidt D, **Czer LSC**, Ren M, Forrester JS, Barath P. Growth factor expression, DNA synthesis, and cellular proliferation after cutting balloon coronary angioplasty. *Circulation* 1992; 86 (Suppl I): I-331.
87. Inducil C, Pepkowitz SH, **Czer L**, Goldfinger D. Objective hemodynamic measurements support the safety of autologous blood donations by patients awaiting heart and lung transplantations. *Transfusion* 1992; 32 (October suppl): 66S.
88. **Czer LSC**, Trento A, Blanche C, Barath P, Admon D, Harasty D, DeRobertis M, Matloff JM. Orthotopic heart transplantation: clinical experience with a new technique. *J Am Coll Cardiol* 1993; 21 (Suppl A): 168A.
89. Tsai T-P, Chau A, Matloff JM, Kass RM, Blanche C, Trento A, Raissi S, Khan S, **Czer LSC**, Chang A, Nessim S. Should cardiac surgery be performed in nonagenarians? *Chest* 1993; 104 (August suppl): 37S.
90. Tyan D, Li VA, **Czer L**, Jordan S. In vivo use of IVIG to reduce HLA cytotoxic antibody and subsequent transplantation with histoincompatible organs. *Human Immunology* 1993; 37(Suppl 1): 114.
91. **Czer L**, Jordan S, Tyan D, Valenza M, Admon D, Barath P, Blanche C, Trento A. Novel approach to treatment of patients with cytotoxic antibodies after heart transplantation: use of intravenous immunoglobulin. *Circulation* 1993; 88(Suppl I): I-94.
92. Bell G, Lones M, **Czer LSC**, Miller JM, Harasty D, Trento A, Fishbein MC. Grade 2 cellular cardiac rejection. Does it exist? *Laboratory Investigation* 1994; 70: 26A.
93. Lones MA, Harasty D, Miller JM, **Czer LSC**, Trento A, Fishbein MC. Humoral rejection in cardiac transplant biopsies. *Laboratory Investigation* 1994; 70: 29A.
94. Khan S, **Czer L**, Baumgartner H, DeRobertis M, Chau A, Matloff J. Is the Bernoulli pressure-velocity relationship correct for St. Jude valves? *J Am Coll Cardiol* 1994; 23 (Feb. special issue): 193A.
95. Ren M, **Czer L**, Aleksic I, Trento A, Blanche C, Barath P. Transfer of human HLA class II alpha chain gene into cultured animal cells. *J Am Coll Cardiol* 1994; 23 (Feb. special issue) 437A.
96. Freimark D, **Czer L**, Admon D, Valenza M, Aleksic I, Barath P, Tixier D, Harasty D, Blanche C, Trento A. Donors with a cocaine history: should they be turned down? *J Heart and Lung Transplantation* 1994; 13 (Jan/Feb suppl): S63.
97. Tixier D, Admon D, **Czer L**, Fishbein M, Chan C, Amador R, Alpert G, Cramer D, Makowka L, Trento A. Transplant atherosclerosis: evidence of humoral rejection in a model of isolated coronary artery transplantation in pigs. *J Heart and Lung Transplantation* 1994; 13 (Jan/Feb suppl): S83.

ABSTRACTS (cont.)

98. Toyoda M, Zhang X-M, Sun Z, **Czer L**, Trento A, Jordan SC. Use of polymerase chain reaction to rapidly detect cytomegalovirus DNA in peripheral blood leukocytes of transplant recipients. *Clin Res* 1994; 42: 83A.
99. Agatep M, Schweiger J, Jordan S, Cohen JL, Trento A, Blanche C, **Czer L**. Improved outcome after combined heart-kidney transplants. *J Am Soc Nephrology* 1994; 5: 992.
100. Toyoda M, **Czer LSC**, Zhang X-M, Sun Z, Trento A, Jordan SC. Polymerase chain reaction for rapid detection of cytomegalovirus DNA in peripheral blood leukocytes of heart transplant recipients. *Circulation* 1994; 90 (Suppl I): I-154.
101. Freimark D, **Czer LSC**, Aleksic I, Barthold C, Trento A, Blanche C, Valenza M, Siegel RJ. Improved left atrial transport and function with orthotopic heart transplantation using bicaval and pulmonary venous anastomoses. *Circulation* 1994; 90 (Suppl I): I-419.
102. Hwang C. Karagueuzian HS, Fishbein MC, **Czer L**, Trento A, Weiss JN, Chen P-S. Demonstration of spiral waves of excitation in human ventricular tissue. *Circulation* 1994; 90 (Suppl I): I-466.
103. Freimark D, **Czer LSC**, Ruan X-M, Aleksic I, Admon D, Blanche C, Trento A, Fishbein MC. Pathogenesis of Quilty lesion in cardiac allografts: relationship to reduced endocardial cyclosporine A. *J Heart and Lung Transplantation* 1995; 14 (January/February suppl): S39.
104. Fredrich R, Toyoda M, **Czer L**, Young S, Galera O, Galfayan K, Trento A, Jordan S. Clinical significance of antibodies to human vascular endothelial cells in cardiac allograft recipients: correlation with type of rejection and cardiac allograft vasculopathy (CAV). *J Heart and Lung Transplant* 1995; 14 (January/February suppl): S58.
105. Aleksic I, **Czer LSC**, Freimark D, Takkenberg JJM, Valenza M, Blanche C, Barath P, Queral CA, Trento A. Total versus standard orthotopic heart transplantation: prolonged ischemic time does not impair resting hemodynamics. *J Am Coll Cardiol* 1995; 25 (February special issue): 141A-142A.
106. Aleksic I, Ren M, **Czer LSC**, Blanche C, Trento A, Mohr FW, Dalichau H, Barath P. Transfer of human HLA class II alpha gene into cultured embryonic chick cardiac myocytes and COS7 tumor cells. *Thoracic and Cardiovascular Surgeon* 1995; 43 (Suppl I): 126.
107. Aleksic I, **Czer LSC**, Freimark D, Takkenberg JJM, Blanche C, Cohen MH, Queral CA, Trento A. Improved resting hemodynamics after total versus standard orthotopic heart transplantation in patients with high preoperative pulmonary vascular resistance. *Eur Heart J* 1995; 16 (Abstract supplement): 210.

ABSTRACTS (cont.)

108. Doering L, Dracup K, Moser DK, **Czer LSC**, Peter CT. Hemodynamic adaptation to orthostatic stress after orthotopic heart transplantation. *Circulation* 1995; 92 (Suppl I): I-10.
109. Aleksic I, **Czer LSC**, Freimark D, Takkenberg JJM, Blanche C, Cohen M, Qeral CA, Trento A. Improved resting hemodynamics after total vs. standard orthotopic heart transplantation in patients with high preoperative pulmonary vascular resistance. *J Am Coll Cardiol* 1996; 27 (February suppl A): 342A.
110. Aleksic I, **Czer LSC**, Freimark D, Takkenberg JJM, Blanche C, Baryalei M, Dalichau H, Trento A. Prolonged ischemic time after total versus standard orthotopic heart transplantation does not impair resting hemodynamics. *Thoracic and Cardiovascular Surgeon* 1996; 44 (Suppl I): 185.
111. Aleksic I, Popov A, Ren M, Dalichau H, **Czer LSC**, Freimark D, Trento A, Blanche C, Barath P. In vivo gene transfer of human HLA class II alpha-chain in rabbit and pig hearts. *Thoracic and Cardiovascular Surgeon* 1996; 44 (Suppl I): 187.
112. Aleksic I, **Czer LSC**, Freimark D, Dalichau H, Baryalei M, Admon D, Blanche C, Trento A. Three different courses of induction immunosuppression with monoclonal antibody OKT3 after heart transplantation. *Cardiovascular Surgery* 1996; 4 (Suppl 1): 160.
113. Doering LV, Dracup KA, Moser DK, **Czer LSC**, Peter CT. Evidence of time dependent autonomic reinnervation following heart transplantation. *Circulation* 1996; 94 (Suppl I): I-13.
114. Ikeda T, Ong JJC, Hwang C, **Czer L**, Trento A, Blanche C, Kass RM, Karagueuzian HS, Chen P-S. Atrial functional reentry induced by a strong premature stimulus in isolated human atria: evidence for an upper limit of vulnerability. *Circulation* 1996; 94 (Suppl I): I-555.
115. Han JB, Fishbein MC, Shintaku P, **Czer L**, Chen LS, Chen P-S. Enhanced nerve sprouting in patients with ventricular arrhythmia after myocardial infarction. *Circulation* 1996;94 (Suppl I): I-606.
116. Wu T-J, Ong JJC, Hwang C, Lee JJ, Fishbein MC, **Czer L**, Trento A, Blanche C, Mandel WJ, Karagueuzian HS, Chen P-S. Generation and maintenance of reentrant wave fronts during ventricular fibrillation in human hearts with dilated cardiomyopathy: role of nonuniform anisotropy. *J Am Coll Cardiol* 1997; 29 (February Suppl A): 4A.
117. Aleksic I, **Czer LSC**, Freimark D, Blanche C, Takkenberg JJM, Baryalei M, Dalichau H, Trento A. Improved resting hemodynamics after total orthotopic heart transplantation with high preoperative pulmonary vascular resistance. *Cardiovascular Surgery* 1997; 5 (Suppl 1): 185.

ABSTRACTS (cont.)

118. Khan S, **Czer L**, Kass R, Fontana G, Raissi S, DeRobertis M, Sandhu M, Trento A. Age, coronary disease, and thromboembolism risk after St. Jude mechanical valve replacement. *J Am College Cardiol* 1998; 31 (Suppl A): 152A.
119. Simonini A, **Czer LSC**, Wang H-M, Trento A, Blanche C, Burdick MD, Strieter RM. Expression of ELR-CXC chemokines are associated with allograft atherosclerosis after human cardiac transplantation and in the rat model. *Circulation* 1998; 98: I-107.
120. Coleman BL, Vredevoe DL, Jordan SC, Brecht LM, **Czer LSC**. Elevated IgA associated with skin test anergy in advanced heart failure. *Circulation* 1998; 98: I-482.
121. Dhar SJ, Cohen MH, Quartel A, Trento A, **Czer LSC**. Comparison of exercise performance in patients with bicaval versus biatrial orthotopic heart transplantation. *Circulation* 1998; 98: I-707.
122. Wu T-J, Yashima M, Doshi R, Kim Y-H, Athill CA, Ong JJC, **Czer L**, Trento A, Blanche C, Kass RM, Garfinkel A, Weiss JN, Fishbein MC, Karagueuzian HS, Chen P-S. Relation between the cellular repolarization characteristics and the critical mass for human ventricular fibrillation. *J Am Coll Cardiol* 1999; 33: 151A.
123. Wong AV, **Czer LSC**, Jordan SC, Blanche C, Nusser P, Harasty D, Mathiasen RA, Sandhu M, Trento A. Prophylaxis of CMV disease in mismatched patients after heart transplant-ation using combined antiviral and immunoglobulin therapy. *J Heart and Lung Transplant* 2000; 19: 66.
124. Wang CK, Wong AV, Wang HM, Qiao JH, **Czer L**, Trento A. Apoptosis via FAS/FAS ligand interaction in lung allograft acute and chronic rejection. *J Heart and Lung Transplant* 2000; 19: 93.
125. Lau SK, **Czer LSC**, Luthringer D. Quilty lesion subclassification in endomyocardial biopsies: value in predicting acute cellular rejection. *Modern Pathology* 2000; 13: 52A.
126. Blanche C, **Czer LSC**, Blanche D, Wong A, Kearney B, Trento A. Combined heart-kidney transplantation with allografts from the same donor. *Cardiovascular Surgery* 2001.
127. Kim DT, Luthringer DJ, Lai AC, Suh G, **Czer L**, Chen LS, Chen P-S, Fishbein MC. Sympathetic nerve sprouting after orthotopic heart transplantation. *PACE* 2003.
128. Puliyananda D, Amet N, Dhawan A, Hilo L, Radha RK, Bunnapradist S, **Czer LSC**, Martin P, Jordan SC, Toyoda M. Heart and liver transplant recipients are at a low risk for polyoma virus BK viremia and nephropathy. *Am J Transplantation* 2003; 3(suppl 5): 510.
129. Soukiasian H, **Czer LSC**, Avital I, Aoki T, Kim Y, Umehara Y, Pass J, Tabrizi R, Magliato K, Fontana G, Cheng W, Demetriou A, Trento A. A novel subpopulation of bone marrow derived myocardial stem cells: potential autologous cell therapy in myocardial infarction. *J Heart and Lung Transplant* 2003; 22: S79.

ABSTRACTS (cont.)

130. Coleman BL, **Czer LSC**, Jordan SC, Mirocha JM, Gillaspie MG, Blanche C, Hickey A, Magliato K, Tyan DB. IL-6 and TNF α cytokine genotypes are associated with acute rejection and lower survival in African American heart transplant recipients. *J Heart and Lung Transplant* 2003; 22: S216.
131. Kobal S, Siegel RJ, **Czer LS**. A portable cardiac ultrasound fits the difficult conditions of developing countries to identify left ventricular hypertrophy in a hypertensive population. *Circulation* 2003; 107: e131-e184.
132. Kim Y, **Czer L**, Soukiasian HJ, Pass J, Trento A. Circulating CD34 antigen-positive cells are increased after acute myocardial infarction and GCSF injection: a potential source of stem cells for myocyte regeneration. *Circulation* 2003; 107: e131-e184.
133. Soukiasian HJ, **Czer LSC**, Avital I, Aoki T, Umehara Y, Demetriou AA, Trento A. Transplantation of a novel sub-population of bone marrow derived cardiac stem cells into rat myocardium. *J Am Coll Surgeons* 2003; 197 (3; suppl): S20.
134. Soukiasian HJ, **Czer LSC**, Nishi GK, McVay C, Chopra RR, Fontana GP, Trento A. Inhibition of graft coronary arteriosclerosis after heart transplantation. *Journal of Cardiovascular Surgery* 2003; 44 (suppl 1 to no. 5): 49.
135. Soukiasian HJ, **Czer LSC**, Nishi GK, McVay C, Chopra RR, Fontana GP, Trento A. Aortic valve replacement in patients with aortic stenosis and severe left ventricular dysfunction: a suitable alternative to transplantation. *Journal of Cardiovascular Surgery* 2003; 44 (suppl 1 to no. 5): 49.
136. Soukiasian HJ, **Czer LSC**, Fontana GP, Nishi GK, Chopra RR, McVay C, Raissi SS, Trento A. Exercise performance with bicaval versus biatrial orthotopic heart transplantation. Which should be performed? *Journal of Cardiovascular Surgery* 2003; 44 (suppl 1 to no. 5): 49.
137. Soukiasian HJ, Wong AV, **Czer LSC**, Lefor ST, Nishi GK, Chopra R, Fontana GP, Demetriou AA, Trento A. Cold ischemic injury and donor-recipient MHC disparity significantly increase post-transplant cardiac graft coronary arteriosclerosis. *J Am Coll Surgeons* 2004; 199 (3; suppl): S25.
138. **Czer LSC**, Trento A, Kass RM, De Robertis M, Blanche C, Raissi S, Fontana G, Cheng W, van Wijk R. Comparison of revascularization alone versus combined revascularization and mitral valve repair for ischemic mitral regurgitation. *Circulation* 2004; 110(suppl III): III-589.

ABSTRACTS (cont.)

139. Kobashigawa JW, Miller LW, Felkner GM, Russel SD, Ewald GA, Zucker M, Goldberg L, Eisen HJ, Rayburn BK, Wagoner LE, Philbin E, Pereira N, Czerska B, Kormos RL, Weston M, Conte J, Hosenpud J, Aaronson K, Hill J, Copeland JG, **Czer L**, Anderson A, et al. 12 Month report of a 3-arm multicenter comparison of tacrolimus (Tac), MMF or Tac/sirolimus (SRL) and steroids vs cyclosporine microemulsion (CyA), MMF and steroids in de novo cardiac transplant recipients. *J Heart and Lung Transplantation* 2005; 24 (supplement): S61.
140. Lee MS, Kapoor N, Jamal F, **Czer L**, Aragon J, Forrester J, Kar S, Dohad S, Kass R, Eigler N, Trento A, Shah PK, Makkar RR. Comparison of coronary artery bypass surgery with percutaneous coronary intervention with drug-eluting stents for unprotected left main coronary artery disease. *Am J Cardiol* 2005; 98 (suppl): 517.
141. Trento A, **Czer LSC**, Goland S, De Robertis M, Mirocha J, Kass RM, Raissi S, Fontana G, Cheng W. Risk factors associated with mortality and re-operation in 252 patients with AVR for congenital bicuspid aortic valve disease. *J Am Coll Cardiol* 2006; 47 (suppl A): 282A.
142. Goland S, **Czer LSC**, Kass RM, Siegel RJ, Mirocha J, De Robertis M, Raissi S, Cheng W, Fontana G, Coleman B, Trento A. Outcomes in cardiac transplant recipients using donor allografts with left ventricular hypertrophy. *J Am Coll Cardiol* 2006; 47 (suppl A): 60A.
143. Coleman BL, **Czer LS**, Jordan SC, Mirocha J, Goland S, Raissi S, Cheng W, Fontana G, Kass RM, Trento A, Tyan DB. Pre-transplant interferon gamma AA genotype predicts lower long-term survival in African and Caucasian-American heart transplant recipients. *J Heart and Lung Transplant* 2006; 25 (suppl): S46.
144. Goland S, **Czer LSC**, Kass RM, Mirocha J, Capelli C, Coleman B, De Robertis M, Raissi S, Cheng W, Fontana G, Trento A. Pre-existing pulmonary hypertension in patients with end-stage heart failure: impact on clinical outcome and hemodynamic follow-up after orthotopic heart transplantation. *J Heart and Lung Transplant* 2006; 25 (suppl): S57.
145. Goland S, **Czer LSC**, Kass RM, De Robertis M, Mirocha J, Coleman B, Capelli C, Raissi S, Cheng W, Fontana G, Trento A. Pre-existing pulmonary hypertension in patients with end-stage heart failure: impact on clinical outcome and hemodynamic follow-up after orthotopic heart transplantation. *J Cardiac Failure* 2006 Aug; 12 (suppl): S48.
146. Wang H, **Czer L**, Trento A. LXR Agonist T1317 Inhibits the Aortic Valve Calcification in ApoE^{-/-} Mice. *J Am Coll Cardiol* 2007 Mar; 49 (suppl A)
147. Goland S, **Czer LSC**, Kass RM, Siegel RJ, Mirocha J, De Robertis M, Lee J, Coleman B, Raissi S, Cheng W, Fontana G, Trento A. Utilization of cardiac allografts with mild or moderate LVH is safe and can expand the donor pool. *J Heart and Lung Transplant* 2007; 26 (suppl): S183.

ABSTRACTS (cont.)

148. **Czer LSC**, Goland S, Kass RM, De Robertis M, Mirocha J, Zivari K, Lee J, Coleman B, Trento A. Induction therapy with Thymoglobulin after heart transplantation: Impact of therapy duration on lymphocyte depletion and recovery, rejection and CMV infection rates. *J Heart and Lung Transplant* 2007; 26 (suppl): S233.
149. Goland S, **Czer LS**, Siegel RJ, Burton K, Naqvi TZ, Zivari K, Rafique A, De Robertis M, Luthringer D, Schwarz E, Kass RM, Trento A. Changes in left and right ventricular structure and function of donor hearts during the first year after heart transplantation using Tissue Doppler Imaging and Myocardial Performance Index. *Circulation* 2007; 116 (suppl II): II-734.
150. Wang H, Goland S, Burton K, **Czer L**, Trento A. MCP-1 blockage inhibits lipoprotein accumulation and valvular calcification in ApoE ^{-/-} mice. *J Am Coll Cardiol* 2008 Mar 11; 51 (suppl A): A276.
151. Colovos C, Coleman B, Reinsmoen N, Cao K, Lai C-H, **Czer L**, Schwarz ER, Simsir SA. Virtual Crossmatch in Heart Transplantation. *J Heart and Lung Transplant* 2009 Feb; 28 (suppl): S88.
152. Cao K, Coleman B, **Czer LS**, Simsir S, Schwarz E, Lai C-H, Ong G, Wang Q, Naim M, Reinsmoen N. No significant impact of HLA specific antibodies (Ab) and donor specific antibodies on heart transplant outcome subsequent to Thymoglobulin induction. *J Heart and Lung Transplant* 2009 Feb; 28 (suppl): S260.
153. Chakravarty T, White AJ, Forrester JS, Mirocha JM, Naik H, Luft U, Kar S, **Czer L**, Fontana G, Trento A, Shah PK, Makkar R. Comparison of coronary artery bypass surgery (CABG) and percutaneous drug-eluting stent implantation (PCI) for treatment of unprotected left main coronary artery (ULMCA) stenosis: 3 year follow-up analysis by propensity score adjustment. *J Am Coll Cardiol* 2009 Mar 10; 53 (suppl A): A34.
154. White AJ, Matsushita S, **Czer LS**, Chakravarty T, Burton K, Schwarz ER, Davis DR, Lee J, Wang Q, Reinsmoen NL, Forrester JS, Marban E, Makkar R. Human cardiosphere-derived adult stem cells originate exclusively from in situ cardiac cells. *J Am Coll Cardiol* 2009 Mar 10; 53 (suppl A): A144.
155. Ruzza A, Vespignani R, **Czer LS**, Jordan S, De Robertis M, Mirocha J, Trento A, Schwarz ER, Simsir S. Long-term survival after combined heart and kidney transplantation is comparable to heart transplantation alone. *Circulation* 2009 Nov; 120 (Suppl 2): S911.
156. Dhesi P, Simsir S, Tehrani F, Daneshvar D, Rafique A, **Czer L**, Schwarz ER. Insertion of left ventricular assist devices as a 'bridge to weight loss' prior to listing for transplantation in obese patients with advanced heart failure. *Circulation* 2009 Nov; 120 (Suppl 2): S844.

ABSTRACTS (cont.)

157. Daneshvar D, Phan A, **Czer L**, De Robertis M, Mirocha J, Schwarz E, Kass RM, Simsir S, Trento A. Heart transplant survival at age 70 and older similar to younger patients. *J Heart Lung Transplant* 2010 Feb; 29: S13.
158. Yanagida R, Ruzza A, Vespignani R, **Czer L**, Schwarz E, Simsir S, Jordan S, Cohen JL, Trento A. Use of ventricular assist device as a bridge to simultaneous heart and kidney transplantation. *J Heart Lung Transplant* 2010 Feb; 29: S14.
159. **Czer LSC**, Coleman B, Simsir S, Schwarz ER, Lai CH, Cao K, Jordan S, Osman A, Jamero G, Phan A, Rafiei M, Reinsmoen N. Desensitization of highly sensitized heart transplant candidates using high-dose intravenous immunoglobulin and rituximab with successful transplantation. *J. Am. Coll. Cardiol.* 2010 Mar 9; 55: A19.E179.
160. Tatischev S, **Czer L**, Kobashigawa J, Luthringer D. Utility of CD68/CD31 vs. CD163/CD31 dual immunostaining techniques to detect antibody mediated rejection in post transplant cardiac biopsies. *Mod Path* 2011 Feb; 24 (Supplement 1): 79A #325.
161. Kittleson M, Patel J, Kawano M, Goldstein Z, Barry O, Schwarz E, **Czer L**, Kobashigawa J. Does Gender Mismatch Increase the Risk of Antibody-Mediated Rejection? *J Am Coll Cardiol* 2011 Mar; 57: E315.
162. Patel J, Azarbal B, Kittleson M, Kawano M, Goldstein Z, Rafiei M, Moradzadeh A, **Czer L**, Kass R, Kobashigawa J. Coronary Angioplasty/Stents for Cardiac Allograft Vasculopathy Does Not Alter Outcome for Heart Transplant Patients with ISHLT CAV2 or CAV3 Disease. *J Heart Lung Transplant* 2011 Apr; 30 (4S): S11.
163. Patel J, Kittleson M, Kawano M, Goldstein Z, Rafiei M, Moradzadeh A, Azarbal B, **Czer L**, Kass R, Kobashigawa J. Hyperlipidemia from Sirolimus: Adverse Impact on Development of Cardiac Allograft Vasculopathy. *J Heart Lung Transplant* 2011 Apr; 30 (4S): S12.
164. Stimpson E, Piponniau L, Patel J, Velleca A, Kawano M, Goldstein Z, Rafiei M, Reinsmoen N, **Czer L**, Esmailian F, Kobashigawa J. Sorting Out the Intricacies of Multiparity Risk on Outcomes after Heart Transplantation. *J Heart Lung Transplant* 2011 Apr; 30 (4S): S27.
165. Kao T, Velleca A, Kittleson MI Piponniau L, Rush J, Kawano M, Goldstein Z, Luthringer D, **Czer L**, Esmailian F, Kobashigawa J. Myth Buster: Does Homogeneous Racial Donor/Recipient Match Improve Outcome after Heart Transplantation? *J Heart Lung Transplant* 2011 Apr; 30 (4S): S27.
166. Kobashigawa J, Patel J, Kittleson M, Velleca A, Kawano M, Moradzadeh A, Goldstein Z, Rafiei M, Dyo J, **Czer L**, Esmailian F. Long-Term Benefit of Renal Sparing Protocols Demonstrate the Lack of Need for Calcineurin Inhibitors. *J Heart Lung Transplant* 2011 Apr; 30 (4S): S54.

ABSTRACTS (cont.)

167. Morrissey RP, **Czer L**, Kittleson M, Patel J, Schwarz E, Jamero G, Kawano MI Rafiei M, Azarbal B, Trento A, Kobashigawa J. Induction vs. Non-Induction in Heart Transplantation: The Controversy Continues. *J Heart Lung Transplant* 2011 Apr; 30 (4S): S56.
168. Patel J, Kawano M, Reed E, Goldstein Z, Rafiei M, Reinsmoen N, Azarbal B, **Czer L**, Trento A, Kobashigawa J. Circulating Antibody after Heart Transplant and Its Association with Poor Outcome: A Prospective Assessment. *J Heart Lung Transplant* 2011 Apr; 30 (4S): S87.
169. Phan A, **Czer L**, Rafiei M, Pixton J, Mirocha J, Schwarz E, De Robertis MA, Coleman B, Luthringer D, Vespignani R, Ruzza A, Yanagida R, Kass R, Trento A. Anti-Thymocyte Globulin Induction Therapy After Heart Transplantation: Impact on Rejection Rates, Survival, and CMV Infection. *J Heart Lung Transplant* 2011 Apr; 30 (4S): S142.
170. Yanagida R, **Czer LSC**, Ruzza A, Vespignani R, Simsir SA, Schwarz ER, De Robertis M, Mirocha J, Coleman B, Runyan C, Jocson R, Olay C, Kass RM, Kobashigawa J, Trento A. Ventricular Assist Device Implantation Provides Opportunity for Significant Weight Loss in Obese Patients with Advanced Heart Failure. *J Heart Lung Transplant* 2011 Apr; 30 (4S): S162.
171. Kittleson M, Patel J, Kawano M, Goldstein Z, Rafiei M, Moradzadeh A, Moriguchi J, **Czer L**, Esmailian F, Kobashigawa J. Challenging the ISHLT Guideline Regarding Switch from Mycophenolate to Sirolimus with Standard Dose Calcineurin Inhibitor. *J Heart Lung Transplant* 2011 Apr; 30 (4S): S182.
172. Kittleson M, Patel J, Esmailian F, Trento A, Kass R, Kawano M, Goldstein Z, Rafiei MI **Czer L**, Hamilton M, Kobashigawa J. Primary Graft Dysfunction: Autopsy Data Sheds Light on Pathogenesis. *J Heart Lung Transplant* 2011 Apr; 30 (4S): S194.
173. Kittleson M, Patel J, Esmailian F, Trento A, Kass R, Kawano M, Goldstein Z, Rafiei M, **Czer L**, Hamilton M, Kobashigawa J. Primary Graft Dysfunction and Autopsy Findings. *Am J Transplant* 2011 Apr; 11 (Supplement 2): 238.
174. Patel J, Azarbal B, Goldstein Z, Rafiei M, Kawano M, Moradzadeh A, Kittleson M, **Czer L**, Trento A, Kobashigawa J. Screening Nuclear Stress Testing as a Prognostic Marker after Heart Transplantation. *Am J Transplant* 2011 Apr; 11 (Supplement 2): 303.
175. Makkar R, Smith RR, Cheng K, Malliaras, Thomson L, Berman D, **Czer L**, Mendizabal A, Johnston PV, Russell S, Lardo A, Gerstenblith G, Marban E. The CADUCEUS (CARDiosphere-Derived aUtologous Stem Cells to Reverse ventricular DySfunction) Trial. *Circulation* 2011.

ABSTRACTS (cont.)

176. Patel J, Shiozaki R, Rafiei, Stern L, Kittleson M, Chang D, **Czer L**, Esmailian F, Kobashigawa J. Application of immunosuppression clinical trial results in reducing the incidence of heart transplant rejection – bridging the new millennium. *J Heart and Lung Transplant* 2012 Apr; 31 (4S): S24.
177. Patel J, Kittleson M, **Czer L**, Rafiei M, Stern L, Patel D, Hage A, Esmailian F, Kobashigawa J. The policy of placing older donors into older recipients: is it worth it? *J Heart and Lung Transplant* 2012 Apr; 31 (4S): S24.
178. **Czer L**, Patel J, Kittleson M, Rafiei M, Stern L, Chang D, Luthringer D, Esmailian F, Kobashigawa J. Consequences of first year rejection after heart transplantation: is the worst yet to come? *J Heart and Lung Transplant* 2012 Apr; 31 (4S): S25.
179. Patel J, Kittleson M, **Czer L**, Rafiei M, Stern L, Esmailian F, Reinsmoen N, Kobashigawa J. Are donor-specific antibodies detected after heart transplantation all bad? *J Heart and Lung Transplant* 2012 Apr; 31 (4S): S35.
180. Coleman B, Patel J, **Czer L**, Mirocha J, Kobashigawa J. Use of Thymoglobulin after heart transplantation: is there a role in African American patients? *J Heart and Lung Transplant* 2012 Apr; 31 (4S): S92.
181. **Czer L**, Patel J, Kittleson M, Rafiei M, Stern L, Esmailian F, Kobashigawa J. Infectious complications of desensitization therapy: is the cure worse than the disease? *J Heart and Lung Transplant* 2012 Apr; 31 (4S): S108.
182. Patel J, Kittleson M, Kansara P, Rafiei M, Stern L, Chang D, Azarbal B, **Czer L**, Esmailian F, Kobashigawa J. Outcomes validation of the new ISHLT cardiac allograft vasculopathy coronary angiogram grading scale. *J Heart and Lung Transplant* 2012 Apr; 31 (4S): S121.
183. **Czer L**, Patel J, Kittleson M, Rafiei M, Stern L, Chang D, Azarbal B, Trento, Kobashigawa J. Distal pruning as an important factor for outcome in the new ISHLT cardiac allograft vasculopathy grading scale. *J Heart and Lung Transplant* 2012 Apr; 31 (4S): S121.
184. Patel J, Kittleson M, Shiozaki R, Rafiei M, Stern L, Azarbal B, **Czer L**, Esmailian F, Kobashigawa J. First-year brain natriuretic peptide (BNP) as a biomarker after heart transplant to predict severity of cardiac allograft vasculopathy (CAV) as per the new ISHLT CAV scale. *J Heart and Lung Transplant* 2012 Apr; 31 (4S): S122.
185. Kobashigawa J, Patel J, Rafiei M, Stern L, Kittleson M, **Czer L**, Esmailian F. Late response to desensitization therapy. *J Heart and Lung Transplant* 2012 Apr; 31 (4S): S158.

ABSTRACTS (cont.)

186. Patel J, Kittleson M, Rafiei M, Stern L, Chang D, **Czer L**, Trento A, Kobashigawa J. Desensitization therapy with immunoglobulin (IVIG) and rituximab for patients awaiting heart transplantation. *J Heart and Lung Transplant* 2012 Apr; 31 (4S): S161.
187. Rafiei M, Patel J, Kittleson M, Patel N, Stern L, Azarbal B, **Czer L**, Trento A, Kobashigawa J. First-year rejection and Cylex scores suggest the importance of acute events in the development of cardiac allograft vasculopathy. *J Heart and Lung Transplant* 2012 Apr; 31 (4S): S168.
188. Stern L, Patel J, Kittleson M, Rafiei M, Dilibero D, Hage A, **Czer L**, Kobashigawa J. Use of generic immunosuppression: does it truly matter? *J Heart and Lung Transplant* 2012 Apr; 31 (4S): S203.
189. Kearney B, Chai W, Patel J, Kittleson M, Rafiei M, Stern L, **Czer L**, Kobashigawa J. Does level of education affect outcome after heart transplantation? *J Heart and Lung Transplant* 2012 Apr; 31 (4S): S203.
190. Patel J, Kittleson M, Rafiei M, Stern L, Patel N, **Czer L**, Esmailian F, Kobashigawa J. Resurgence of photopheresis for recalcitrant cellular and antibody-mediated cardiac allograft rejection. *J Heart and Lung Transplant* 2012 Apr; 31 (4S): S223.
191. **Czer L**, Patel J, Kittleson M, Rafiei M, Stern L, Chang D, Trento A, Kobashigawa J. Combined heart-kidney transplant compared to heart transplant alone may reduce long term development of cardiac allograft vasculopathy. *J Heart and Lung Transplant* 2012 Apr; 31 (4S): S229.
192. Moriguchi J, Patel J, Kittleson M, Rafiei M, Stern L, **Czer L**, Trento A, Kobashigawa J. Older patients with hemodynamic compromise rejection: what happened to immunosenescence? *J Heart and Lung Transplant* 2012 Apr; 31 (4S): S233.
193. **Czer L**, Lee D, Patel J, Kittleson M, Rafiei M, Stern L, Hage A, Esmailian F, Trento A, Kobashigawa J. Tricuspid regurgitation in the 1st year after heart transplant: does it lead to gloom and doom? *J Heart and Lung Transplant* 2012 Apr; 31 (4S): S233.
194. Patel J, Kittleson M, Rafiei M, Stern L, Tang Z, Chang D, Luthringer D, **Czer L**, Trento A, Kobashigawa J. The natural history of biopsy negative rejection after heart transplantation. *J Heart and Lung Transplant* 2012 Apr; 31 (4S): S235.
195. Moriguchi J, Patel J, Kittleson M, Rafiei M, Stern L, Chai W, Chang D, Trento A, **Czer L**, Kobashigawa J. Risk for deep vein thrombosis and pulmonary embolism after heart transplantation: characterization of an old problem. *J Heart and Lung Transplant* 2012 Apr; 31 (4S): S235.
196. Kobashigawa J, Patel J, Kittleson M, Rafiei M, Stern L, **Czer L**, Reinsmoen N, Esmailian F. Anti-HLA DQ antibodies: does strength of antibody result in subsequent greater cardiac allograft vasculopathy? *J Heart and Lung Transplant* 2012 Apr; 31 (4S): S235.

ABSTRACTS (cont.)

197. Kansara P, Kransdorf E, Kittleson M, Patel J, Coleman B, Jamero G, Runyan C, Olay C, Jocson R, **Czer L**, Trento A, Kass R, Esmailian F, Kobashigawa J, Moriguchi J. Improved outcomes in “crash and burn” patients through BiVAD support. *J Heart and Lung Transplant* 2012 Apr; 31 (4S): S267.
198. Chai W, Patel J, Kittleson M, **Czer L**, Rafiei M, Stern L, Esmailian F, Kobashigawa J. Risk for deep vein thrombosis and pulmonary embolism after heart transplantation: Characterization of an old problem. *J Am Coll Cardiol* 2012; 59(13): E922.
199. Perkel D, Patel J, Kittleson M, Chang D, **Czer L**, Esmailian F, Kobashigawa J. CMV infection in the era of tacrolimus/mycophenolate: Is there still an impact to develop cardiac allograft vasculopathy? *J Am Coll Cardiol* 2012; 59(13): E923.
200. Sue E, Patel J, Kittleson M, **Czer L**, Trento A, Esmailian F, Kobashigawa J. Does strict diabetic control after heart transplantation lead to better outcome? *J Am Coll Cardiol* 2012; 59(13): E930.
201. Kai B, Patel J, Kittleson M, **Czer L**, Trento A, Esmailian F, Kobashigawa J. Does persistent first-year low of high cardiac index results in poor outcomes after heart transplantation? *J Am Coll Cardiol* 2012; 59(13): E990.
202. Tadwalkar R, Patel J, Kittleson M, **Czer L**, Kobashigawa J. Consequences of first-year rejection after heart transplantation: Is the worse yet to come? *J Am Coll Cardiol* 2012; 59(13): E992.
203. Patel J, Kittleson M, **Czer L**, Rafiei M, Stern L, Reinsmoen N, Kobashigawa J. Maintenance Immunosuppression and *De Novo* Antibody Production after Heart Transplantation: Does the Choice of Drugs Matter? *Am J Transplant.* 2012; 12 (Suppl 3): 73-74.
204. Patel J, Kittleson M, **Czer L**, Rafiei M, Stern L, Patel DP, Hage A, Esmailian F, Kobashigawa J. The Policy of Placing Older Donors into Older Recipients: Is it Worth it? *Am J Transplant.* 2012; 12 (Suppl 3): 96.
205. Moriguchi J, Kittleson M, Patel J, Coleman B, Jamero G, Runyan C, Olay C, Jocson R, Chang D, **Czer L**, Trento A, Esmailian F, Kobashigawa J. Are Sensitized VAD Patients Similar to Sensitized non-VAD Patients in Terms of Outcome? *Am J Transplant.* 2012; 12 (Suppl 3): 120-121.
206. Patel J, Kittleson M, **Czer L**, Rafiei M, Stern L, Reinsmoen N, Kobashigawa J. Are Donor-Specific Antibodies Detected after Heart Transplant All Bad? *Am J Transplant.* 2012; 12 (Suppl 3): 121.
207. Kobashigawa J, Patel J, Kittleson M, Rafiei M, Stern L, **Czer L**, Reinsmoen N, Esmailian F. Anti-HLA DQ Antibodies: Does Strength of Antibody Result in Subsequent Greater Cardiac Allograft Vasculopathy? *Am J Transplant.* 2012; 12 (Suppl 3): 382.

ABSTRACTS (cont.)

208. Kobashigawa J, Patel J, Rafiei M, Stern L, Kittleson M, **Czer L**, Reinsmoen N, Esmailian F. Late Response to Desensitization Therapy. *Am J Transplant.* 2012; 12 (Suppl 3): 382.
209. Dilibero D, Patel J, Kittleson M, Rafiei M, Stern L, Hage A, **Czer L**, Kobashigawa J. Use of Generic Immunosuppression: Does it Truly Matter? *Am J Transplant.* 2012; 12 (Suppl 3): 384.
210. Rafiei M, **Czer L**, Patel J, Kittleson M, Stern L, Chang D, Esmailian F, Kobashigawa J. Combined Heart-Kidney Transplant Compared to Heart Transplant Alone May Reduce Long Term Development of Cardiac Allograft Vasculopathy. *Am J Transplant.* 2012; 12 (Suppl 3): 384.
211. Kansara P, **Czer L**, Patel J, Kittleson M, Mirocha J, Moriguchi J, Chang D, De Robertis M, Trento A, Kass R, and Kobashigawa J. Prior Cardiac Surgery is a Predictor of Mortality in the First-Year in Heart Transplant Recipients. *Am J Transplant.* 2012; 12 (Suppl 3): 476.
212. Stern L, Patel J, Kobashigawa L, Rafiei M, Velleca A, Kittleson M, **Czer L**, Bairey Merz N, Kobashigawa J. Is Hormone Replacement Therapy (HRT) in Postmenopausal Women Associated with Poor Outcome after Heart Transplantation? *Am J Transplant.* 2012; 12 (Suppl 3): 477.
213. Kransdorf E, **Czer L**, Patel J, Zakowski P, Gaultier C, Zabner R, Chang D, Kittleson M, Kobashigawa J. High Prevalence and Reactivation of Chagas Disease in Heart Transplant Recipients. *Am J Transplant.* 2012; 12 (Suppl 3): 477-478.
214. Moriguchi J, Kansara P, Kransdorf E, Kittleson M, Patel J, Runyan C, Olay C, Jocson R, **Czer L**, Esmailian F, Kobashigawa J. Biventricular Assist Device May be Superior to Left Ventricular Assist Device for Crash and Burn Patients. *Circulation* 2012; 126: A9934.
215. Coleman B, Patel J, **Czer L**, Mirocha J, Kobashigawa J. Thymoglobulin Induction May Confer Survival Benefit in Younger African-American Patients: Review of the United Network for Organ Sharing Database. *Circulation* 2012; 126: A10807.
216. Patel J, Kittleson M, Kansara P, Rafiei M, Stern L, Chang D, Azarbal B, **Czer L**, Esmailian F, Kobashigawa J. The New ISHLT Cardiac Allograft Vasculopathy Coronary Angiogram Grading Scale: Does it Have Prognostic Relevance? *Circulation* 2012; 126: A9717.
217. Kransdorf E, Moriguchi J, Kittleson M, Runyan C, Olay C, Jocson R, **Czer L**, Trento A, Esmailian F, Kobashigawa J. The Use of the Model for End-Stage Liver Disease Score Predicts 90-Day Mortality in Patients Undergoing HeartMate II Implantation. *Circulation* 2012; 126: A9724.

ABSTRACTS (cont.)

218. Lin JC, Cheng W, Kass R, De Robertis MA, Mirocha J, **Czer L**, Trento A. Coronary Bypass Surgery with Radial Artery Graft Improved Survival in the Diabetic Population. *Circulation* 2012; 126: A16991.
219. Rafiei M, Patel J, Kittleson M, Shiozaki R, Stern L, Azarbal B, **Czer L**, Esmailian F, Kobashigawa J. First-Year Brain Natriuretic Peptide as a Biomarker after Heart Transplant Predicts Outcome and Severity of Cardiac Allograft Vasculopathy. *Circulation* 2012; 126: A9890.
220. Tadwalkar R, Kittleson M, Patel J, Moriguchi J, Rafiei M, Osborne A, Chang D, **Czer L**, Esmailian F, Reinsmoen N, Kobashigawa J. Establishing a PRA Threshold to Treat Sensitized Patients Awaiting Heart Transplant in the Era of the Virtual Crossmatch. *J Am College of Cardiology*. 2013; 61(10) Suppl A: 163.
221. Dhiantravan V, Patel J, Kittleson M, Rafiei M, Osborne A, Chang D, **Czer L**, Kobashigawa J. Mycophenolate not Azathioprine with Increased Risk for Skin Cancer after Heart Transplant. *J Am College of Cardiology*. 2013; 61(10) Suppl A: 195.
222. Moradzadeh A, Kittleson M, Patel J, Rafiei M, Osborne A, Chang D, **Czer L**, Kobashigawa J. The Risk of Clostridium Difficile in Heart Transplant Patients on Different Immunosuppression Regimens. *J Am College of Cardiology*. 2013; 61(10) Suppl A: 195.
223. Aaronson A, Kittleson M, Patel J, Rafiei M, Osborne A, Chang D, **Czer L**, Kobashigawa J. Benefit of Tacrolimus/Mycophenolate to Reduce Cardiac Allograft Vasculopathy after Heart Transplantation. *J Am College of Cardiology*. 2013; 61(10) Suppl A: 195.
224. Rafiei M, Kittleson M, Patel J, Osborne A, Chang D, **Czer L**, Reinsmoen N, Kobashigawa J. Anti-thymocyte Gammaglobulin May Prevent Antibody Production after Heart Transplantation. *J Am College of Cardiology*. 2013; 61(10) Suppl A: 196.
225. Geft D, Patel J, Kittleson M, Chang D, Rafiei M, Osborne A, **Czer L**, Esmailian F, Kobashigawa J. Use of Cylex Immune Monitoring Score to Guide Immunosuppression After Heart Transplantation Reduces Infection Risk. *J Am College of Cardiology*. 2013; 61(10) Suppl A: 196.
226. Kansara P, **Czer L**, Patel J, Mirocha J, Kittleson M, De Robertis M, Moriguchi J, Chang D, Ramzy D, Kass R, Esmailian F, Trento A, Kobashigawa J. Early Mortality and Morbidity in Heart Transplant Recipients with Prior History of Cardiac Surgery: Analysis of United Network for Organ Sharing Database. *J Am College of Cardiology*. 2013; 61(10) Suppl A: 196.
227. Song H, Kittleson M, Patel J, Rafiei M, Osborne A, Chang D, Ramzy D, Hage A, **Czer L**, Kobashigawa J. Change in Cylex Scores Predicts Risk for Infection in the First-Year following Heart Transplantation. *J Am College of Cardiology*. 2013; 61(10) Suppl A: 196.

ABSTRACTS (cont.)

228. Patel J, Kittleson M, Rafiei M, Osborne A, Chang D, **Czer L**, Esmailian F, Reinsmoen N, Kobashigawa J. The incidence of circulating antibodies at the time of Pathology Defined Antibody-Mediated Rejection after Heart Transplantation. *J Heart and Lung Transplant*. 2013; 32(4): S20-S21.
229. Kittleson M, Patel J, Rafiei M, Osborne A, Jamero G, Chang D, Azarbal B, **Czer L**, Kobashigawa J. Even Mild Renal Insufficiency is a Risk for Mortality after Heart Transplant. *J Heart and Lung Transplant*. 2013; 32(4): S40.
230. Patel J, Kittleson M, Rafiei M, Osborne A, Chang D, **Czer L**, Kobashigawa J. Proliferation Signal Inhibitors Reduce Severity of Cardiac Allograft Vasculopathy after Heart Transplantation. *J Heart and Lung Transplant*. 2013; 32(4): S50.
231. Patel J, Kittleson M, Rafiei M, Osborne A, Aaronson A, Chang D, Azarbal B, **Czer L**, Moriguchi J, Kobashigawa J. Benefit of Tacrolimus/Mycophenolate to Reduce Cardiac Allograft Vasculopathy after Heart Transplantation. *J Heart and Lung Transplant*. 2013; 32(4): S50.
232. Kobashigawa J, Tadwalkar R, Kittleson M, Patel J, Moriguchi J, Rafiei M, Osborne A, Chang D, **Czer L**, Esmailian F, Reinsmoen N. Establishing a PRA Threshold to treat Sensitized Patients Awaiting Heart Transplant in the Era of the Virtual Crossmatch. *J Heart and Lung Transplant*. 2013; 32(4): S53.
233. Geft D, Patel J, Kittleson M, Chang D, Rafiei M, Osborne A, Hage A, **Czer L**, Esmailian F, Kobashigawa J. Use of Cylex Immune Monitoring Score to Guide Immunosuppression after Heart Transplantation Reduces Infection Risk. *J Heart and Lung Transplant*. 2013; 32(4): S73.
234. Kobashigawa J, Kittleson M, Rafiei M, Osborne A, Chang D, **Czer L**, Ramzy D, Esmailian F, Patel J. Cylex Scores May Predict Risk for Infection in the First Year Following Heart Transplantation. *J Heart and Lung Transplant*. 2013; 32(4): S74.
235. Thottam M, Patel J, Kittleson M, Rafiei M, Osborne A, Velleca A, Piponnier L, Chang D, **Czer L**, Hamilton M, Kobashigawa J. Cardiac Rehabilitation after Heart Transplantation Reduces Development of Cardiac Allograft Vasculopathy. *J Heart and Lung Transplant*. 2013; 32(4): S80.
236. Patel J, Kittleson M, Rafiei M, Osborne A, Chang D, **Czer L**, Reinsmoen N, Trento A, Kobashigawa J. The Development and Impact of *de novo* Circulating Antibodies in Non-Sensitized Patients after Heart Transplantation. *J Heart and Lung Transplant*. 2013; 32(4): S86.
237. Kittleson M, Patel J, Rafiei M, Osborne A, Chang D, Ramzy D, **Czer L**, Reinsmoen N, Kobashigawa J. Pre-Transplant Circulating Antibodies Predict Antibody-Mediated Rejection after Heart Transplant Using the New ISHLT Grading Scale. *J Heart and Lung Transplant*. 2013; 32(4): S87-S88.

ABSTRACTS (cont.)

238. Kransdorf E, Kittleson M, Patel J, Rafiei M, Osborne A, Chang D, **Czer L**, Hage A, Zakowski P, Kobashigawa J. High Rate of Reactivation of Chagas Disease After Heart Transplantation in the United States. *J Heart and Lung Transplant*. 2013; 32(4): S130
239. Kittleson M, Patel J, Rafiei M, Osborne A, Moradzadeh A, Chang D, **Czer L**, Zakowski P, Kobashigawa J. The Development of Clostridium Difficile in Heart Transplant Patients on Different Immunosuppression Regimens. *J Heart and Lung Transplant*. 2013; 32(4): S131
240. Coleman B, Patel J, Mirocha J, **Czer L**, Kobashigawa J. Induction Therapy in African American Heart Transplant Recipients: Analysis of the UNOS Database. *J Heart and Lung Transplant*. 2013; 32(4): S134-S135
241. Kansara P, Patel J, Kittleson M, Rafiei M, Osborne A, Chang D, **Czer L**, Esmailian F, Trento A, Kobashigawa J. Early Mortality and Morbidity in First 60 Days in Adult Heart Transplant Recipients with Prior History of Cardiac Surgery: Analysis of United Network for Organ Sharing database. *J Heart and Lung Transplant*. 2013; 32(4): S162
242. Daun T, Patel J, Kittleson M, Rafiei M, Osborne A, Velleca A, Piponniau L, Chang D, **Czer L**, Hamilton M, Kobashigawa J. Does Regular exercise after heart transplantation have any benefit? Real life experience. *J Heart and Lung Transplant*. 2013; 32(4): S198
243. Piponniau L, Kittleson M, Patel J, Rafiei M, Osborne A, Dhiantravan V, Chang D, **Czer L**, Hage A, Hamilton M, Moriguchi J, Kobashigawa J. Mycophenolate not Azathioprine is Associated with Increased Risk for Skin Cancer after Heart Transplant. *J Heart and Lung Transplant*. 2013; 32(4): S199
244. Phan A, Kittleson M, Patel J, Rafiei M, Osborne A, Chang D, **Czer L**, Ramzy D, Esmailian F, Kobashigawa J. ATG Induction Improves Outcome for Sensitized Patients Who Have Undergone Heart Transplantation. *J Heart and Lung Transplant*. 2013; 32(4): S200
245. Kittleson M, Patel J, Rafiei M, Osborne A, Shiozaki R, Chang D, Moriguchi J, **Czer L**, Kobashigawa J. Failed Prednisone Taper Off after heart transplant: Is there a price to be paid? *J Heart and Lung Transplant*. 2013; 32(4): S200
246. Rush J, Kittleson M, Patel J, Rafiei M, Osborne A, Velleca A, Piponniau L, Chang D, **Czer L**, Kobashigawa J. Men Versus Women: Outcome Differences on Cyclosporine and Tacrolimus. *J Heart and Lung Transplant*. 2013; 32(4): S201
247. Velleca A, Kittleson M, Patel J, Rafiei M, Osborne A, Ngan A, Hage A, Chang D, **Czer L**, Kobashigawa J. Tacrolimus- versus Cyclosporine-induced Diabetes Leads to More Diabetic Complications after Heart Transplantation. *J Heart and Lung Transplant*. 2013; 32(4): S202

ABSTRACTS (cont.)

248. Kobashigawa J, Patel J, Kittleson M, Chang D, **Czer L**, Daun T, Trento A, Esmailian F. Results of a Randomized Trial of Allomap vs. Heart Biopsy in the first year after Heart Transplant: Early Invasive Monitoring Attenuation through Gene Expression Trial. *J Heart and Lung Transplant*. 2013; 32(4): S203
249. Morlend R, Kittleson M, Patel J, Rafiei M, Osborne A, Hage A, Chang D, **Czer L**, Moriguchi J, Trento A, Kobashigawa J. Complications on the Heart Transplant Waiting List is Common: Reducing Wait List Time for Sensitized Patients May Avoid Complications. *J Heart and Lung Transplant*. 2013; 32(4): S208
250. Wei J, Azarbal B, Cheng R, Geft D, Rafiei M, Patel J, **Czer L**, Kobashigawa J. Cardiac Allograft Vasculopathy is Less Frequent in Contemporary Heart Transplant Population. *J Heart and Lung Transplant*. 2013; 32(4): S209-S210
251. Stimpson E, Patel J, Kittleson M, Rafiei M, Osborne A, Lee F, Chang D, Hage A, Ramzy D, **Czer L**, Hamilton M, Kobashigawa J. The Obesity Paradox. *J Heart and Lung Transplant*. 2013; 32(4): S212
252. Kittleson M, Patel J, Rafiei M, Osborne A, Yabuno J, Chang D, Azarbal B, **Czer L**, Hamilton M, Kobashigawa J. Chronic Anemia is Not a Predictor for Poor Outcome after Heart Transplantation. *J Heart and Lung Transplant*. 2013; 32(4): S254-S255
253. Kittleson M, Patel J, Rafiei M, Osborne A, Tittle M, Chang D, **Czer L**, Esmailian F, Trento A, Kobashigawa J. Longer and *Shorter* Hospital Stay after Heart Transplant Both Risk Factors for Suboptimal Outcome. *J Heart and Lung Transplant*. 2013; 32(4): S263
254. Kobashigawa J, Kittleson M, Rafiei M, Osborne A, Chang D, **Czer L**, Reinsmoen N, Patel J. Poor Outcomes In Non-Sensitized Patients Developing de Novo Circulating Antibodies After Heart Transplantation. *Am J Transplant*. 2013; 13 (suppl 5): 70-71
255. Rafiei M, Kittleson M, Patel J, Osborne A, Chang D, **Czer L**, Kobashigawa J. Persistent Asymptomatic C4d Staining in the First Year After Heart Transplantation is a Marker for Cardiac Allograft Vasculopathy. *Am J Transplant*. 2013; 13 (suppl 5): 71
256. Patel J, Kittleson M, Rafiei M, Osborne A, Chang D, **Czer L**, Kobashigawa J. Tacrolimus-Induced Diabetes Compared to Cyclosporine May Lead to More Diabetic Complications Post Heart Transplant. *Am J Transplant*. 2013; 13 (suppl 5): 94
257. Kittleson M, Patel J, Rafiei M, Osborne A, Chang D, **Czer L**, Kobashigawa J. The Role of Cardiac Rehabilitation After Heart Transplantation in the Reduction of Cardiac Allograft Vasculopathy. *Am J Transplant*. 2013; 13 (suppl 5): 452
258. Patel J, Kittleson M, Rafiei M, Osborne A, Chang D, **Czer L**, Kobashigawa J. First Year Mild Renal Insufficiency Associated With Increased Mortality After Heart Transplant. *Am J Transplant*. 2013; 13 (suppl 5): 453

ABSTRACTS (cont.)

259. Patel J, Kittleson M, Rafiei M, Osborne A, Chang D, **Czer L**, Reinsmoen N, Kobashigawa J. The Presence of Circulating Antibodies at The Time of Pathology Defined Antibody-Mediated Rejection After Heart Transplant: Are They Out There? *Am J Transplant.* 2013; 13 (suppl 5): 453-454
260. Osborne A, Patel J, Kittleson M, Rafiei M, Chang D, **Czer L**, Kobashigawa J. Kidney Dialysis After Heart Transplantation: The Short and Long Term Outcomes. *Am J Transplant.* 2013; 13 (suppl 5): 454
261. Patel J, Kittleson M, Rafiei M, Osborne A, Chang D, **Czer L**, Kobashigawa J. Severity of Cardiac Allograft Vasculopathy After Heart Transplant Is Reduced With Proliferation Signal Inhibitors. *Am J Transplant.* 2013; 13 (suppl 5): 454
262. Kobashigawa J, Kittleson M, Rafiei M, Osborne A, Chang D, **Czer L**, Reinsmoen N, Patel J. Comparable Waiting Time for Highly Sensitized Patients Awaiting Heart Transplant Using Desensitization Therapy and the Virtual Crossmatch. *Am J Transplant.* 2013; 13 (suppl 5): 455
263. Patel J, Kittleson M, Rafiei M, Osborne A, Chang D, **Czer L**, Kobashigawa J. Pathology and Clinical Progression of Biopsy Proven pAMR1 After Heart Transplantation. *Am J Transplant.* 2013; 13 (suppl 5): 455
264. Patel J, Kittleson M, Rafiei M, Osborne A, Chang D, **Czer L**, Kobashigawa J. Potential Downfall of Failed Prednisone Wean After Heart Transplant. *Am J Transplant.* 2013; 13 (suppl 5): 457
265. Patel J, Kittleson M, Rafiei M, Osborne A, Chang D, **Czer L**, Kobashigawa J. ATG Induction for Sensitized Patients Who Have Undergone Heart Transplant: Is it Beneficial? *Am J Transplant.* 2013; 13 (suppl 5): 457
266. Kobashigawa J, Patel J, Kittleson M, Chang D, **Czer L**, Daun T, Trento A, Esmalian F. Intravascular Ultrasound (IVUS) Results of a Randomized Trial of Allomap vs. Heart Biopsy in the 1st Year after Heart Transplant. *Am J Transplant.* 2013; 13 (suppl 5): 549
267. Kittleson M, Patel J, Rafiei M, Osborne A, Chang D, Azarbal B, **Czer L**, Esmalian F, Reinsmoen N, Kobashigawa J. Comparison of Maintenance Immunosuppression and de novo Antibody Production in the First-Year After Heart Transplant. *Circulation.* 2013; 128 (22S): A10549
268. Kai B, Reinsmoen N, Yu Z, Liou F, Yabuno J, Patel J, Kittleson M, Hamilton M, Chang D, **Czer L**, Kobashigawa J. Does Anything Work for the Highly Sensitized Patients Awaiting Heart Transplant? *Am Coll Cardiol.* 2014; 63 (12_S)

ABSTRACTS (cont.)

269. Grigorian-Shamajan L, Yu Z, Liou F, Patel J, Kittleson M, Azarbal B, Chang D, **Czer L**, Kobashigawa J. Percutaneous Coronary Intervention versus Medical Therapy for Moderate Coronary Lesions after heart Transplantation: What to do? *Am Coll Cardiol*. 2014; 63 (12_S)
270. Gurudevan S, Arabia F, Esmailian, Ramzy D, **Czer L**, Kobashigawa J, Moriguchi J. The Total Artificial Heart: An Effective Bridge to Transplantation in Patients with Advanced Heart Failure. *Am Coll Cardiol*. 2014; 63 (12_S)
271. Kafi A, Patel J, Kittleson M, Yu Z, Liou F, Yabuno J, Kao T, **Czer L**, Chang DH, Hage A, Ramzy D, Kobashigawa J. Abnormal Pulmonary Function Tests Contraindicate Heart Transplant. *J Heart Lung Transplant*. 2014; 33(4): S141-142
272. Kittleson M, Patel J, Yu Z, Liou F, Aquino A, Velleca A, **Czer L**, Chang DH, Hamilton M, Trento A, Reinsmoen N, Kobashigawa J. Do Redo Heart Transplant Patients Have an Increased Risk of Antibody Development? *J Heart Lung Transplant*. 2014; 33(4): S284
273. Lipson-Altman N, Reinsmoen N, Kittleson M, Luthringer D, Patel J, Liou F, Yu Z, Kearny B, **Czer L**, Chang DH, Ramzy D, Kobashigawa J. Does the Ability for Donor Specific Antibodies to Bind Complement Always Result in C4d Staining in the Endomyocardial Biopsy After Heart Transplant? *J Heart Lung Transplant*. 2014; 33(4): S83
274. Moriguchi J, Arabia F, Patel J, Kittleson M, Yu Z, Liou F, Yabuno J, Chang DH, **Czer L**, Hage A, Ramzy D, Kobashigawa J. Does VAD Placement Reduce Weight in Obese Severe Heart Failure Patients? *J Heart Lung Transplant*. 2014; 33(4): S209
275. Moriguchi J, Arabia F, Jocson R, Patel J, Kittleson M, Liou F, Yu Z, Ernsst W, Hamilton M, Chang DH, **Czer L**, Kobashigawa J. Extracorporeal membrane Oxygenation as a Bridge to Decision for INTERMACS 1 Patients. *J Heart Lung Transplant*. 2014; 33(4): S250-251
276. Stimpson E, Dilibero D, Kittleson M, Patel J, Yu Z, Liou F, Yabuno J, Zakowski P, **Czer L**, Trento A, Esmailian F, Kobashigawa J. Hepatitis B Vaccination Confers an Increased Rate of Transplant for Patients on the Heart Transplant Waiting List. *J Heart Lung Transplant*. 2014; 33(4): S268
277. Sasevich MJ, Esmailian F, Rihbany K, Pouldar T, Yu Z, Liou F, Ramzy D, Arabia F, Trento A, **Czer L**, Hamilton M, Kobashigawa J. Is Pre-Existing Liver Cirrhosis and Fibrosis a Contraindication to Heart Transplantation? *J Heart Lung Transplant*. 2014; 33(4): S157
278. Kobashigawa J, Moriguchi J, Reinsmoen N, Kittleson M, Yu Z, Liou F, Ngan A, Runyan M, Henry H, Chang DH, **Czer L**, Arabia F. Sensitized VADs vs. Sensitized Non-VADs: Is There an Immunological Difference? *J Heart Lung Transplant*. 2014; 33(4): S305

ABSTRACTS (cont.)

279. Yu Z, Patel J, Kittleson M, Liou F, Yabuno J, Jamero G, Chang DH, **Czer L**, Azarbal B, Trento A, Esmailian F, Kobashigawa J. The Risk of Prior Chest Radiation Therapy in Patients Who Undergo Heart Transplantation. *J Heart Lung Transplant*. 2014; 33(4): S170-171
280. Kittleson M, Chehrazi-Raffle A, Patel J, Yu Z, Liou F, Johnson M, Stimpson E, Hage A, Chang DH, **Czer L**, Zakowski P, Kobashigawa J. Toxoplasma Serology Mismatch with Increased Mortality? Clarifying the Literature. *J Heart Lung Transplant*. 2014; 33(4): S179-180
281. Patel J, Kittleson M, Yu Z, Liou F, Yabuno J, Aggarwal C, Kearny B, Chang DH, **Czer L**, Esmailian F, Kobashigawa J. Proliferative Signal Inhibitors and Deep Vein Thrombosis: Is There a Connection? *J Heart Lung Transplant*. 2014; 33(4): S276-277
282. Balasubramanya S, Arabia F, Trento A, Ramzy D, Chang DH, Kittleson M, **Czer L**, Moriguchi J, Kobashigawa J. Extracorporeal Membrane Oxygenation as a Bridge to Recovery, Bridge to Ventricular Assist Device and Bridge to Heart Transplantation: A Retrospective Review of Data From a Single Tertiary Care Institution. *J Heart Lung Transplant*. 2014; 33(4): S78
283. Moriguchi J, Arabia F, Kittleson M, Patel J, Yu Z, Liou F, Ernst W, Huie N, Hage A, Chang D, **Czer L**, Kobashigawa J. Heart Transplantation vs. Ventricular Assist Device as Destination Therapy in Older Patients: Are They Comparable? *Am J Transplant*. 2014; 14(S3): 52
284. Arabia F, Moriguchi, Jocson R, Kittleson M, Patel J, Yu Z, Liou F, Chang D, **Czer L**, Ramzy D, Esmailian F, Kobashigawa J. Single Center Experience of Total Artificial Heart as a Bridge to Heart Transplantation. *Am J Transplant*. 2014; 14(S3): 52
285. Esmailian F, Kobashigawa J, Thottam M, Yu Z, Liou F, Patel J, Kittleson M, **Czer L**, Trento A. Heart in the Box With Good 1-Year Outcome Post Heart Transplantation. *Am J Transplant*. 2014; 14(S3): 58
286. Patel J, Kittleson M, Ramzy D, Yu Z, Liou F, Yabuno J, Arabia F, Moriguchi J, **Czer L**, Kobashigawa J. Perioperative Bleeding Risk of Anti-Platelet Therapy Prior to Heart Transplant. *Am J Transplant*. 2014; 14(S3): 59
287. Liou F, Patel J, Kittleson M, Yu Z, Luu M, Piponniau L, Luthringer D, **Czer L**, Chang D, Hamilton M, Esmailian F, Kobashigawa J. Does Heart-Kidney Transplant Truly Confer Protective Benefits Against Rejection? *Am J Transplant*. 2014; 14(S3):424
288. Rush J, Johnson M, Kao T, Patel J, Liou F, Yu Z, Luu M, Chang D, **Czer L**, Trento A, Esmailian F, Kobashigawa J. Risk of High Risk Donors in Heart Transplantation. *Am J Transplant*. 2014; 14(S3):424

ABSTRACTS (cont.)

289. Patel J, Kittleson M, Moriguchi J, Liou F, Yu Z, Yabuno J, Azarbal B, Chang D, **Czer L**, Kobashigawa J. Cyclosporine vs. Tacrolimus: Which Is a Better Match With Everolimus? *Am J Transplant.* 2014; 14(S3):430
290. Jamero G, Kittleson M, Patel J, Liou F, Yu Z, Dilibergo D, Perry N, Chang D, **Czer L**, Hage A, Esmailian F, Kobashigawa J. Are First Year Mycophenolate Trough Levels Associated With the Subsequent Outcomes After Heart Transplant? *Am J Transplant.* 2014; 14(S3): 432
291. Yabuno J, Patel J, Kittleson M, Yu Z, Liou F, Chang D, **Czer L**, Hamilton M, Trento A, Reinsmoen N, Esmailian F, Kobashigawa J. A Lower Cylex Score May Be a Useful Tool to Prevent the Development of Circulating Antibodies After Heart Transplantation? *Am J Transplant.* 2014; 14(S3):432
292. Moriguchi J, Arabia F, Jocson R, Patel J, Kittleson M, Yu Z, Liou F, Siu M, **Czer L**, Chang D, Trento A, Kobashigawa J. Complicated Ventricular Assist Device Patients With Good Post-Transplant Outcomes Supports 1A Upgrade. *Am J Transplant.* 2014; 14(S3):421
293. Moriguchi J, Arabia F, Jocson R, Kittleson M, Patel J, Yu Z, Liou F, Runyan C, **Czer L**, Chang D, Esmailian F, Kobashigawa J. Tightly Controlled Diabetes By Hemoglobin A1c Does Not Appear to Neutralize the Adverse Effects of Diabetes On Outcomes After Left Ventricular Assist Device Placement. *Am J Transplant.* 2014; 14(S3): 421
294. Arabia F, Moriguchi J, Jocson R, Lee A, Ramzy D, Esmailian F, Liou F, Yu Z, Chang D, Kittleson M, **Czer L**, Kobashigawa J. Freedom Driver With the Total Artificial Heart: A Single Center Experience. *Am J Transplant.* 2014; 14(S3): 422
295. Johnson M, Stimpson E, Piponniau L, Kao T, Kittleson M, Patel J, Liou F, Yu Z, Chang D, **Czer L**, Hamilton M, Esmailian F, Kobashigawa J. The Real Story About Drug Abuse Donor Hearts After Heart Transplant. *Am J Transplant.* 2014; 14(S3): 423
296. Reich H, Awad M, Sasevich M, Nissen N, Colquhoun S, Esmailian F, Trento A, Kobashigawa J, **Czer L**. Combined Heart and Liver Transplantation in a High-Volume Transplant Center: The Cedars-Sinai Experience. *Am J Transplant.* 2014; 14(S3): 424
297. Kobashigawa J, Patel J, Kittleson M, Liou F, Yu Z, Rush J, Stimpson E, Hage A, **Czer L**, Esmailian F. Impact of the 2006 Donor Heart Allocation UNOS Policy Using Median Waitlist Times for Patients Awaiting Heart Transplant. *Am J Transplant.* 2014; 14(S3): 426
298. Yu Z, Kittleson M, Patel J, Liou F, Yabuno J, Piponniau L, Chang D, **Czer L**, Azarbal B, Esmailian F, Kobashigawa J. Moderate Pericardial Effusions After Heart Transplant: Do They Require Proactive Intervention? *Am J Transplant.* 2014; 14(S3): 427

ABSTRACTS (cont.)

299. Kittleson M, Patel J, Liou F, Yu Z, Lipson-Altman N, Parikh A, Velleca A, Chang D, **Czer L**, Hamilton M, Esmailian F, Kobashigawa J. Beta Blockers to Slow Heart Rate for Sinus Tachycardia After Heart Transplantation: Is It Helpful? *Am J Transplant*. 2014; 14(S3): 429
300. Jamero G, Kittleson M, Patel J, Liou F, Yu Z, Dilibergero D, Perry N, Chang D, **Czer L**, Hage A, Esmailian F, Kobashigawa J. Are First Year Mycophenolate Trough Levels Associated With the Subsequent Outcomes After Heart Transplant? *Am J Transplant*. 2014; 14(S3): 432
301. Sachdev E, Patel J, Kittleson M, Liou F, Luu M, Esmailian F, Chang D, **Czer L**, Kobashigawa J. The use of vitamin C and E after heart transplant revisited. *JACC* 2015; 65 (suppl A): A189.
302. Vanichsarn C, Cheng R, Azarbal B, Kittleson M, **Czer L**, Patel J, Kobashigawa J. Antithymocyte globulin induction therapy in cardiac transplantation is associated with decreased coronary plaque progression. *JACC* 2015; 65 (suppl A): A241.
303. Esmailian F, Patel J, Kittleson M, Kao T, Liou F, Siddiqui S, Azarbal B, Chang DH, **Czer L**, Trento A, Kobashigawa J. Shorter Cold Ischemic Time in Older Donors Post-Heart Transplant Appears to be Protective. *J Heart Lung Transplant*. 2015 Apr; 34: S17.
304. Patel J, Reinsmoen N, Kittleson M, Dilibergero D, Liou F, Chang DH, Hamilton M, **Czer L**, Esmailian, Kobashigawa J. Plasmapheresis and Bortezomib for Sensitized Patients Awaiting Heart Transplantation – Worth the Effort? *J Heart Lung Transplant* 2015 Apr; 34: S30-S31.
305. Patel J, Dilibergero D, Kittleson M, Sana S, Liou F, Chang DH, Hage A, **Czer L**, Trento A, Reinsmoen N, Kobashigawa J. Terminal Complement Inhibition for Complement Inhibition for Highly Sensitized Patients Undergoing Heart Transplantation – Doable? *J Heart Lung Transplant* 2015 Apr; 34: S31.
306. Kawano J, Patel J, Kittleson M, Liou F, Wong D, Jamero G, Azarbal B, Chang DH, **Czer L**, Trento A, Kobashigawa J. Rubidium Positron Emission Tomography and Coronary Flow Reserve Predicts Graft Function after Heart Transplant. *J Heart Lung Transplant* 2015 Apr; 34: S48.
307. Kawano J, Kittleson M, Patel J, Azarbal B, Liou F, Siddiqui S, Wong D, Chang DH, Ramzy D, **Czer L**, Kobashigawa J. Do Abnormal Regadenoson Scans Predict Subsequent Poor Outcome? *J Heart Lung Transplant* 2015 Apr; 34: S49.
308. Johnson M, Velleca A, Kittleson M, Patel J, Liou F, Siddiqui S, Aintablian T, Chang DH, Azarbal B, **Czer L**, Esmailian F, Kobashigawa J. Inpatient Rehab for Prolonged Hospital Stay After Heart Transplantation Prevents Hospital Readmissions and Infections. *J Heart Lung Transplant* 2015 Apr; 34: S74.

ABSTRACTS (cont.)

309. Kobashigawa J, Kittleson M, Liou F, Shiozaki R, Siddiqui S, Piponniau L, Geft D, Hamilton M, **Czer L**, Reinsmoen, Patel J. The Time Course of Development of Anti-HLA Antibodies Following Heart Transplantation. *J Heart Lung Transplant* 2015 Apr; 34: S116.
310. Arabia F, Kittleson M, **Czer L**, Hajj J, Passano E, Liou F, Siddiqui S, Chang DH, Kobashigawa J, Moriguchi J. The Risk of Hospital Readmissions Following Mechanical Circulatory Support Placement. *J Heart Lung Transplant* 2015 Apr; 34: S126.
311. Ghafourian K, Patel J, Kittleson M, Passano E, Liou F, Siddiqui S, Yabuno J, Geft D, Chang DH, **Czer L**, Trento A, Kobashigawa J. Does Time on Ventricular Assist Device Compromise Post-Transplant Outcome? *J Heart Lung Transplant* 2015 Apr; 34: S178-S179.
312. Patel J, Vescio R, Kittleson M, Siddiqui S, Liou F, Yabuno J, Piponniau L, Kearney B, Hamilton M, **Czer L**, Kobashigawa J. Single Center Experience with Amyloid Patients in the Current Era of Disease Specific Medications. *J Heart Lung Transplant* 2015 Apr; 34: S184.
313. Kittleson M, Patel J, Liou F, Siddiqui S, Chang DH, Hage A, Hamilton M, **Czer L**, Trento A, Esmailian F, Kobashigawa J. Combined Kidney Transplant in Patients Needing Redo Heart Transplant: Viable Option? *J Heart Lung Transplant* 2015 Apr; 34: S187.
314. McMenamy M, Arabia F, **Czer L**, Kittleson M, Passano E, Liou F, Yabuno J, Chang DH, Esmailian F, Kobashigawa J, Moriguchi J. Breaking the Myth of Obesity as a Contraindication to Continuous Flow Left Ventricular Assist Devices. *J Heart Lung Transplant* 2015 Apr; 34: S193.
315. Reich H, Tcherniantchouk O, Arabia FA, Esmailian F, Ramzy D, Lam LD, Moriguchi J, Dunhill JA, De Robertis MA, **Czer L**. Presence of Multifactorial, Acquired Hypercoagulability After Implantation of Left Ventricular Assist Devices or Total Artificial Hearts. *J Heart Lung Transplant* 2015 Apr; 34: S206.
316. Runyan C, Moriguchi J, Kittleson M, **Czer L**, Passano E, Liou F, Chang DH, Ramzy, Esmailian F, Kobashigawa J, Arabia F. Reliability of the Freedom Driver after Total Artificial Heart Implantation. *J Heart Lung Transplant* 2015 Apr; 34: S207.
317. Runyan C, Arabia F, **Czer L**, Kittleson M, Passano E, Liou F, Yabuno J, Henry H, Chang DH, Kobashigawa J, Moriguchi J. Left Ventricular Assist Device vs. Total Artificial Heart: Which Causes More Cerebrovascular Accidents? *J Heart Lung Transplant* 2015 Apr; 34: S213.
318. Arabia F, **Czer L**, Kittleson M, Passano E, Yabuno J, Liou F, Siddiqui S, Chang DH, Ramzy D, Kobashigawa J, Moriguchi J. Does Gender Make a Difference after Total Artificial Heart Implantation? *J Heart Lung Transplant* 2015 Apr; 34: S219-S220.

ABSTRACTS (cont.)

319. Henry H, Arabia F, Kittleson M, **Czer L**, Passano E, Yabuno J, Siddiqui S, Antifantis E, Chang DH, Kobashigawa J, Moriguchi J. Does the Specific Type of Caregiver Impact Readmission after Mechanical Circulatory Support Device Placement? *J Heart Lung Transplant* 2015 Apr; 34: S230.
320. Stimpson, Kao T, Kim L, Morrison S, Patel J, Kittleson M, Liou F, Siddiqui S, Yabuno J, **Czer L**, Kobashigawa J. Care after Heart Transplant, No One Better Than Family: Wrong. *J Heart Lung Transplant* 2015 Apr; 34: S236.
321. Reich H, Chan JL, **Czer L**, Mirocha J, Annamalai A, Cheng W, Jordan SC, Chaux G, Ramzy D. Combined Lung-Kidney Transplantation: An Analysis of the UNOS/OPTN Database. *J Heart Lung Transplant* 2015 Apr; 34: S247.
322. Rush J, Kittleson M, Patel J, Stimpson E, Kao T, Liou F, Aintablian, Siddiqui S, Chang DH, **Czer L**, Esmailian F, Kobashigawa J. Is There a Risk of Cocaine and Methamphetamine Use in Heart Donors? *J Heart Lung Transplant* 2015 Apr; 34: S276-S277.
323. Kittleson M, Patel J, Liou F, Siddiqui, Yabuno J, Chang DH, Ramzy D, **Czer L**, Esmailian F, Reinsmoen N, Kobashigawa J. Low Level Donor Specific Antibodies at Transplant does not Appear to be Associated with the Development of Cardiac Allograft Vasculopathy after Heart Transplantation. *J Heart Lung Transplant* 2015 Apr; 34: S286.
324. Cheng R, Vanichsarn C, Azarbal B, **Czer L**, Kittleson M, Patel J, Kobashigawa J. Rapid Progression of Allograft Coronary Artery Stenosis is Decreased in Patients Who Received Antithymocyte Globulin Induction at the Time of Transplant. *J Heart Lung Transplant* 2015 Apr; 34: S290.
325. Ghafourian K, Moriguchi J, Kittleson, **Czer L**, Passano E, Liou F, Huie N, Chang DH, Trento A, Arabia F, Kobashigawa J. Drop in Estimated Glomerular Filtration Rate at 1 Year after Heart Transplantation – Concern for Poor Outcome. *J Heart Lung Transplant* 2015 Apr; 34: S292.
326. Liou F, Kittleson M, Patel J, Siddiqui S, Luu M, Kearney B, Ramzy D, Chang DH, **Czer L**, Reinsmoen N, Kobashigawa J. Anti-Human Leukocyte Antigen Antibody Class Affects Outcomes after Heart Transplant. *J Heart Lung Transplant* 2015 Apr; 34: S298-S299.
327. Siddiqui S, Kittleson M, Patel J, Liou F, Aintablian T, Chang DH, Hage A, **Czer L**, Esmailian F, Kobashigawa J. Risk Factors for Hospital Admissions for Rejection Following Heart Transplantation: The Real Story. *J Heart Lung Transplant* 2015 Apr; 34: S299-S300.

ABSTRACTS (cont.)

328. Kumar P, Liou F, Patel J, **Czer L**, Kobashigawa J, Luthringer D. Recurrence of Amyloid in Endomyocardial Biopsies Following Orthotopic Heart Transplantation. *J Heart Lung Transplant* 2015 Apr; 34: S317.
329. Arabia F, **Czer L**, Kittleson M, Passano E, Liou F, Yabuno J, Henry H, Chang DH, Esmailian, Kobashigawa J, Moriguchi J. The Selection Process for the Total Artificial Heart. *Am J Transplant* 2015; 15 (suppl 3).
330. Patel J, Vescio R, Kittleson M, Siddiqui S, Liou F, Yabuno J, Piponniau L, Kearney B, Hamilton M, **Czer L**, Kobashigawa J. Heart Transplant for Amyloid Patients in the Current Era of Bortezomib. *Am J Transplant* 2015; 15 (suppl 3).
331. Velleca A, Kittleson M, Perry N, Patel J, Liou F, Siddiqui S, Rush J, Ramzy D, **Czer L**, Chang DH, Kobashigawa J. Increased Length of Stay after Heart Transplant: What are the Risk Factors? *Am J Transplant* 2015; 15 (suppl 3).
332. Kobashigawa J, Kittleson M, Patel P, Liou F, Siddiqui S, Chang DH, Azarbal B, Ramzy D, **Czer L**, Patel J. Outcome of Renal Sparing Protocol in a Cross-Sectional Analysis after Heart Transplant. *Am J Transplant* 2015; 15 (suppl 3).
333. Stimpson E, Kao T, Kim L, Morrison S, Patel J, Kittleson M, Liou F, Siddiqui S, Yabuno J, **Czer L**, Kobashigawa J. Social Support after Heart Transplant. *Am J Transplant* 2015; 15 (suppl 3).
334. Kawano J, Kittleson M, Patel J, Azarbal B, Liou F, Siddiqui S, Wong D, Chang DH, Ramzy L, **Czer L**, Kobashigawa J. Predictive Value of Regadenoson Scans after Heart Transplant. *Am J Transplant* 2015; 15 (suppl 3).
335. Liou F, Kittleson M, Patel J, Siddiqui S, Luu M, Kearney B, Ramzy D, Chang D, **Czer L**, Reinsmoen N, Kobashigawa J. Effects of Anti-Human Leukocyte Antigen Antibody After Heart Transplantation. *Am J Transplant*. 2015; 15 (suppl 3).
336. Patel J, Reinsmoen N, Kittleson M, Dilibero D, Liou F, Chang DH, Hamilton M, **Czer L**, Esmailian, Kobashigawa J. Outcome of Bortezomib/Plasmapheresis for the Sensitized Patient Awaiting Heart Transplant. *Am J Transplant* 2015; 15 (suppl 3).
337. Patel J, Reinsmoen N, Kittleson M, Velleca A, Dilibero D, Liou F, Chang DH, Hage A, **Czer L**, Esmailian F, Kobashigawa J. Rituximab with Intravenous Immune Globulin in Sensitized Patients Awaiting Heart Transplant: Does it Work? *Am J Transplant* 2015; 15 (suppl 3).
338. Patel J, Dilibero D, Kittleson M, Sana S, Liou F, Chang D, Hage A, **Czer L**, Trento A, Reinsmoen N, Kobashigawa J. The Use of Eculizumab to Treat the Highly Sensitized Patient Awaiting Heart Transplant. *Am J Transplant*. 2015; 15 (suppl 3).

ABSTRACTS (cont.)

339. Jameró G, Moriguchi J, **Czer L**, Kittleson M, Siddiqui S, Liou F, Arman D, Lam L, Chang DH, Zakowski P, Kobashigawa J, Arabia F. Anti-Thymocyte Globulin Induction in Infected Mechanical Circulatory Support Patients: Is it Safe? *Am J Transplant* 2015; 15 (suppl 3).
340. Arabia F, Kittleson M, **Czer L**, Hajj J, Passano E, Liou F, Siddiqui S, Chang DH, Kobashigawa J, Moriguchi J. Assessment of Hospital Readmissions after Mechanical Circulatory Support. *Am J Transplant* 2015; 15 (suppl 3).
341. Henry H, Arabia F, Kittleson M, **Czer L**, Passano E, Yabuno J, Siddiqui, Antifantis E, Chang DH, Kobashigawa J. Type of Caregiver and Outcome after Mechanical Circulatory Support Placement. *Am J Transplant* 2015; 15 (suppl 3).
342. Kittleson M, Patel J, Liou F, Siddiqui S, Fong A, Johnson M, Chang DH, **Czer L**, Esmailian F, Reinsmoen N, Kobashigawa J. The Effects of Donor Specific Anti-Human Leukocyte Antigen Antibodies Late after Heart Transplantation. *Am J Transplant* 2015; 15 (suppl 3).
343. Kobashigawa J, Kittleson M, Liou F, Siddiqui S, Shiozaki R, Piponniau L, Geft D, Hamilton M, **Czer L**, Reinsmoen N, Patel J. Natural History of Anti- Human Leukocyte Antigen Antibodies After Heart Transplant. *Am J Transplant*. 2015; 15 (suppl 3).
344. Kittleson M, Patel J, Liou F, Siddiqui S, Yabuno J, Chang DH, Ramzy D, **Czer L**, Esmailian F, Reinsmoen N, Kobashigawa J. Is There a Protective Value for Low Level Donor Specific Antibodies to Prevent Cardiac Allograft Vasculopathy after Heart Transplant? *Am J Transplant* 2015; 15 (suppl 3).
345. Patel J, Kittleson M, Siddiqui S, Liou F, Yabuno J, Merchant M, Chang D, Hamilton M, **Czer L**, Kobashigawa J. Does Switching to proliferation Signal Inhibitors Decrease the risk of Developing Subsequent Malignancies in heart Transplant Patients? *Circulation* 2015; 132: A15858.
346. Yabuno J, Patel J, Kittleson M, Luu M, Liou F, Siddiqui S, Chang D, **Czer L**, Hamilton M, Kobashigawa J. Patients with Autoimmune Disease: Not a Contraindication for Heart Transplantation. *Circulation*. 2015; 132: A13688.
347. Yang M, Sana S, Rush J, Aintablian T, Kittleson M, Geft D, **Czer L**, Kobashigawa J. C1q Assay is Not Completely Reliable to Predict a Positive Prospective Cytotoxic Donor-Specific Crossmatch Prior to Heart Transplantation. *J Am Coll Cardiol*. 2016; 67(13): S1375-S1375.
348. Zarrini P, Aintablian T, Kittleson M, Chang D, Geft D, **Czer L**, Kobashigawa J. Anti-Thymocyte Globulin Protects Against Ischemia Reperfusion Injury in the Immediate Post Heart Transplant Period. *J Am Coll Cardiol*. 2016; 67(13): S1452-S1452.

ABSTRACTS (cont.)

349. Kittleson M, Patel J, **Czer L**, Passano E, Aintablian T, Runyan C, Henry H, Chang D, Esmailian F, Moriguchi J, Kobashigawa J. Comparison of 6 Month Hospitalizations in Mechanical Circulatory Support Patients vs Heart Transplant Patients. *J Heart Lung Transplant.* 2016; 35(4): S262
350. Patel J, Kittleson M, **Czer L**, Aintablian T, Johl M, Daun T, Kearney B, Chang D, Azarbal B, Hamilton M, Esmailian F, Kobashigawa J. Does ACE Inhibitor Use in Heart Transplantation Decrease the Development of Cardiac Allograft Vasculopathy? *J Heart Lung Transplant.* 2016; 35(4): S198.
351. Patel J, Kittleson M, **Czer L**, Chang D, Aintablian T, Norris E, Velleca A, Rush J, Stimpson E, Hage A, Trento A, Kobashigawa J. Donor Heart Turn Down, Is It Rational? *J Heart Lung Transplant.* 2016; 35(4): S213.
352. Moriguchi J, **Czer L**, Henry H., Runyan C, Aintablian T, Passano E, Chang D, Geft D, Arabia F. MCS Driveline Infections: Are They Truly Risk Factors for Poor Outcome? *J Heart Lung Transplant.* 2016; 35(4): S257-S258.
353. Kittleson M, Patel J, **Czer L**, Aintablian T, Rodriguez G, Norland K, Perry N, Chang D, Arabia F, Hamilton M, Azarbal B, Kobashigawa J. The Clinical Application of Non-Invasive Assessment of Coronary Flow Reserve via Rubidium in Heart Transplant Patients. *J Heart Lung Transplant.* 2016; 35(4): S198.
354. Kobashigawa J, Patel J, Kittleson M, **Czer L**, Aintablian T, Yang M, Sana S, Rush J, Stimpson E, Geft D, Ramzy D, Reinsmoen N. When a Prospective Crossmatch Is Warranted in the Virtual Crossmatch (VXM) Era. *J Heart Lung Transplant.* 2016; 35(4): S210-S211.
355. Kobashigawa J, Kittleson M, Patel J, Aintablian T, Zarrini P, Lipson A, Kao T, Daun T, Chang D, Trento A, Hage A, **Czer L**. Thymoglobulin Provides Protection Against Ischemia Reperfusion in the Immediate Post-Transplant Period. *J Heart Lung Transplant.* 2016; 35(4): S279.
356. Patel J, Kittleson M, **Czer L**, Aintablian T, Stimpson E, Daun T, Manayan T, Rodriguez G, Chang D, Ramzy D, Kobashigawa J. Chronic Lung Disease Fev1/Fvc < 70% and Primary Graft Dysfunction; a Marker for Prolonged Intubation Immediately Post-Transplantation. *J Heart Lung Transplant.* 2016; 35(4): S298-S299.
357. Neyer J, Kittleson M, Patel J, **Czer L**, Aintablian T, Rodriguez G, Jocson R, Runyan C, Chang D, Moriguchi J, Trento A, Kobashigawa J. Desensitization in Total Artificial Heart Patients. *J Heart Lung Transplant.* 2016; 35(4): S287.
358. Luu M, Patel J, Kittleson M, **Czer L**, Aintablian T, Norland K, Perry N, Chang D, Hamilton M, Geft D, Kobashigawa J. Lower Dose Tacrolimus Monotherapy in Heart Transplant Patients: Is It Safe? *J Heart Lung Transplant.* 2016; 35(4): S289-S280.

ABSTRACTS (cont.)

359. Kittleson M, Patel J, **Czer L**, Aintablian T, Daun T, Johnson M, Chang D, Trento A, Geft D, Kobashigawa J. Outcome of Patients Proceeding to Heart Transplant with Low Level Donor-Specific Antibodies: How Do They Do? *J Heart Lung Transplant*. 2016; 35(4): S281-S282.
360. Kittleson M, Patel J, **Czer L**, Aintablian T, Rodriguez G, Velleca A, Kearney B, Chang D, Hamilton M, Esmailian F, Zhang X, Reinsmoen N, Kobashigawa J. Proliferation Signal Inhibitors Prevent Donor-Specific Antibody Production in Sensitized Patients after Heart Transplantation. *J Heart Lung Transplant*. 2016; 35(4): S281.
361. Moriguchi J, Kittleson M, Patel J, **Czer L**, Aintablian T, Jocson R, Runyan C, Chang D, Azarbal B, Arabia F, Kobashigawa J. Removal of Ventricular Assist Device at the Time of Heart Transplant in Sensitized Patients Results in Reduced Antibody Production. *J Heart Lung Transplant*. 2016; 35(4): S285.
362. Patel J, Kittleson M, **Czer L**, Aintablian T, Sharoff R, Rodriguez G, Kearney B, Perry N, Hage A, Esmailian F, Kobashigawa J. Severity of Hypertension After Heart Transplant: Does it Impact Outcome? *J Heart Lung Transplant*. 2016; 35(4): S295.
363. Patel J, Kittleson M, **Czer L**, Aintablian T, Sharoff R, Kim B, Velleca A, Kearney B, Chang D, Azarbal B, Hamilton M, Trento A, Kobashigawa J. Treatment of Sleep Apnea with Heart Transplantation: Does It Help? *J Heart Lung Transplant*. 2016; 35(4): S285.
364. Runyan C, Henry H, Huie N, Moriguchi J, Kittleson M, **Czer L**, Chang D, Passano E, Aintablian T, Kobashigawa J, Esmailian F, Arabia F. Can Patients with Restrictive Physiology Be Successfully Bridged to Transplant with left Ventricular Support Alone Versus Biventricular Support? *J Heart Lung Transplant*. 2016; 35(4): S383-384.
365. Kittleson M, Patel J, **Czer L**, Aintablian T, Rush J, Johnson M, Chang D, Ramzy D, Geft D, Kobashigawa J. Are Pediatric Donor Hearts Viable in Adult Recipients? *J Heart Lung Transplant*. 2016; 35(4): S59.
366. Patel J, Kittleson M, **Czer L**, Aintablian T, Phan D, Leong D, Rush J, Stimpson E, Chang D, Hage A, Trento A, Kobashigawa J. Prolonged Corrected QT Interval in the Donor Heart: Is There a Risk? *J Heart Lung Transplant*. 2016; 35(4): S60.
367. Stimpson E, Velleca A, Kao T, Kim L, Kittleson M, Patel J, **Czer L**, Chang D, Hamilton M, Ramzy D, Kobashigawa J. Care Giver Support for Heart Transplant: Does the Type of Provider Matter? *J Heart Lung Transplant*. 2016; 2016; 35(4): S146.
368. **Czer LS**, Awad M, De Robertis MA, Mirocha J, Patel J, Chang DH, Kittleson M, Kobashigawa J, Esmailian F, Jordan S, Trento A. Combined Heart and Kidney Transplant: A 23 Year Experience. *J Heart Lung Transplant*. 2016; 35(4): S138-S139.

ABSTRACTS (cont.)

369. Esmailian F, Perry P, Luu M, Patel J, Kittleson M, **Czer L**, Aintablian T, Zarrini P, Velleca A, Rush J, Arabia F, Kobashigawa J. Vasoplegia After Heart Transplantation: Unraveling the Enigma. *J Heart Lung Transplant*. 2016; 35(4): S166-S167.
370. Esmailian F, Chan JL, Reich H, Ramzy D, Thottam M, Aintablian T, Liou F, Patel J, Kittleson M, **Czer LS**, Trento A, Kobashigawa J. Intermediate Outcomes with Ex-Vivo Allograft Perfusion for Heart Transplantation. *J Heart Lung Transplant*. 2016; 35(4): S86-S87.
371. Neyer J, Patel J, Kittleson M, Chang D, Luu M, Aintablian T, Passano E, **Czer L**, Esmailian F, Kobashigawa J. Heart and Kidney Transplants in Patients with Mechanical Circulatory Support: Who Needs a Kidney? *Am J Transplant*. 2016;16 (suppl 3).
372. Patel J, Kittleson M, Chang D, Aintablian T, **Czer L**, Trento A, Kobashigawa J. Outcome of the Various Pathology Grades of Antibody-Mediated Rejection After Heart Transplantation. *Am J Transplant*. 2016;16 (suppl 3).
373. Kittleson M, Patel J, **Czer L**, Velleca A, Aintablian T, Chang D, Esmailian F, Kobashigawa J. Is Donor Methamphetamine Use a Contraindication in Heart Transplantation? *Am J Transplant*. 2016;16 (suppl 3).
374. Kobashigawa J, Kittleson M, **Czer L**, Aintablian T, Passano E, Chang D, Esmailian F, Patel J. Gender Mismatch in the UNOS Heart Transplant Database: Not a Factor in Younger Heart Transplant Patients. *Am J Transplant*. 2016;16 (suppl 3).
375. Arabia F, Kittleson M, **Czer L**, Chang D, Aintablian T, Passano E, Rodriguez G, Runyon C, Kobashigawa J, Moriguchi J. The Largest Single Center Experience with Total Artificial Heart Implantation: Characterization of Outcome. *Am J Transplant*. 2016;16 (suppl 3).
376. Patel J, Kittleson M, Chang D, Aintablian T, Velleca A, Ramzy D, **Czer L**, Kobashigawa J. The Impact of Complement Binding Donor Specific Antibodies in the First Year After Heart Transplantation. *Am J Transplant*. 2016;16 (suppl 3).
377. Mohan R, Patel J, Kittleson M, Chang D, Aintablian T, **Czer L**, Esmailian F, Kobashigawa J. Liver Evaluation for Heart Transplantation: Which Is Better, Noninvasive Scans or Liver Biopsy? *Am J Transplant*. 2016;16 (suppl 3).
378. Chang D, Patel J, Kittleson M, Aintablian T, **Czer L**, Ramzy D, Kobashigawa J. Prednisone Wean After Dual Heart and Kidney Transplantation: Is There a Risk? *Am J Transplant*. 2016;16 (suppl 3).
379. Leong D, Aintablian T, Patel J, Kittleson M, Geft D, **Czer L**, and Kobashigawa J. Angiographic Dye Prior to Combined Heart-Kidney Donation does not Appear to Harm Donor Kidney Function after Transplant. *J Am Coll Cardiol*. 2017; 69(11): 1430

ABSTRACTS (cont.)

380. Barone H, Hajj J, Runyan C, Huie N, Jocson R, Geft D, Passano E, **Czer L**, Moriguchi J, Kobashigawa J, Arabia F. Managing Driveline Repairs in Total Artificial Heart Patients: A Single Center Experience. *J Heart Lung Transplant*, 2017; 36(4), S419.
381. Chang D, Kittleson M, Patel J, Aintablian T, Hamilton M, Geft D, Kransdorf E, **Czer L**, Kobashigawa J, Arabia F, Moriguchi J. Does Socioeconomic Status Impact Outcome Following Mechanical Circulatory Support Device Implantation? *J Heart Lung Transplant*, 2017; 36(4), S435–S436.
382. Chang D, Kittleson M, Patel J, Aintablian T, Levine R, Geft D, Kransdorf E, **Czer L**, Trento A, Esmailian F, Kobashigawa J. Treatment of Primary Graft Dysfunction with Plasmapheresis Improves Outcome. *J Heart Lung Transplant*, 2017;36(4), S147.
383. Cheng R, Ramzy D, Azarbal B, Esmailian F, Geft D, Chang D, Passano E, **Czer L**, Kobashigawa J, Moriguchi J, Arabia, F. Clinical Outcomes of Impella Microaxillary Pumps When Used in Patients with Cardiogenic Shock Bridged Successfully to Durable Mechanical Circulatory Support and Cardiac Transplantation. *J Heart Lung Transplant*, 2017; 36(4), S139.
384. Mohan R, Neyer J, Patel J, Kittleson M, Aintablian T, Levine R, Chang D, **Czer L**, JMoriguchi J, Kobashigawa J, ArabiaF. Pre-Implant Moderate-Severe Fibrosis on Liver Biopsy Predicts Adverse Outcomes After Mechanical Circulatory Support. *The Journal of Heart and Lung Transplantation*, 2017; 36(4), S124–S125.
385. Kransdorf E, Kittleson M, Patel J, Aintablian T, Velleca A, Stimpson E, Geft D, Chang D, **Czer L**, Trento A, Kobashigawa A. Predicted Heart Mass Is the Optimal Metric for Size Matching in Heart Transplantation. *J Heart Lung Transplant*, 2017; 36(4), S113–S114.
386. Patel J, Kittleson M, Aintablian T, Levine R, Curry M, Hage A, Geft D, Chang D, **Czer L**, Ramzy D, Kobashigawa J. Does the New ISHLT Primary Graft Dysfunction (PGD) Grading Scale in Heart Transplantation Predict Outcome? *J Heart Lung Transplant*, 2017; 36(4), S146.
387. Patel J, Kittleson M, Vescio R, Aintablian T, Sharoff R, Levine R, Geft D, Chang D, **Czer L**, Trento A, Kobashigawa J. Transthyretin Amyloid Patients > 70 Years of Age Appear as Good Candidates for Heart Transplantation. *J Heart Lung Transplant*, 2017; 36(4), S387.
388. Sana S, Patel J, Kittleson M, Aintablian T, Rafiei M, Luthringer D, Zhang X, Reinsmoen N, **Czer L** Kobashigawa J. The Incidence of Donor-Specific Antibody in the Presence of Biopsy-Proven Antibody-Mediated Rejection After Heart Transplantation. *J Heart Lung Transplant*, 2017; 36(4), S198.

ABSTRACTS (cont.)

389. Chang D, Kittleson M, Patel J, Aintablian T, Velleca A, Jamero G, Kransdorf E, Geft D, **Czer L**, Esmailian F, Kobashigawa J. Is Tacrolimus/Proliferation Signal Inhibitor (PSI) Comparable to Cyclosporine/PSI After Heart Transplantation? *J Heart Lung Transplant*, 2017; 36(4), S303.
390. Kobashigawa J, Kittleson M, Aintablian T, Azarbal B, Hage A, Kransdorf E, Geft D, Chang D, **Czer L**, Esmailian F, Zhang X, Reinsmoen N, Patel J. Only Persistent Donor Specific Antibodies Are Associated with Subsequent Cardiac Allograft Vasculopathy after Heart Transplantation. *J Heart Lung Transplant*, 2017; 36(4), S292.
391. Patel J, Kittleson M, Aintablian T, Esmailian G, Velleca A, Hage A, Kransdorf E, Geft D, Chang D, **Czer L**, Kobashigawa J. Despite FDA Black Box Warning, Proliferation Signal Inhibitor (PSI) in the First Year with Induction Therapy Appears Safe in Heart Transplant Patients. *J Heart Lung Transplant* 2017; 36(4), S303–S304.
392. Chang D, Kittleson M, Aintablian T, Arakawa L, Jamero G, Geft D, Kransdorf E, **Czer L**, Ramzy D, Kobashigawa J. Side Effects of Proliferation Signal Inhibitors Limit Their Practical Use After Heart Transplantation. *J Heart Lung Transplant*, 2017; 36(4), S301.
393. Moriguchi J, Kittleson M, Patel J, Aintablian T, Kwan J, Kransdorf E, Geft D, Chang D, **Czer L**, Kobashigawa J, Arabia F. Combined Heart-Kidney Transplant vs Heart Alone Transplant in Patients with Total Artificial Heart: Are they Viable? *J Heart Lung Transplant*, 2017;36(4), S329.
394. Chang D, Kittleson M, Patel J, Aintablian T, Rodriguez G, Levine R, Geft D, Kransdorf E, **Czer L**, Esmailian F, Kobashigawa J. Coronary Vasospasm after Heart Transplantation. Does it Portend Poor Outcome? *J Heart Lung Transplant*, 2017; 36(4), S294.
395. Barone H, Coleman B, Aronow H, Runyan C, Hajj J, Huie N, Passano E, **Czer L**, Kobashigawa J, Moriguchi J, Arabia F. Implementing Practices to Improve Self-Care Among Caregivers of Patients with Mechanical Circulatory Support. *J Heart Lung Transplant*. 2017;36(4), S359–S360.
396. Coleman B, Barone H, Aronow H, Runyan C, Hajj J, Huie N, Passano E, **Czer L**, Kobashigawa J, Moriguchi J, Arabia F. Mechanical Circulatory Support Caregiver Gender Burden and Benefit: Is There a Difference? *J Heart Lung Transplant*, 2017; 36(4), S358–S359.
397. Conte A, Hajj J, Yang S, Passano E, Barone H, Chang D, Esmailian F, **Czer L**, Kobashigawa J, Moriguchi J, Arabia F. Utilization of Transverse Abdominis Plexus Block for Treatment of Left Ventricular Assist Device Associated Driveline Pain / Abdominal Pain Refractory to Conventional Multi-Modal Therapy: A Case Series. *J Heart Lung Transplant*, 2017; 36(4), S358.

ABSTRACTS (cont.)

398. Cheng R, Azarbal B, Chang D, Aintablian T, **Czer L**, Patel J, Kobashigawa J. Angiogenesis on Coronary Angiography Is a Marker for Accelerated Cardiac Allograft Vasculopathy as Assessed by Intravascular Ultrasound. *J Heart Lung Transplant*, 2017; 36(4), S294–S295.
399. Nikolova A, Geft D, Chang D, Chung J, Jocson R, Aintablian T, Passano E, **Czer L**, Kobashigawa J, Moriguchi J, Arabia F. What Factors Influence Right Ventricular Function Improvement in the Setting of Pulmonary Arterial Pressure Normalization After Left Ventricular Assist Device Placement? *J Heart Lung Transplant*, 2017;36(4), S351–S352.
400. Kobashigawa J, Kittleson M, Aintablian T, Chang D, Geft D, **Czer L**, Esmailian F, Patel J. The Outcome of Heart Transplant Patients with Hemodynamic Compromise Rejection in the Current Era. *J Heart Lung Transplant*, 2017, 36(4), S288–S289.
401. Geft D, Kittleson M, Patel J, Aintablian T, Levine R, Hashimoto M, Kransdorf E, Chang D, **Czer L**, Ramzy D, Kobashigawa J. The Story on Extracorporeal Membrane Oxygenation (ECMO) Directly to Mechanical Circulatory Support or to Heart Transplantation. *J Heart Lung Transplant*, 2017; 36(4), S336–S337.
402. Kobashigawa J, Reinsmoen N, Zhang X, Kittleson M, Aintablian T, Krems J, Kransdorf E, Chang D, **Czer L**, Esmailian F, Patel J. The Risk of Naïve vs Memory Patients Awaiting Heart Transplantation: Does It Make a Difference in Post-Transplant Outcomes? *J Heart Lung Transplant*, 2017;36(4), S287–S288.
403. Kobashigawa J, Kittleson M, Sana S, Aintablian T, Levine R, Azarbal B, Geft D, Chang D, **Czer L**, Luthringer D, Patel J. Correlation of the Grades of Antibody-Mediated Rejection to 1-Year IVUS results after Heart Transplantation. *J Heart Lung Transplant*, 2017; 36(4), S288.
404. Megna D, Esmailian F, Patel J, Kittleson M, Aintablian T, Stimpson E, Kransdorf E, Geft D, Chang D, **Czer L**, Kobashigawa J. Success for Combined Heart and Kidney Transplantation. *J Heart Lung Transplant*, 2017; 36(4), S229.
405. Liou F, Kittleson M, Patel J, Aintablian T, Kao T, Kransdorf E, Geft D, Chang D, **Czer L**, Ramzy D, Kobashigawa J. Donor Heart Diastolic Dysfunction: Do You Take This Heart for Transplantation? *J Heart Lung Transplant*, 2017; 36(4), S43.
406. Johl M, Patel J, Kittleson M, **Czer L**, Aintablian T, Velleca A, Hamilton M, Geft D, Chang D, Ramzy D, Kobashigawa J.. ACE Inhibitors or ARBs - Do They Improve Outcome After Heart Transplantation? *J Heart Lung Transplant* 2017; 36(4), S234–S235.

ABSTRACTS (cont.)

407. Geft D, Kittleson M, Patel J, Aintablian T, Yabuno K, Kearney B, Kransdorf E, Chang D, **Czer L**, Trento A, Kobashigawa J. Severe Tricuspid Regurgitation After Heart Transplantation: Does It Require Surgical Repair? *J Heart Lung Transplant*, 2017; 36(4), S223–S224.
408. Patel J, Kittleson M, Aintablian T, Kwan J, Musto N, Kearney B, Geft D, Chang D, **Czer L**, Esmailian F, Kobashigawa J. Donor Heart Turn Down in the Field: What's Going On? *J Heart Lung Transplant*, 2017; 36(4), S44.
409. Reich H, Ramzy D, Mirocha J, De Robertis M, Chung J, Esmailian F, Chang D, Moriguchi J, **Czer L**, Trento A, Arabia F. Not all INTERMACS Level 1's are the Same: Survival After Total Artificial Heart Implantation with or without Temporary Circulatory Support. *J Heart Lung Transplant*, 2017; 36(4), S348-S349.
410. Volod O, Lam L, Barglowski M, Mirocha J, Runyan C, Moriguchi J, **Czer L**, Arabia F. Comparison of Activated Partial Thromboplastin Time (aPTT) and Anti-Factor Xa for Low Intensity Unfractionated Heparin Monitoring in Patients with Mechanical Circulatory Support Devices (MCSD). *J Heart Lung Transplant*, 2017; 36(4), S443.
411. Kransdorf E, Kittleson M, Patel J, Aintablian T, Levine R, Kearney B, Musto N, Hage A, Geft D, **Czer L**, Esmailian F, Trento A, Kobashigawa J. Risk of Amiodarone and Permanent Pacemaker Placement After Heart Transplantation. *Am J Transplant* 2017; 17 (Suppl 3).
412. Leong D, Azarbal B, Patel J, Kittleson M, **Czer L**, Aintablian T, Chang D, Geft D, Kobashigawa J. In the Modern Era, Cytomegalovirus does Not Appear to Increase Intimal Thickening After Heart Transplantation. *Am J Transplant*. 2017; 17 (suppl 3).
413. Patel J, Kittleson M, **Czer L**, Aintablian T, Stimpson E, Azarbal B, Geft D, Chang D, Esmailian F, Kobashigawa J. Post-Transplant Sensitization: Does it Make a Difference in the Development of First-Year Intimal Thickening? *Am J Transplant*. 2017; 17 (suppl 3).
414. Patel J, Kittleson M, **Czer L**, Aintablian T, Kao T, Geft D, Chang D, Esmailian F, Kobashigawa J. Primary Graft Dysfunction Post Heart Transplantation: Is There Greater Risk for De Novo Donor-Specific Antibody Development? *Am J Transplant*. 2017; 17 (suppl 3).
415. Patel J, Kittleson M, Zhang X, Klapper E, Aintablian T, Murayama K, **Czer L**, Geft D, Chang D, Kobashigawa J. Photopheresis for Recalcitrant Rejection After Heart Transplantation: Worthwhile? *Am J Transplant*. 2017; 17 (suppl 3).
416. Patel J, Kittleson M, **Czer L**, Aintablian T, Sharoff R, Levine R, Velleca A, Ramzy D, Esmailian F, Kobashigawa J. Severe Tricuspid Regurgitation After Heart Transplantation: Does It Require Surgical Repair? *Am J Transplant*. 2017; 17 (suppl 3).

ABSTRACTS (cont.)

417. Rafiei M, Moriguchi J, Kittleson M, Patel J, Aintablian T, Passano E, Sharoff R, Kwan J, Kransdorf E, Chang D, **Czer L**, Kobashigawa J, Arabia F. Does the Model for End Stage Liver Disease (MELD) Score Predict Outcome in Total Artificial Heart Patients? *Am J Transplant*. 2017; 17 (suppl 3).
418. Kransdorf E, Kittleson M, Patel J, Pando M, **Czer L**, Kobashigawa J. The Ultimate Calculated Panel Reactive Antibody Value Predicts Mortality After Heart Transplantation. *Am J Transplant* 2017; 17 (suppl 3).
419. Nikolova AA, Hitzeman, TC, Baum R, Geft D, Chang D, Moriguchi J, Hage A, Azarbal B, Czer L, Kittleson M, et al. Plasma cBIN1 correlates with myocardial health in HFpEF patients. *Eur J Heart Fail* 2017 May; 19 (suppl 1): 183.
- 420.

LECTURES AND PRESENTATIONS

1. Clinical utility of technetium-99m RBC wall motion scintigraphy in determining etiology of cardiogenic shock early after open-heart surgery. American College of Chest Physicians, 49th Annual Scientific Assembly. Chicago, Illinois. October 25, 1983.
2. Acute and chronic arrhythmias and conduction disturbances complicating cardiac operation for the removal of left atrial myxomas. American College of Chest Physicians, 49th Annual Scientific Assembly. Chicago, Illinois. October 25, 1983.
3. Clinical utility of technetium-99m RBC wall motion scintigraphy in determining etiology of cardiogenic shock early after open-heart surgery. American Heart Association, 56th Scientific Sessions. Anaheim, California. November 16, 1983.
4. Determinants of survival following mitral valve replacement and coronary revascularization. American Heart Association, 56th Scientific Sessions. Anaheim, California. November 16, 1983.
5. Vascular access - which site? The High Risk Patient, Fifth Annual Cedars-Sinai Symposium. Universal City, California. January 13, 1984.
6. A five year experience with the St. Jude valve. American Federation of Clinical Research, Western Section. Carmel, California. February 10, 1984.
7. The St. Jude valve: a five year experience. American College of Cardiology, 33rd Annual Scientific Sessions. Dallas, Texas. March 26, 1984.
8. Streptokinase dissolution of St. Jude valve thrombosis under guidance of digital-enhanced cinefluoroscopy. American College of Chest Physicians, 50th Annual Scientific Assembly. Dallas, Texas. October 11, 1984.
9. Mitral bioprostheses - Improved hemodynamic differentiation of pathologic from physiologic stenosis. American College of Cardiology, 34th Annual Scientific Sessions. Anaheim, California. March 12, 1985.
10. Influence of coronary artery disease on results of cardiac valve replacement. International Society for Cardiovascular Surgery, XVII World Congress. Monte Carlo, Monaco. August 29, 1985.
11. DDAVP improves platelet function in patients with prolonged bleeding time and hemorrhage after cardiopulmonary bypass. American College of Chest Physicians, 51st Annual Scientific Assembly. New Orleans, Louisiana. October 30, 1985.
12. Bypass surgery in septuagenarians and octogenarians. American College of Chest Physicians, 51st Annual Scientific Assembly. New Orleans, Louisiana. October 31, 1985.

LECTURES AND PRESENTATIONS (cont.)

13. Prospective trial of DDAVP in treatment of severe platelet dysfunction and hemorrhage after cardiopulmonary bypass. American Heart Association, 58th Scientific Sessions. Washington, D.C. November 12, 1985.
14. Utility of intraoperative color Doppler flow imaging after surgical correction of valvular regurgitation. American College of Cardiology, 35th Annual Scientific Sessions. Atlanta, Georgia. March 12, 1986.
15. Impact of coronary artery disease and myocardial revascularization on results of aortic valve replacement. American College of Cardiology, 35th Annual Scientific Sessions. Atlanta, Georgia. March 12, 1986.
16. Esmolol for hypertension early after cardiac surgery. American College of Cardiology, 35th Annual Scientific Sessions. Atlanta, Georgia. March 12, 1986.
17. Intraoperative evaluation of mitral regurgitation: superiority of Doppler color flow mapping. American Heart Association, 59th Scientific Sessions. Dallas, Texas. November 19, 1986.
18. Desmopressin and control of bleeding following cardiac surgery. Symposium sponsored by Armour Pharmaceutical Company; American Association of Thoracic Surgeons. Chicago, Illinois. April 8, 1987.
19. Intraoperative detection and quantitation of mitral regurgitation by Doppler color flow mapping. American Federation for Clinical Research, 44th Annual National Meeting. San Diego, California. May 1, 1987.
20. Mitral regurgitant jet size by Doppler color flow mapping: Influence of afterload. American Federation for Clinical Research, 44th Annual National Meeting. San Diego, California. May 2, 1987.
21. Reduction in sudden late death by concomitant revascularization after aortic valve replacement. American Federation for Clinical Research, 44th Annual National Meeting. San Diego, California. May 2, 1987.
22. Reduction in sudden late death by concomitant revascularization with aortic valve replacement. Western Thoracic Surgical Association, 13th Annual Meeting. Colorado Springs, Colorado. June 26, 1987.
23. Prevention of hemorrhage after cardiac surgery with use of desmopressin. Symposium sponsored by Fisons Pharmaceuticals. Melbourne, Australia. September 21, 1987.
24. Use of desmopressin for control of mediastinal bleeding after open-heart surgery. Symposium sponsored by Fisons Pharmaceuticals. Sydney, Australia. September 23, 1987.

LECTURES AND PRESENTATIONS (cont.)

25. Current status of valve repair and replacement. American Heart Association (San Diego), 37th Annual Meeting. San Diego, California. October 9, 1987.
26. Complex cardiac diseases requiring surgical therapy. An Affair of the Heart (Reunion of Cardiac Surgical Patients). Schubert Theatre, Century City, California. October 18, 1987.
27. Ischemic mitral regurgitation: comparative evaluation of revascularization vs. repair by Doppler color flow mapping. American Heart Association, 60th Scientific Sessions. Anaheim, California. November 18, 1987.
28. Left ventricular afterload: an important determinant of mitral regurgitant jet size by Doppler color flow mapping. American Heart Association, 60th Scientific Sessions. Anaheim, California. November 18, 1987.
29. Echocardiographic and Doppler evaluation of prosthetic valves. First International Symposium on Echocardiography and Doppler in Cardiac Surgery. Vienna, Austria. April 25, 1988.
30. Intraoperative Doppler color flow mapping for evaluation of ischemic mitral regurgitation. First International Symposium on Echocardiography and Doppler in Cardiac Surgery. Vienna, Austria. April 26, 1988.
31. Tricuspid valve repair: operative and follow-up evaluation by Doppler color flow mapping. Western Thoracic Surgical Association, 14th annual meeting. Waikoloa, Hawaii. June 25, 1988.
32. Uses of desmopressin after surgery. Symposium sponsored by Rorer Pharmaceuticals. Boston, Massachusetts. July 26, 1988.
33. Epicardial imaging: technique and image planes. Second International Symposium on Echocardiography and Doppler in Cardiac Surgery. Salzburg, Austria. May 1, 1989.
34. Doppler assessment of prosthetic valves. Second International Symposium on Echocardiography and Doppler in Cardiac Surgery. Salzburg, Austria. May 1, 1989.
35. A Ten-Year Experience with the St. Jude valve. Western Thoracic Surgical Association, 15th Annual Meeting. Monterey, California. June 24, 1989.
36. Causes and diagnosis of mediastinal bleeding. Royal North Shore Hospital. Sydney, Australia. February 26, 1990.
37. Pharmacologic treatment of mediastinal bleeding. Symposium sponsored by Rorer Pharmaceuticals. Sydney and Melbourne, Australia. February 26 and 27, 1990.

LECTURES AND PRESENTATIONS (cont.)

38. Flow dependence of Doppler velocities in normal St. Jude valves. American College of Cardiology Poster Presentation, 39th Scientific Sessions. New Orleans, Louisiana. March 20, 1990.
39. Treatment of mitral stenosis: repair, replacement, or valvuloplasty. American College of Cardiology Luncheon Panel, 39th Scientific Sessions. New Orleans, Louisiana. March 31, 1990.
40. Valve repair surgery: impact of anatomy on surgical decision-making. Third International Symposium on Echocardiography and Doppler in Cardiac Surgery. Vienna, Austria. May 9, 1990.
41. Epicardial coronary echo guidance of intraop excimer laser angioplasty. Third International Symposium on Echocardiography and Doppler in Cardiac Surgery; Poster Session. Vienna, Austria. May 11, 1990.
42. Update on Heart Transplantation. Cardiology Grand Rounds, Cedars-Sinai Medical Center. Los Angeles, California. January 15, 1991.
43. Heart and lung transplantation at Cedars-Sinai Medical Center. Methodist Hospital. Arcadia, California. February 7, 1991.
44. Mediastinal bleeding and blood salvage techniques. St. Agnes Medical Center. Fresno, California. February 13, 1991.
45. Criteria for transplantation. St. Agnes Medical Center. Fresno, California. February 13, 1991.
46. A decade of experience with the St. Jude valve. St. Jude Medical Asia-Pacific Symposium. Napa Valley, California. February 16, 1991.
47. Which patients should receive cardiac transplantation? American College of Cardiology Luncheon Panel, 40th Scientific Sessions. Atlanta, Georgia. March 4, 1991.
48. Annuloplasty rings: Hemodynamic properties and effects on LV function. Fourth International Symposium on Echocardiography and Doppler in Cardiac Surgery. Innsbruck, Austria. May 27, 1991.
49. Cholesterol, fat and saturated fats: reducing your risk. Heart Health Forum. Santa Monica, California. June 22, 1991.
50. Heart transplantation: experience at Cedars-Sinai Medical Center. Medical Management of the Cardiac Surgical patient. Cedars-Sinai Medical Center, Los Angeles, California. July 13, 1991.

LECTURES AND PRESENTATIONS (cont.)

51. Cardiology Conference, Daniel Freeman Memorial Hospital. Los Angeles, California. July 18 and 19, 1991.
52. When to perform cardiac transplantation. American Heart Association, 59th Fall Symposium. Century City, California. September 11, 1991.
53. Heart transplantation - patient selection and results. San Fernando Valley Cardiologists' Dinner. Studio City, California. November 6, 1991.
54. Ring and suture annuloplasty for ischemic mitral regurgitation. American Heart Association, 64th Scientific Sessions. Anaheim, California. November 13, 1991.
55. The present and future of heart transplantation. Cardiac Catheterization Conference, St. John's Hospital. Santa Monica, California. November 22, 1991.
56. Heart transplantation: Cedars-Sinai Medical Center experience. Medical noon conference, Encino Hospital. Encino, California. February 24, 1992.
57. The current status of multi-organ transplantation. Medical noon conference, Pomona Valley Hospital. Pomona, California. February 25, 1992.
58. New developments in heart transplantation. Symposium: Medical Management of the Cardiac Surgery Patient. Cedars-Sinai Medical Center, Los Angeles, California. July 11, 1992.
59. New technique of orthotopic heart transplantation. American College of Cardiology, 42nd Annual Scientific Session. Anaheim, California. March 16, 1993.
60. Annuloplasty techniques for treatment of mitral regurgitation in ischemic cardiomyopathy. Second International Symposium on Heart Failure. Geneva, Switzerland. May 19, 1993.
61. Chairman, Abstract Session on Heart Transplantation. Second International Symposium on Heart Failure. Geneva, Switzerland. May 19, 1993.
62. Clinical experience with a new technique of orthotopic heart transplantation. Second International Symposium on Heart Failure. Geneva, Switzerland. May 20, 1993.
63. Results of 1000 St. Jude valve replacements, and special perspective on anticoagulation, valve thrombosis, echocardiographic evaluation of the St. Jude valve. Cardiovascular Surgery Grand Rounds. Kaiser Foundation Hospital. San Francisco, California. September 24, 1993.
64. Novel approach to treatment of patients with cytotoxic antibodies after heart transplantation: use of intravenous immunoglobulin. American Heart Association, 66th Scientific Sessions. Atlanta, Georgia. November 8, 1993.

LECTURES AND PRESENTATIONS (cont.)

65. Update on research in heart transplantation. First Annual Scientific Retreat. Cedars-Sinai Research Institute. Santa Monica, California. November 18, 1993.
66. Use of intravenous immune globulin to suppress cytotoxic antibodies after heart transplantation. Research in Progress. Cedars-Sinai Medical Center. Los Angeles, California. December 9, 1993.
67. Five-year experience with cardiac transplantation. Cardiology Grand Rounds. Cedars-Sinai Medical Center. Los Angeles, California. February 15, 1994.
68. Five-year experience with heart transplantation at Cedars-Sinai Medical Center. Cardiology Grand Rounds and Dinner meeting; Antelope Valley Medical Center. Lancaster, California. February 22, 1994.
69. Orthotopic heart transplantation with total excision of recipient atria, bicaval and pulmonary vein anastomosis: clinical experience and early results. Western Association of Transplant Surgeons 189th Annual Meeting. Lahaina, Maui, Hawaii. March 15, 1994.
70. Unexpected results of heart transplantation in patients over 60 years of age. Western Association of Transplant Surgeons, 18th Annual Meeting. Lahaina, Maui, Hawaii. March 15, 1994.
71. New advances in heart transplantation. Surgical Grand Rounds. Cedars-Sinai Medical Center. Los Angeles, California. June 6, 1994.
72. The St. Jude valve -- 1000 cases. Review of clinical experience, embolism, thrombosis, hemorrhage, and anticoagulation policy. Marin General Hospital. San Francisco, California. December 7, 1994.
73. The mitral valve: preoperative and intraoperative evaluation. Symposium on Use of 2-D Echocardiography and Echo-Doppler in the Peri-operative Period. Cedars-Sinai Medical Center. Marina del Rey, California. March 3, 1995.
74. Use of echocardiography in the pre and postoperative evaluation of the heart transplant patient. Symposium on the Use of 2-D Echocardiography and Echo-Doppler in the Peri-operative Period. Cedars-Sinai Medical Center. Marina del Rey, California. March 4, 1995.
75. Chagas' cardiomyopathy. Department of Medicine. Grand Rounds. Cedars-Sinai Medical Center. Los Angeles, California. November 1, 1995.
76. Influence of alcohol on donor heart function before and after transplantation. Research in Progress. Cedars-Sinai Medical Center. Los Angeles, California. January 4, 1996.

LECTURES AND PRESENTATIONS (cont.)

77. Heart Transplantation Program: Update on Research at Cedars-Sinai Medical Center. Cardiology Grand Rounds. Cedars-Sinai Medical Center. Los Angeles, California. August 12, 1997.
78. Cardiac Transplantation. West Coast Cardiovascular Review Course for Cardiology Boards and Recertification. Cedars-Sinai Medical Center. Los Angeles, California. October 7, 1997.
79. Acute and Chronic Rheumatic Fever. Royal Victoria Hospital. Banjul, Gambia, West Africa. March 28, 1998.
80. The effect of monoclonal antibody therapy on survival and rejection after heart transplantation. Sharp Memorial Hospital. San Diego, California. May 15, 1998.
81. A new model of transplant atherosclerosis in the rat. (Hai-Mei Wang, DDS). Laverna Titus 19th Young Investigators Forum. City of Hope Medical Center. Duarte, California. May 20, 1998.
82. ACI to Lewis heterotopic heart transplant model of transplant atherosclerosis. Research in Progress. Cedars-Sinai Medical Center. Los Angeles, California. June 4, 1998.
83. Diagnosis and treatment of rejection. 1st International Symposium on Intensive Cardiac Care. International Conference Center. Jerusalem, Israel. June 29, 1998.
84. Prolongation of cardiac allograft survival with intracoronary viral II-10 (vII-10) gene transfer. (Charles Wang, MD). XVII World Congress of the Transplantation Society. Montreal, Canada. July 14, 1998.
85. Review of research at CSMC: Heart transplant update. Cardiology Grand Rounds. Cedars-Sinai Medical Center. Los Angeles, California. August 11, 1998.
86. Clinical experience in heart transplantation. Presentation to Payor Relations. Los Angeles, California. October 19, 1998.
87. Clinical and research experience in heart transplantation. Presentations to URN, Bristol Park Medical Group, and MediCal. Los Angeles, California. July - December 1998.
88. Review of heart transplantation. Hoag Memorial Hospital Presbyterian. Newport Beach, California. February 10, 1999.
89. Clinical heart transplantation at Cedars-Sinai Medical Center. Presentation to Avandel, Inc, an insurer for high-risk and catastrophic illnesses. Los Angeles, California. May 21, 1999.

LECTURES AND PRESENTATIONS (cont.)

90. Advances in heart transplantation. Transplantation in the 21st Century: A Symposium for Case Managers (Blue Cross, Health Net, Pacificare, Aetna, and other health insurers represented). Woodland Hills, California. October 21, 1999.
91. Valvular Heart Disease. Invited lecture. Royal Victoria Hospital. Banjul, Gambia, West Africa. March 30, 2000.
92. Echocardiography for Diagnosis of Heart Disease. Invited lecture. Royal Victoria Hospital. Banjul, Gambia, West Africa. March 30, 2000.
93. Prophylaxis of CMV disease in mismatched patients after heart transplantation using combined antiviral and immunoglobulin therapy. (Presented by Angela Wong, M.D.) International Society for Heart and Lung Transplantation. Osaka, Japan. April 7, 2000.
94. Medical Mission to the Gambia using portable color Doppler echocardiography. Echocardiography weekly conference. Cedars-Sinai Medical Center. Los Angeles, California. May 10, 2000.
95. Update on Cardiac Transplantation: Indications, Evaluations and Results. Invited lecture. State-of-the-Art Management of Heart Failure. Fairmont Miramar Hotel. Santa Monica, California. May 20, 2000.
96. Revascularization alone versus revascularization combined with mitral valve repair for ischemic mitral regurgitation. Invited lecture. International Forum on Ischemic Mitral Regurgitation. Monterey, California. October 14, 2000.
97. Update on Heart Transplantation 2000. The Latest Trends in Transplantation: A Symposium for Case Managers. Los Angeles, California. October 19, 2000.
98. Inhibition of immune-mediated injury by cyclosporin reduces coronary artery disease after transplantation. (Presented by Andreas Kamlot, M.D.) The Society of University Surgeons, 62nd annual meeting. Chicago, Illinois. February 8, 2001.
99. Congestive Heart Failure – New Therapies. Invited lecture. Royal Victoria Hospital. Banjul, The Gambia, West Africa. March 29, 2001.
100. Surgical Treatment of Advanced Congestive Heart Failure. Invited lecture. State-of-the-Art Management of Congestive Heart Failure 2001. Newport Beach, California. May 19, 2001.
101. Management of Patients with Positive Panel Reactive Antibodies Prior to Transplantation. Discussion and case presentations to Leslie Miller, M.D. (Visiting Professor). Los Angeles, California. June 14, 2001.
102. Update on Heart Transplant and Ventricular Assist Devices. Presentation to Blue Shield of California. Los Angeles, California. July 18, 2001.

LECTURES AND PRESENTATIONS (cont.)

103. Alternatives to Heart Transplantation in the Surgical Treatment of Advanced Congestive Heart Failure. Cardiology Grand Rounds, Cedars-Sinai Medical Center. Los Angeles, California. August 14, 2001.
104. Cold ischemic injury and donor-recipient MHC disparity accelerate graft vascular disease. Wong AV, Czer LSC, Soukiasian HJ, Kamlot A, Lefor T, Trento A. (Presented by Angela Wong, M.D.) The Society of University Surgeons, 63rd annual meeting. Honolulu, Hawaii. February 14, 2002.
105. Heart Transplantation at Cedars-Sinai Medical Center – Summary of Program Results. Presentation to PacifiCare. Los Angeles, California. April 12, 2002.
106. What it means to be a cardiologist – college preparation, medical school, postgraduate training, clinical work, research, medical missions. Symposium for Pre-Health Professions Club at Santa Monica College. Santa Monica, California. May 2, 2002.
107. Thoracic aortic repair in the octogenarian population. Soukiasian HJ, Raissi SS, Kleisli T, Magliato KE, Kim YH, Tabrizi R, Czer LSC, Cheng W, Fontana GP, Kass RM, Trento A. (Poster presented by Harmik Soukiasian, M.D.) Aortic Surgery Symposium VIII, Mount Sinai School of Medicine. New York City, NY. May 2-3, 2002.
108. Total circulatory arrest for the replacement of the descending and thoracoabdominal aorta. (Poster presented by Thomas Kleisli and Harmik Soukiasian, M.D.) Aortic Surgery Symposium VIII, Mount Sinai School of Medicine. New York City, NY. May 2-3, 2002.
109. Stem cells for regeneration of myocardium. Soukiasian HJ, Czer LSC, Demetriou AA, Trento A. (Presented by Harmik Soukiasian, M.D.) First place prize, Carl A. Lipkin, M.D., Resident Research Symposium, Dept. of Surgery, Cedars-Sinai Medical Center. Los Angeles, CA. June 13, 2002.
110. Biventricular support in patients with profound cardiogenic shock: a single center experience. Magliato KE, Kleisli T, Soukiasian HJ, Tabrizi R, Coleman B, Hickey A, Czer LSC, Blanche C, Cheng W, Fontana GP, Kass RM, Raissi SS, Trento A. (Poster presented by Kathy E. Magliato, M.D.) 48th Annual Meeting of the American Society for Artificial Internal Organs. New York City, NY. June 12-15, 2002.
111. Novel heart transplant techniques. Invited lecture, presented by Lawrence Czer, M.D. Third International Meeting on Intensive Cardiac Care. Tel-Aviv, Israel. June 27, 2002.
112. Update on current treatment for acute rejection in heart transplant recipients. Invited lecture. Third International Meeting on Intensive Cardiac Care. Tel-Aviv, Israel. June 27, 2002.

LECTURES AND PRESENTATIONS (cont.)

113. Heart transplantation for end-stage congestive heart failure. Medical Grand Rounds, Sepulveda Veterans Administration Hospital. North Hills, California. September 12, 2002.
114. Prevention and treatment of rejection after heart transplantation. Cardiology Grand Rounds, Cedars-Sinai Medical Center. Los Angeles, California. September 24, 2002
115. Inhibition of graft coronary arteriosclerosis after heart transplantation. Soukiasian HJ, Czer LSC, Fontana GP, Magliato KE, Nishi GK, Avital I, Wong A, Blanche C, Raissi SS, Kass R, Trento A. (presented by Harmik Soukiasian, M.D.). Cardiac BioIntervention Symposium. San Francisco, California. October 4, 2002.
116. Exercise performance after heart transplantation: comparison of biatrial and bicaval techniques. Soukiasian HJ, Czer LSC, Fontana GP, Magliato KE, Nishi GK, Avital I, Wong A, Cohen MH, Adrian MS, Quartel W, Dhar SC, Barnard JR, Blanche C, Raissi SS, Kass R, Trento A. (Presented by Harmik Soukiasian, M.D.) Cardiac BioIntervention Symposium. San Francisco, CA. October 4, 2002.
117. IL-6 and TNF- α genotypes predict acute rejection and lower survival in African American heart transplant recipients (presented by Bernice Coleman, R.N., Ph.D.). American Society for Histocompatibility and Immunogenetics, 28th Annual Meeting. Nashville, Tennessee. October 21, 2002.
118. Update on heart transplantation. Cardiology Grand Rounds, Cedars-Sinai Medical Center. Presented by Ann Hickey, M.D., Carlos Blanche, M.D., and Lawrence Czer, M.D. Los Angeles, California. November 5, 2002.
119. Aortic valve replacement in patients with aortic stenosis and severe left ventricular dysfunction: a suitable alternative to transplantation. Soukiasian HJ, Czer LSC, Magliato KE, Nishi GK, Avital I, Major K, Raissi SS, Trento A. (Presented by Harmik Soukiasian, M.D.) American College of Surgeons – 14th Annual Conference of the Southern California Chapter, and the Annual Trauma Conference. Santa Barbara, California. January 25, 2003.
120. Autologous beta-2-microglobulin-negative cells as a source of stem cells for regeneration of damaged myocardium. Research in Progress, Cedars-Sinai Medical Center. Soukiasian HJ, Czer LSC, Trento A. (Presented by Harmik Soukiasian, M.D.) Los Angeles, California. February 20, 2003.
121. A novel sub-population of bone marrow derived myocardial stem cells: potential autologous cell therapy in myocardial infarction. Soukiasian HJ, Czer LSC, Avital I, Aoki T, Kim YH, Umehara Y, Pass J, Tabrizi R, Magliato K, Fontana GP, Cheng W, Demetriou AA, Trento A. (Presented by Harmik Soukiasian, M.D.) International Society for Heart and Lung Transplantation, 23rd Annual Meeting and Scientific Session. Vienna, Austria. April 10, 2003.

LECTURES AND PRESENTATIONS (cont.)

122. IL-6 and TNF α cytokine genotypes are associated with acute rejection and lower survival in African American heart transplant recipients. Presented by Bernice Coleman, R.N., Ph.D. International Society for Heart and Lung Transplantation, 23rd Annual Meeting and Scientific Session. Vienna, Austria. April 12, 2003.
123. Review of selected abstracts from the Annual Meeting and Scientific Sessions of the International Society for Heart and Lung Transplantation, April 9-12, 2003, in Vienna, Austria. Presented by Lawrence Czer, M.D., at the Transplant Committee, Cedars-Sinai Medical Center. Los Angeles, California. April 16, 2003.
124. Transplantation of a novel subpopulation of bone-marrow derived cardiac stem cells into rat myocardium: potential autologous cell therapy in myocardial infarction. Soukiasian HJ, Czer LSC, Trento A. (Presented by Harmik Soukiasian, M.D.) First place prize, 2003 Paul Rubenstein, M.D., Excellence in Resident Research Abstract & Awards Presentation, Cedars-Sinai Medical Center. Los Angeles, California. May 22, 2003.
125. A portable cardiac ultrasound fits the difficult conditions of developing countries to identify left ventricular hypertrophy in a hypertensive population. Presented by Lawrence Czer, M.D. American Heart Association Second Asia Pacific Scientific Forum. Honolulu, Hawaii. June 9, 2003.
126. Circulating CD34 antigen-positive cells are increased after acute myocardial infarction and G-CSF injection: a potential source of stem cells for myocyte regeneration. Kim YH, Czer LSC, Soukiasian HJ, Oh YS, Pass J, Mirocha J, Trento A. (Presented by Harmik Soukiasian, M.D., and Lawrence Czer, M.D.) American Heart Association Second Asia Pacific Scientific Forum. Honolulu, Hawaii. June 10, 2003.
127. Current status of heart-kidney transplantation and other dual or triple organ transplants: indications and contraindications for transplant and retransplant. Invited lecture, presented by Lawrence Czer, M.D. Medi-Cal Advisory Committee on Anatomic Transplants (MACAT) on Cardiothoracic (Heart, Lung and combined Heart-Lung) Transplantation (CTT). San Francisco, California. June 25, 2003.
128. Heart transplantation: comparison of three implant techniques. Invited lecture, presented by Lawrence Czer, M.D. Third World Congress on Heart Disease. Washington, D.C. July 14, 2003.
129. Cardiac surgery, transplantation, and ventricular assist devices. Session moderator. Third World Congress on Heart Disease. Washington, D.C. July 15, 2003.
130. Heart transplantation at Cedars-Sinai Medical Center. Presented by Lawrence Czer, M.D., to Interlink Health Services (F. Dennis Irwin, M.D., Chief Medical Officer). Cedars-Sinai Medical Center. Los Angeles, CA. October 3, 2003.

LECTURES AND PRESENTATIONS (cont.)

131. New stented prostheses: are they better? Invited lecture, presented by Lawrence Czer, M.D. Controversies in Adult Cardiac Surgery. Santa Monica, CA. October 3, 2003.
132. Transplantation of a novel sub-population of bone-marrow derived cardiac stem cells into rat myocardium. Soukiasian HJ, Czer LSC, Avital I, Aoki T, Kim YH, Umehara Y, Demetriou AA, Trento A. (Presented by Harmik Soukiasian, M.D.). American College of Surgeons, Owen H. Wangenstein Surgical Forum, 89th Annual Clinical Congress. Chicago, Illinois. October 21, 2003.
133. Exercise performance with bicaval vs biatrial orthotopic heart transplantation. Soukiasian HJ, Czer LSC, Fontana GP, Nishi GK, Chopra RR, McVay C, Raissi SR, Trento A. (Poster presentation by Harmik Soukiasian, M.D.) International Society of Cardio-Thoracic Surgeons, 13th World Congress. San Diego, California. On display November 1-5, 2003.
134. Aortic valve replacement in patients with aortic stenosis and severe left ventricular dysfunction: a suitable alternative to transplantation. Soukiasian HJ, Czer LSC, Nishi GK, McVay C, Chopra RR, Fontana GP and Trento A. (Presented by Harmik Soukiasian, M.D.). International Society of Cardio-Thoracic Surgeons, 13th World Congress. San Diego, California. November 4, 2003.
135. Inhibition of immune-mediated graft coronary arteriosclerosis after heart transplantation. Soukiasian HJ, Czer LSC, Nishi GK, McVay C, Chopra RR, Fontana GP and Trento A (Presented by Harmik Soukiasian, M.D.). International Society of Cardio-Thoracic Surgeons, 13th World Congress. San Diego, California. November 4, 2003.
136. Inhibition of graft coronary arteriosclerosis after heart transplantation. Soukiasian HJ, Czer LSC, Nishi GK, Avital I, Spivak J, Trento A. (Presented by Harmik Soukiasian, M.D.) Southern California Chapter of the American College of Surgeons. Santa Barbara, California. January 16, 2004.
137. Total circulatory arrest for the replacement of the descending thoracoabdominal aorta. Soukiasian HJ, Raissi SS, Lefor AT, Czer LSC, Trento A. (Presented by Harmik J. Soukiasian MD.). Pacific Coast Surgical Association, 75th Annual Scientific Session. Maui, Hawaii. February 15, 2004.
138. Thoracic Aortic Surgery in Solid Organ Transplant Recipients. Kleisli T, Raissi SS, Soukiasian HJ, Kass RM, Cheng W, Fontana GP, Magliato KE, Czer LSC, Hickey A, Trento A. (Presented by Harmik Soukiasian, M.D., and Thomas Kleisli). Aortic Surgery Symposium IX. New York, NY. April 22-23, 2004.
139. Heart Transplantation Program Review and Site Visit at Cedars-Sinai Medical Center. Presented by Lawrence Czer, M.D., to Blue Cross – Blue Shield Quality Centers of Transplant. Cedars-Sinai Medical Center. Los Angeles, CA. May 24, 2004.

LECTURES AND PRESENTATIONS (cont.)

140. Update on Heart Transplantation 2004. Presented by Lawrence Czer, M.D. Cardiology Grand Rounds. Cedars-Sinai Medical Center. Los Angeles, CA. July 13, 2004.
141. Cold Ischemic Injury and Donor-Recipient MHC Disparity Significantly Increase Post-Transplant Cardiac Graft Coronary Arteriosclerosis. Soukiasian HJ, Wong AV, Czer LSC, Lefor AT, Nishi GK, Chopra R, Fontana GP, Demetriou AA, Trento A. (Presented by Harmik Soukiasian, M.D.) American College of Surgeons, Owen H. Wangenstein Surgical Forum, 90th Annual Clinical Congress. New Orleans, LA. October 14, 2004.
142. Aortic Valve Replacement In Patients With Aortic Stenosis And Severe Left Ventricular Dysfunction: A Suitable Alternative To Transplantation. Soukiasian HJ, Czer LSC, Lefor AT, Margulies DR, Nishi GK, Feldmar DA, Trento A. (Presented by Harmik Soukiasian, M.D.) Western Surgical Association 112th Scientific Session. Lake Las Vegas - Henderson, Nevada. November 7-10, 2004
143. Comparison of revascularization alone versus combined revascularization and mitral valve repair for ischemic mitral regurgitation. Czer LSC, Trento A, Kass RM, De Robertis M, Blanche C, Raissi S, Fontana G, Cheng W, van Wijk R. (Poster presented by Lawrence S.C. Czer, M.D.). American Heart Association, Scientific Sessions. November 9, 2004.
144. Heart Transplantation Program Review and Site Visit at Cedars-Sinai Medical Center. Presented by Lawrence Czer, M.D., to Blue Shield Center of Excellence. Cedars-Sinai Medical Center. Los Angeles, CA. April 4, 2005.
145. Congenitally Bicuspid Aortic Valve Replacement: Cedars-Sinai Experience. Czer LSC, Goland S, De Robertis M, Mirocha J, Kass RM, Raissi S, Fontana G, Cheng W, Trento A. Presented by Lawrence S.C. Czer, M.D. Cardiology Grand Rounds. Cedars-Sinai Medical Center. June 28, 2005.
146. Cardiac surgical intensive care. Orientation for 1st year cardiology fellows. Presented by Lawrence S. C. Czer, M.D., at Core Curriculum lecture series to cardiology fellows. Cedars-Sinai Medical Center. July 11, 2005.
147. Update on Heart Transplant Program at Cedars-Sinai Medical Center – Past Performance and Future Goals. Presented by Lawrence Czer, M.D., to Comprehensive Transplant Center Leadership Committee. Cedars-Sinai Medical Center. July 25, 2005.
148. Management of Bicuspid Aortic Valve and Ascending Aortic Aneurysm. Controversies in the Treatment of Cardiovascular Disease. Czer LSC, Goland S, De Robertis M, Mirocha J, Kass RM, Raissi S, Fontana G, Cheng W, Trento A. Invited lecture, presented by Lawrence Czer, M.D. Santa Monica, California. October 7, 2005.
149. Cardiac Allograft Rejection Prevention and Treatment. Lecture to Cardiology fellows. Presented by Lawrence Czer, M.D. Cedars-Sinai Medical Center. October 24, 2005.

LECTURES AND PRESENTATIONS (cont.)

150. Classification of Cardiac Allograft Rejection and Approach to Rejection Treatment. Lecture to Cardiology fellows. Presented by Lawrence Czer, M.D. Cedars-Sinai Medical Center. January 23, 2006.
151. Heart Transplantation Program Review and Site Visit at Cedars-Sinai Medical Center. Presented by Lawrence Czer, M.D., to CalOptima (HMO for state of California MediCal). Cedars-Sinai Medical Center. Los Angeles, CA. February 3, 2006.
152. Update in Heart Transplantation. Transplant Grand Rounds. Invited lecture, presented by Lawrence Czer, M.D., at Cedars-Sinai Medical Center. Los Angeles, CA. February 14, 2006.
153. New Indications, Diagnostic and Therapeutic Strategies, and Results of Heart Transplantation. Transplant Nursing Case Manager Clinical Conference. Presented by Lawrence Czer, M.D., at Cedars-Sinai Medical Center. Los Angeles, CA. March 1, 2006.
154. Outcomes in cardiac transplant recipients using donor allografts with left ventricular hypertrophy. Goland S, Czer LSC, Kass RM, Siegel RJ, Mirocha J, De Robertis M, Raissi S, Cheng W, Fontana G, Coleman B, Trento A. Poster presented by Sorel Goland, M.D., and Lawrence S.C. Czer, M.D., at the American College of Cardiology, 55th Annual Scientific Sessions, Atlanta, Georgia, March 13, 2006.
155. Risk factors associated with mortality and re-operation in 252 patients with AVR for congenital bicuspid aortic valve disease. Czer LSC, Goland S, De Robertis M, Mirocha J, Kass RM, Raissi S, Fontana G, Cheng W, Trento A. Presented by Lawrence S.C. Czer, M.D., at the American College of Cardiology, 55th Annual Scientific Sessions, Atlanta, Georgia, March 13, 2006.
156. Pre-existing pulmonary hypertension in patients with end-stage heart failure: impact on clinical outcome and hemodynamic follow-up after heart transplantation. Goland S, Czer LSC, Kass RM, Siegel RJ, Mirocha J, De Robertis M, Raissi S, Cheng W, Fontana G, Coleman B, Trento A. Presented by Lawrence S.C. Czer, M.D., at the International Society of Heart and Lung Transplantation, Annual Meeting and Scientific Sessions, Madrid, Spain, April 6, 2006.
157. Ventricular assist devices for cardiogenic shock. Lecture to Cardiology fellows. Presented by Lawrence Czer, M.D. Cedars-Sinai Medical Center. May 22, 2006.
158. Postoperative care of the cardiac surgical patient: hypotension and bleeding. Lecture to Medical residents. Presented by Lawrence Czer, M.D. Cedars-Sinai Medical Center. June 28, 2006.
159. Update on heart transplantation program and heart transplant research at Cedars-Sinai Medical Center. Cardiology Grand Rounds. Presented by Lawrence Czer, M.D. Cedars-Sinai Medical Center, August 22, 2006.

LECTURES AND PRESENTATIONS (cont.)

160. Heart transplant program review, fiscal year ending July 2006. Presented by Lawrence Czer, M.D., to Comprehensive Transplant Center Leadership Group. Cedars-Sinai Medical Center, August 29, 2006.
161. Comparison of revascularization alone versus combined revascularization and mitral valve repair for ischemic mitral regurgitation. Invited lecture. Presented by Lawrence Czer, M.D., at Controversies and Advances in the Treatment of Cardiovascular Disease – The Sixth in the Series. Beverly Hills Hotel, Beverly Hills, October 5, 2006.
162. Congestive Heart Failure. Moderator, Lawrence Czer, M.D., at Controversies and Advances in the Treatment of Cardiovascular Disease – The Sixth in the Series. Beverly Hills Hotel, Beverly Hills, October 6, 2006.
163. Heart Transplantation 2007. Lecture to Cardiology fellows and Thoracic Surgery resident. Thoracic Surgery Core Curriculum. Presented by Lawrence Czer, M.D. Cedars-Sinai Medical Center. January 9, 2007.
164. Heart Transplantation – surgical and medical aspects. Lecture to Surgery residents. General Surgery Core Curriculum. Presented by Lawrence Czer, M.D. Cedars-Sinai Medical Center. January 23, 2007.
165. LXR Agonist T1317 Inhibits the Aortic Valve Calcification in ApoE^{-/-} Mice. Wang H, Czer L, Trento A. Presented by Haimei Wang DDS at the American College of Cardiology, 56th Annual Scientific Sessions, New Orleans, Louisiana, March 26, 2007.
166. Utilization of cardiac allografts with mild or moderate LVH is safe and can expand the donor pool. Goland S, Czer LSC, Kass RM, Siegel RJ, Mirocha J, De Robertis M, Lee J, Coleman B, Raissi S, Cheng W, Fontana G, Trento A. Presented by Sorel Goland, M.D., at the International Society of Heart and Lung Transplantation, Annual Meeting and Scientific Sessions, San Francisco, California, April 27, 2007.
167. Induction therapy with Thymoglobulin after heart transplantation: Impact of therapy duration on lymphocyte depletion and recovery, rejection and CMV infection rates. Czer LSC, Goland S, Kass RM, De Robertis M, Mirocha J, Zivari K, Lee J, Coleman B, Trento A. Presented by Lawrence Czer, M.D., at the International Society of Heart and Lung Transplantation, Annual Meeting and Scientific Sessions, San Francisco, California, April 27, 2007.
168. New Diagnostic Methods and Imaging Techniques. Session Moderated by Lawrence S.C. Czer, M.D. at the 13th World Congress on Heart Disease, Annual Scientific Sessions, Vancouver, B.C., Canada, July 31, 2007.

LECTURES AND PRESENTATIONS (cont.)

169. Donor cardiac allografts with mild or moderate LVH can be safely used for transplantation. Czer LSC, Goland S, Siegel RJ, Mirocha J, De Robertis M, Lee J, Coleman B, Trento A. Invited lecture, presented by Lawrence Czer, M.D., at the 13th World Congress on Heart Disease, Annual Scientific Sessions, Vancouver, B.C., Canada, July 31, 2007.
170. Heart Transplantation 2007: Update and New Insights. Cardiology Grand Rounds. Presented by Lawrence S.C. Czer, M.D. Cedars-Sinai Medical Center, Los Angeles, California, August 7, 2007.
171. The Future of Heart Transplantation and Ventricular Assist Devices. Dinner Meeting and Talk for Cardiologists and Cardiac Surgeons in Lancaster. Presented by Lawrence S.C. Czer, M.D. and Sinan Simsir, M.D. Lancaster, California, September 14, 2007.
172. Transplantation: A Scarce Commodity: Evaluation, Indications, and Outcomes. Invited Lecture, presented by Lawrence S.C. Czer, M.D., at Controversies and Advances in the Treatment of Cardiovascular Disease – The Seventh in the Series. California Chapter of the American College of Cardiology, Cardiac Care Associate - afternoon session on Heart Failure – An Epidemic Under the Microscope. Beverly Hills, California, October 4, 2007.
173. Outcomes in Cardiac Transplant Recipients Using Donor Hearts with Left Ventricular Hypertrophy. Poster presented by Presented by Lawrence S.C. Czer, M.D., at Controversies and Advances in the Treatment of Cardiovascular Disease – The Seventh in the Series. Beverly Hills, California, October 4 & 5, 2007.
174. Heart Transplantation 2007: Recent Trends and Outcomes. Lecture to Surgery Residents. Presented by Lawrence S.C. Czer, M.D. Cedars-Sinai Medical Center, Los Angeles, California, October 9, 2007.
175. Changes in Left and Right Ventricular Structure and Function of Donor Hearts During the First Year After Heart Transplantation Using Tissue Doppler Imaging and Myocardial Performance Index. Sorel Goland, Lawrence S.C. Czer, Robert J. Siegel, Kevin Burton, Tasneem Z. Naqvi, Kaveh Zivari, Rafique Asim, Michele A. De Robertis, Daniel Luthringer, Ernst Schwarz, Robert M. Kass, Alfredo Trento. Presented by Sanjay Kaul MD and Kevin Burton PhD at the American Heart Association Scientific Sessions. Orlando, Florida, November 7, 2007.
176. Heart Transplantation 2007: Evaluation, Indications, and Outcomes. Medical Grand Rounds. Presented by Lawrence S.C. Czer, M.D. Cedars-Sinai Medical Center, Los Angeles, California, November 9, 2007.
177. Review of Heart Transplantation at Cedars-Sinai Medical Center 2007: United Resources Network. Presented by Lawrence S.C. Czer, M.D. Cedars-Sinai Medical Center, Los Angeles, California, December 18, 2007.

LECTURES AND PRESENTATIONS (cont.)

178. Review and Update on Ventricular Assist Devices at Cedars-Sinai Medical Center. Invited lecture. Presented by Lawrence S.C. Czer, M.D. Cardiology Grand Rounds. Cedars-Sinai Medical Center, Los Angeles, California, February 5, 2008.
179. Update on Heart Transplantation and Left Ventricular Assist Devices at Cedars-Sinai Medical Center 2008: Blue Shield. Presented by Lawrence S.C. Czer, M.D. Cedars-Sinai Medical Center, Los Angeles, California, July 28, 2008.
180. Ventricular Assist Devices - review of current devices and clinical results. Core Curriculum for Cardiology fellows. Presented by Lawrence S.C. Czer, M.D. Cedars-Sinai Medical Center, Los Angeles, California, August 19, 2008.
181. Review of Heart Transplantation and Ventricular Assist Devices. Presented by Lawrence S.C. Czer, M.D., and Sinan Simsir, M.D. Apex Cardiology Group. Santa Monica, California, August 26, 2008.
182. The Promise of Cardiac Stem Cells. Invited Lecture. Presented by Lawrence Czer, M.D. Controversies in the Treatment of Cardiovascular Disease. The Eighth in a Series. Beverly Hills, California, September 3, 2008.
183. Heart transplantation and left ventricular assist devices – competitive or complementary strategies in the treatment of advanced heart failure? Invited lecture. Presented by Lawrence Czer, M.D. Cardiology Grand Rounds. Cedars-Sinai Medical Center, Los Angeles, California, September 9, 2008.
184. Postoperative Care of the Cardiac Surgical Patient. Core Curriculum for Cardiology fellows. Presented by Lawrence S.C. Czer, M.D. Cedars-Sinai Medical Center, Los Angeles, California, September 30, 2008.
185. Twenty year perspective of heart transplantation. Heart and lung transplant 20 year reunion. Lawrence S.C. Czer, M.D., Master of Ceremonies, and event speaker. Cedars-Sinai Medical Center, Los Angeles, California, December 10, 2008.
186. Heart Transplantation and Left Ventricular Assist Devices: Experience at Cedars-Sinai Medical Center and Future Directions. Kaiser Permanente Medical Group Center of Excellence presentation by Lawrence S.C. Czer, M.D. Cedars-Sinai Medical Center, Los Angeles, California, February 20, 2009.
187. Immunologic Monitoring in Thoracic Transplantation and Review of Heart Transplant and VAD Programs at Cedars-Sinai Medical Center. Invited lecture. Presented by Lawrence S.C. Czer, M.D., and Nancy Reinsmoen, Ph.D. Cardiology Grand Rounds. Cedars-Sinai Medical Center, Los Angeles, California, May 19, 2009.
188. A Primer on Cardiac Stem Cell Biology. Invited lecture. Presented by Lawrence S.C. Czer, M.D. Cardiology Grand Rounds. Cedars-Sinai Medical Center, Los Angeles, California, July 14, 2009.

LECTURES AND PRESENTATIONS (cont.)

189. Bioprosthetic valve degeneration in a small animal model with LXR agonist, MCP-1 antibody, and valve leaflet implantation. Presented by Kevin Burton Ph.D., and Lawrence S.C. Czer, M.D. Research in Progress. Cedars-Sinai Medical Center, Los Angeles, California, July 16, 2009.
190. Heart Failure: Pharmacologic Therapy, Ventricular Assist Devices, and Cardiac Transplantation: A Moderated Panel Discussion. Panelist: Lawrence Czer, M.D. Controversies in the Treatment of Cardiovascular Disease. The Ninth in a Series. Beverly Hills, California, October 2, 2009.
191. Human cardiosphere-derived cells: from concept to clinical application. Invited lecture. Presented by Lawrence S.C. Czer, M.D. Cardiac Stem Cell Differentiation and Biopsy-derived Cardiac Regenerative Cells: clinical implications of basic research. Rome, Italy. October 16, 2009.
192. Immunology and rejection. Invited lecture. Presented by Lawrence S.C. Czer, M.D. Nursing symposium on transplantation. Cedars-Sinai Medical Center, Los Angeles, California. October 19, 2009.
193. Postoperative care of the cardiac surgical patient. Presented by Lawrence S.C. Czer, M.D. Cardiology Fellows curriculum. Cedars-Sinai Medical Center, Los Angeles, California. January 26, 2010.
194. Desensitization of highly HLA-sensitized heart transplant candidates using high dose intravenous immunoglobulin and rituximab with successful transplantation. Presented by Lawrence S.C. Czer, M.D. American College of Cardiology Scientific Sessions. Atlanta, Georgia. March 14, 2010.
195. Desensitization protocol and results in highly HLA-sensitized heart transplant candidates using high-dose intravenous immunoglobulin and rituximab with successful transplantation. Invited lecture. Presented by Lawrence S.C. Czer, M.D. Consensus Conference on Antibody Mediated Rejection in Heart Transplantation. International Society for Heart and Lung Transplantation. April 20, 2010.
196. Heart transplant survival at age 70 and older similar to younger patients. Daneshvar D, Phan A, Czer L, De Robertis M, Mirocha J, Schwarz E, Kass RM, Simsir S, Trento A. Presented by Daniel Daneshvar, M.D. International Society for Heart and Lung Transplantation. April 21, 2010.
197. Use of ventricular assist device as a bridge to simultaneous heart and kidney transplantation. Yanagida R, Ruzza A, Vespignani R, Czer L, Schwarz E, Simsir S, Jordan S, Cohen JL, Trento A. Presented by Roh Yanagida, M.D. International Society for Heart and Lung Transplantation. April 21, 2010.

LECTURES AND PRESENTATIONS (cont.)

198. What is new in advanced heart failure, ventricular assist devices, and heart transplantation? A review of important findings at the American College of Cardiology and International Society for Heart and Lung Transplantation Scientific Sessions. Invited lecture. Presented by Lawrence S.C. Czer, M.D. Heart Institute and Cardiology Grand Rounds. May 4, 2010.
199. Post-Transplant Clinical Complications: Hypertension, Hyperlipidemia, Diabetes, Osteoporosis, Renal dysfunction. Invited lecture. Presented by Lawrence S.C. Czer, M.D. An Overview of Heart Transplantation. Cedars-Sinai Medical Center, Los Angeles, California. July 19, 2010.
200. Cardiac diagnosis and management of complications of amyloid. Invited lecture. Presented by Lawrence S.C. Czer, M.D. Multidisciplinary Amyloid Conference. Cedars-Sinai Medical Center, Los Angeles, California. August 19, 2010.
201. Class II – III patients failing medical therapy: are LVAD's indicated? Invited lecture. Presented by Lawrence S.C. Czer, M.D. Controversies and Advancement in the Treatment of Cardiovascular Disease: The Tenth in the Series. Beverly Hills, California. October 8, 2010.
202. Outpatient Management with an Implanted Device. Invited lecture. Presented by Lawrence S.C. Czer, M.D. Heart Transplantation and Advanced Heart Failure: An Expert Review of Diagnosis and Treatment Options. Los Angeles, California. October 15 – 16, 2010.
203. Heart Transplantation: Indications, Surgical Considerations, and Management. Presented by Lawrence S.C. Czer, M.D. Surgery Core Curriculum. Cedars-Sinai Medical Center, Los Angeles, California. February 8, 2011.
204. Utility of CD68/CD31 vs. CD163/CD31 dual immunostaining techniques to detect antibody mediated rejection in post transplant cardiac biopsies. Presented by Tatischev S, Czer L, Kobashigawa J, Luthringer D. 100th Annual Meeting, United States and Canadian Academy of Pathology. Feb 2011.
205. Prevention of Heart Failure: Is It Possible? Invited Lecture. Presented by Lawrence S.C. Czer, M.D. Optimal Care and New Therapies for Advanced Heart Disease. Bakersfield, California. May 21, 2011.
206. Promising New Therapies for Heart Failure. Invited Lecture. Presented by Lawrence S.C. Czer, M.D. Optimal Care and New Therapies for Advanced Heart Disease. Newport Beach, California. September 17, 2011.
207. New Therapies for Acute Decompensated Heart Failure, and Prevention of Heart Failure. Invited Lecture. Presented by Lawrence S.C. Czer, M.D. Optimal Care and New Therapies for Advanced Heart Disease. Las Vegas, Nevada. October 22, 2011.

LECTURES AND PRESENTATIONS (cont.)

208. Heart Transplant and Ventricular Assist Devices – Update. Invited Lecture. Presented by Lawrence S.C. Czer, M.D. Preventative and Consultative Heart Center of Excellence. Cedars-Sinai Medical Center. Los Angeles, California. March 7, 2012.
209. Technologic Advances in Heart Transplant. Invited Lecture. Presented by Lawrence S.C. Czer, M.D. OneLegacy Board of Directors, Advisory Board, and Foundation Board Retreat. Laguna Beach, California. March 17, 2012.
210. Late Response to Desensitization Therapy. Kobashigawa J, Patel J, Rafiei M, Stern L, Kittleson M, Czer L, Esmailian F. Presented by Lawrence S.C. Czer, M.D. International Society for Heart and Lung Transplantation. Prague, Czech Republic. April 18, 2012.
211. Consequences of First Year Rejection after Heart Transplantation: Is the Worse yet to Come? Czer L, Patel J, Kittleson M, Rafiei M, Stern L, Chang D, Luthringer D, Esmailian F, Kobashigawa J. Presented by Lawrence S.C. Czer, M.D. International Society for Heart and Lung Transplantation. Prague, Czech Republic. April 19, 2012.
212. Combined Heart-Kidney Transplant Compared to Heart Transplant Alone May Reduce Long Term Development of Cardiac Allograft Vasculopathy. Czer L, Patel J, Kittleson M, Rafiei M, Stern L, Chang D, Trento A, Kobashigawa J. Presented by Lawrence S.C. Czer, M.D. International Society for Heart and Lung Transplantation. Prague, Czech Republic. April 19, 2012.
213. Infectious Complications of Desensitization Therapy: Is the Cure Worse Than the Disease? Czer L, Patel J, Kittleson M, Rafiei M, Stern L, Esmailian F, Kobashigawa J. Presented by Lawrence S.C. Czer, M.D. International Society for Heart and Lung Transplantation. Prague, Czech Republic. April 20, 2012.
214. Distal Pruning as an Important Factor for Outcome in the New ISHLT Cardiac Allograft Vasculopathy Grading Scale. Czer L, Patel J, Kittleson M, Rafiei M, Stern L, Chang D, Azarbal B, Trento, Kobashigawa J. Presented by Lawrence S.C. Czer, M.D. International Society for Heart and Lung Transplantation. Prague, Czech Republic. April 21, 2012.
215. Promising New Therapies. Invited Lecture. Presented by Lawrence S.C. Czer, M.D. Optimal Care and New Therapies for Advanced Heart Disease. Ventura, California. May 12, 2012.
216. Promising New Therapies for Advanced Heart Failure. Invited Lecture. Presented by Lawrence S.C. Czer, M.D. Optimal Care and New Therapies for Advanced Heart Disease. Riverside, California. September 15, 2012.
217. Cardiac Stem Cells and Heart Failure. Invited Lecture. Presented by Lawrence S.C. Czer, M.D. Optimal Care and New Therapies for Advanced Heart Disease. Riverside, California. September 15, 2012.

LECTURES AND PRESENTATIONS (cont.)

218. LVAD, Magnet Operation and ICD Management Pre and Post Endoscopy. Invited Lecture. Presented by Lawrence S.C. Czer, M.D. 13th Annual Educational Meeting in Gastroenterology. Los Angeles, California. March 2, 2013.
219. Cardiac Stem Cells in Advanced Heart Disease. Invited Lecture. Presented by Lawrence S.C. Czer, M.D. Success with Failure: An Advanced Heart Disease Symposium. Los Angeles, California. March 7, 2013.
220. Are the Pathology Working Formulations the Gold Standard for Diagnosing AMR in Heart and Lung in 2013? Working Formulation for AMR – Heart. Invited Lecture. Presented by Lawrence S.C. Czer, M.D. International Society for Heart and Lung Transplantation. Montreal, Canada. April 25, 2013.
221. Renal Dysfunction Does Not Contraindicate Ventricular Assist Device as Destination Therapy or as Bridge to Single Heart or Combined Heart and Kidney Transplantation. Ruzza A, Esmailian F, Vespignani R, Yanagida R, Awad M, Mirocha J, Ramzy D, Moriguchi J, Trento A, Czer L. Presented by Lawrence S.C. Czer, M.D. International Society for Heart and Lung Transplantation. Montreal, Canada. April 25, 2013.
222. Promising New Therapies and Systems to Improve Care for Advanced Heart Failure. Invited Lecture. Presented by Lawrence S.C. Czer, M.D. Optimal Care and New Therapies for Advanced Heart Disease. Long Beach, California. May 11, 2013.
223. Stem Cell Therapy for Acute Myocardial Infarction. Invited Lecture. Presented by Lawrence S.C. Czer, M.D. 8th Annual Cardiac Symposium. San Antonio Community Hospital. Upland, California. May 18, 2013.
224. Medical Missions and Volunteer Work in Medicine. Invited Lecture. Keynote speaker. Presented by Lawrence S.C. Czer, M.D. Forty second Commencement Ceremony. University of California at Davis School of Medicine. Davis, California. June 1, 2013.
225. Advances in the Treatment of Heart Failure and Cardiac Transplantation. Invited Lecture. Presented by Lawrence S.C. Czer, M.D. Fountain Valley Regional Hospital and Medical Center. Fountain Valley, California. June 3, 2013.
226. History of Heart Transplantation at Cedars-Sinai Medical Center. Invited Lecture. Presented by Lawrence S.C. Czer, M.D. Twenty-fifth Anniversary of Heart and Lung Transplant Programs at Cedars-Sinai. Los Angeles, California. October 24, 2013.
227. Surgical Considerations in Mechanical Circulatory Support. Moderated by Lawrence S.C. Czer, M.D. Experts in MCS Therapy: Current State of the Art. Los Angeles, California. November 2, 2013.
228. Joint AHA/ACC Session: ACCF/AHA Guidelines for Management of Chronic Heart Failure: 2013 Update – Mechanical Support for the Failing Heart. Invited Lecture. American Heart Association Scientific Sessions. Dallas, Texas. November 17, 2013.

LECTURES AND PRESENTATIONS (cont.)

229. What is the Future of Biological Therapies for End-Stage Heart Disease? Xenotransplantation. Invited Lecture. Controversies & Advances in the Treatment of Cardiovascular Disease. Beverly Hills, California. November 22, 2013.
230. Mechanical Circulatory Support with Ventricular Assist Devices and the Total Artificial Heart. Lecture Series for Advanced Heart Failure and Transplant Cardiology fellows. Los Angeles, California. March 11, 2014.
231. Components of a Successful Mechanical Circulatory Support Program. Invited Lecture. Preceptorship for Bakersfield Heart Hospital. Los Angeles, California. May 30, 2014.
232. Short Term Mechanical Circulatory Support. Lectures Series for Advanced Heart Failure and Transplant Cardiology fellows. Los Angeles, California. July 8, 2014.
233. Heart-Kidney Transplantation. Invited Lecture. International Society for Heart and Lung Transplantation. 35th Annual Scientific Sessions. Nice, France. April 15, 2015.
234. Cardiac Stem Cells in Heart Failure. Invited Lecture. Success with Failure. Long Beach, California. May 29, 2015.
235. Short Term Mechanical Circulatory Support. Lectures Series for Advanced Heart Failure and Transplant Cardiology fellows. Los Angeles, California. September 22, 2015.
236. Heart-Kidney Transplantation. Invited Lecture. Heart Institute Grand Rounds. Los Angeles, California. September 29, 2015.
237. Review of the ROADMAP trial. Invited Lecture. Heart Failure Summit – Partnering in HeartMate II Patient Care. Los Angeles, California. March 5, 2016.
238. Does ACE Inhibitor Use in Heart Transplantation Decrease the Development of Cardiac Allograft Vasculopathy? International Society for Heart and Lung Transplantation. 36th Annual Scientific Sessions. Washington, DC. Apr 27, 2016.
239. Treatment of Sleep Apnea with Heart Transplantation: Does it Help? International Society for Heart and Lung Transplantation. 36th Annual Scientific Sessions. Washington, DC. April 28, 2016.
240. Combined Heart and Kidney Transplant: A 23 Year Experience. International Society for Heart and Lung Transplantation. 36th Annual Scientific Sessions. Washington, DC. April 29, 2016.
241. Heart and Kidney Transplants in Patients with Mechanical Circulatory Support: Who Needs a Kidney? American Transplant Congress 2016. Boston, MA. June 12, 2016.

LECTURES AND PRESENTATIONS (cont.)

242. Patient management of the HeartWare left ventricular assist device. HeartWare Training Program. Los Angeles, California. July 15, 2016.
243. Short term mechanical circulatory support. Lectures Series for Advanced Heart Failure and Transplant Cardiology fellows. Los Angeles, California. July 26, 2016.
244. Stem Cell Therapy for Heart Failure. Optimal Care and New Therapies for Advanced Heart Disease. Costa Mesa, California. Oct 29, 2016.
245. Advanced Cardiac Treatment: Heart Transplantation & Artificial Devices. Medical Grand Rounds, Los Robles Hospital and Medical Center. Thousand Oaks, California. Mar 17, 2017.
246. The outcome of heart transplant patients with hemodynamic compromise rejection in the current era. International Society for Heart and Lung Transplantation. 37th Annual Scientific Sessions. San Diego, CA. April 6, 2017.

OTHER PROFESSIONAL ACTIVITIES

MEDICAL NEWS RELEASES, MEDICAL CITATIONS, AND MEDIA APPEARANCES

The St. Jude valve: a five-year review
Cardio (April 1984), pp 23-24.

Durability and few complications seen with St. Jude bileaflet valve.
Cardiology Times (July 1984), p 16.

Patients with new postoperative fascicular conduction disturbances may be at high risk.
Cardiology Times (July 1984), pp 1 & 5.

Fibrinolytic clears thrombi in valve replacement.
Internal Medicine News and Cardiology New (January 1-14, 1985), p 48.

Blood product needs cut after heart surgery.
The Medical Post (Canada; December 24, 1985), p 20.

DDAVP lessens blood product utilization after open heart surgery.
CBS Evening News, 5:25 pm, February 17, 1986.

New agents provoke discussion. Bleeding disorders.
Convention Reporter. A report on the 58th annual scientific sessions of the American Heart Association. (January 1986; vol. 16), p 9.

Bleeding after cardiopulmonary bypass. Laurence A. Harker, M.D.
New England Journal of Medicine 1986; 314:1446-48.

Intraoperative Doppler color flow mapping.
Lifetime Medical Television. Recorded May 3, 1987.

Noninvasive evaluation of the St. Jude Medical heart valve.
Cardiologist's Report, Report No. 1, page 2, 1987; St. Jude Medical, Inc.

Use of desmopressin acetate to reduce blood loss after open-heart surgery.
Clinical Cardiology Alert, July 1987, vol 6, pp 27-28.

Aortic valve replacement plus bypass.
Medical Portfolio for Thoracic and Cardiovascular Surgeons. Vol 6, No. 1, April 1988.

Adding bypass to valve replacement.
Medical Outlook for Cardiologists. Vol 5, No 2, July 1988.

MEDICAL NEWS RELEASES, MEDICAL CITATIONS, AND MEDIA APPEARANCES (cont.)

Lowering cholesterol after bypass surgery. Twelve year follow-up of European Cooperative Study. NBC Evening New, 4:25 p.m., August 10, 1988.

Comparative clinical experience with porcine bioprosthetic and St. Jude valve replacement. Year Book of Cardiology, 1988 (Schlant RC, Collins JJ, Engle MA, Frye RL, Kaplan NM, O'Rourke RA, Editors), pages 252-256.

Use of DDAVP to reduce blood loss after cardiac surgery.
Year Book of Critical Care Medicine, 1988 (Mark C. Rogers, M.D., ed).

Desmopressin for bleeding after open-heart surgery.
Year Book of Anesthesia, 1988 (Ronald D. Miller, M.D., editor), pp 246-247.

Reduction in sudden death by AVR and CABG.
Year Book of Cardiology, 1989; (John J. Collins, M.D., editor), Chapter 5, pp 249-250.

Mitral valve replacement: impact of coronary artery disease.
Annotated bibliography for the cardiology section of the MKSAP (Medical Knowledge Self-Assessment Program), 1988; reference 49.

Intraoperative echocardiography and Doppler color flow mapping.
Cardiothoracic Surgery, Contempo '90. JAMA, 1990; 263:2628-2629.

Heart Transplantation: Bobby Clark 6 months after surgery.
NBC evening news, 4:45 p.m., December 23, 1990.

Mechanical, porcine valves judged similar at 10 years.
Cardio, October 1991; pp 21-23.

Clinical controversies in aortic stenosis.
Modern Concepts of Cardiovascular Disease. 1991. Blase Carabello, M.D.

Advanced noninvasive analysis of the St. Jude medical valve.
Cardiologist's Report, Report No. 3, 1991.

Press conference on heart-liver transplant recipient (Christine Galan).
Cedars-Sinai Medical Center, October 29, 1998.
Television channels: 2, 4, 5, 7, 9, 11, 34, 52. Radio: KFWB, KNX 1070.
Newspapers: Los Angeles Times, Daily Breeze, San Diego Union-Tribune.

Follow-up press conference on heart-liver transplant recipient (Christine Galan).
Cedars-Sinai Medical Center, November 9, 1998.
Television channels: 2, 4, 5, 7, 9, 11, 34, 52. Radio: KFWB, KNX 1070.
Newspapers: Los Angeles Times, Daily Breeze, San Diego Union-Tribune.

MEDICAL NEWS RELEASES, MEDICAL CITATIONS, AND MEDIA APPEARANCES (cont.)

SCOPPC conference - Christine Galan. Cedars-Sinai Medical Center, April 19, 1999.
Television channels: 2, 4, 7. Radio: KFWB, KNX 1070.

Double heart-liver recipient, Christine Galan. Frontiers of Medicine (PBS Television Series).
Airing nationwide May 12 and later, throughout year 1999.

Nerve sprouting and ventricular arrhythmias. Science News 2000; 157:332 (May 20).

Sonosite goes to The Gambia. Sonosite Moments; running through 2001 and 2002 on the
Sonosite website at www.sonosite.com

News conference on patient with portable Thoratec biventricular assist device – Charles Jones.
Cedars-Sinai Medical Center, August 1, 2001.
Television channels: 2, 4, 7, 9, and CNN. Radio: KFWB, KNX.

News report on Vincent Rankin, heart transplant recipient with compelling personal interest story.
Cedars-Sinai Medical Center, April 8, 2003. Television channels KCAL-9 and KCBS-2.

His-N-Hers heart transplants: An Orange county husband and wife each have heart transplants six
years apart and performed by the same transplant surgeon and cardiologist. News release
November 19, 2003.

Cardiologist and husband/wife heart transplant recipients featured on KFWB radio. December 8,
2003. Radio: KFWB News.

4 Hearts, 1 Loving Marriage. Article about Mark and Sandra Landau, a husband and wife, both of
whom had heart transplants. Front page, Column One article by Jeff Gottlieb, Los Angeles Times,
December 1, 2004.

If they only knew about that heart... Article about Edna Sigmon, who received a heart transplant
on Valentine's Day, by Dennis McCarthy, L.A. Daily News, Sunday edition, February 13, 2005.

Kelli Jaunsen awaiting heart and liver transplant. WCIA 3 News and Morning Show ("Medical
Center") covering Champaign, Urbana, Decatur, Danville, and Springfield, Illinois, January 17,
2007.

Double transplant news alert on Kelli Jaunsen by Dawndy Mercer, WIS-TV News 10, Columbia,
South Carolina, January 25, 2007.

Successful double heart liver transplant. KESQ News channel 3, Palm Springs, California, March
18, 2007.

Medical Mission to Sierra Leone. Heart Beat (Division of Cardiology Newsletter), April 15, 2007.

MEDICAL NEWS RELEASES, MEDICAL CITATIONS, AND MEDIA APPEARANCES (cont.)

17 Years Of Perspective: Attorney Gerald Edelstein Understands The Value Of Organ Donation. Medical News Today, May 7, 2007.

Transplanted heart transplanted again. Reuters, CNN and CNN.com, FOX News, MSNBC, USAToday.com, KABC-TV and KABC-AM 790, May 11-14, 2007.

A transplanted heart used for a second recipient at Cedars-Sinai Medical Center. Wall Street Journal, front page, May 12, 2007.

Donated heart used in three different bodies. Live interview by Australian Broadcasting Corporation in Canberra, Australia, May 14, 2007.

Patient given a third-hand heart. Daily Mail, United Kingdom, May 14, 2007.

Transplanted heart re-transplanted. ShortNews.com, Germany. May 14, 2007.

Twice transplanted heart – Michael Iwuchukwu. KNBC-TV Channel 4 News story and interview by Bruce Hensel MD, aired in Los Angeles May 14, 2007, and distributed to NBC affiliates in 10 other major markets.

Heart 2 Heart. (The Story of Mark and Sandra Landau). Reader's Digest, pages 145 – 151, July 2007.

Rare use of drug derived from leech saliva lets heart transplant – and wedding – proceed. Medical News Today, August 23, 2007.

Waiting for a Miracle. (The Story of Kelli Jaunsen). Reader's Digest, pages 126 – 132, November 2007.

Recipient of two donor organs grateful for a chance at life. The Desert Sun, November 15, 2007.

Patient with AIDS finds heart-assist device is an option when transplant is not. Newswise Medical News, December 27, 2007.

Palm Desert transplant survivor makes journey of recovery. Press-Enterprise, May 12, 2008. First heart transplant patient at Cedars-Sinai returns for 20th anniversary. Los Angeles Times, December 10, 2008.

First heart transplant patient returns for 20th anniversary at Cedars-Sinai Medical Center. KABC-TV Channel 7 News and KTTV-TV Channel 11 News stories, aired in Los Angeles on December 10, 2008, and distributed to KABC and KTTV affiliates in other major markets.

Doctor practices what his faith preaches: Cedars-Sinai cardiologist Dr. Lawrence Czer makes regular trips to Africa with his Christian church to help the needy by providing free medical care. Los Angeles Times, September 21, 2009.

MEDICAL NEWS RELEASES, MEDICAL CITATIONS, AND MEDIA APPEARANCES (cont.)

Deserving of an ovation: Re “Doctor practices what his faith preaches.” Letter to the Editor, Los Angeles Times, September 29, 2009.

Two minutes with Lawrence Czer, M.D. Medical Staff Pulse, Cedars-Sinai Medical Center, Los Angeles, November 24, 2009.

Sudden Cardiac Death (Story about Desiree Morrell and her family). WDEF Channel 12 and CBS News affiliates throughout the US. May 21, 2010.

Young Goleta Man Awaiting Heart Transplant Makes ‘Miracle’ Recovery (Frontpage story about Bryson Williams). Online Newspaper in Santa Barbara (www.noozhawk.com), published June 3, 2010.

Mother and Son Receive Heart Transplants. KNBC News 4 story. KNBC Channel 4 and NBC affiliates throughout the US. Sept 2, 2010.

Awaiting Heart Transplant, Goleta Man Increasingly Optimistic about Future. Online Newspaper in Santa Barbara (www.noozhawk.com), published October 10, 2010.

Ava Kaufman – Making a Difference. Story of Ava Kaufman, Brenda Brown, and Earl Hines. NBC Nightly News and Affiliates throughout the US. February 21, 2011.

Cedars-Sinai Heart Institute Ranked First Nationally in 2010 Adult Heart Transplants. News Release. Los Angeles. March 9, 2011.

Heart attacks and Daylight Savings Time. Interview on Fox 11 News. Los Angeles. March 11, 2012.

New Therapies for Heart Disease. Interview on Fox 11 News. Los Angeles. May 12, 2012.

Hands-only CPR. Interview on KNBC News. Los Angeles. June 8, 2012.

ATTENDANCE AT SCIENTIFIC MEETINGS AND NIH GRANT STEERING COMMITTEES

- 1981 American College of Cardiology. San Francisco, California. March 14-19.
- 1982 International Symposium on the Mitral Valve. San Diego, California. October 23-24.
- 1983 American College of Chest Physicians. Chicago, Illinois. October 23-27.
- American Heart Association. Anaheim, California. November 14-17.
- 1984 The High Risk Patient. (Cedars-Sinai Medical Center). Los Angeles, California. January 12-14.
- American Federation of Clinical Research. Carmel, California. February 7-10.
- American College of Cardiology. Dallas, Texas. March 25-29.
- American College of Chest Physicians. Dallas, Texas. October 8-12.
- Cardiology Update. (Cedars-Sinai Medical Center). Los Angeles, California. November 9-10.
- 1985 American College of Cardiology. Anaheim, California. March 10-14.
- Third Curriculum on Color Flow Mapping and Cardiac Doppler. Anaheim, California. March 7-9.
- Coronary Angioplasty and Application of Digital Angiography. Orange, California. October 24-25.
- American College of Chest Physicians. New Orleans, Louisiana. October 28 - November 1.
- American Heart Association. Washington, D.C. November 11-14.
- 1986 Cardiology Update. (Cedars-Sinai Medical Center). Los Angeles, California. February 13-15.
- American College of Cardiology. Atlanta, Georgia. March 9-13.
- American Heart Association. Dallas, Texas. November 17-20.
- 1987 American Federation for Clinical Research. San Diego, California. May 1-4.
- Western Thoracic Surgical Association. Colorado Springs, Colorado. June 24-28.
- NIH Grant Steering Committee. Bethesda, Maryland. August 17-18.

ATTENDANCE AT SCIENTIFIC MTGS AND NIH GRANT STEERING COMMITTEES (cont'd)

- NIH Grant Steering Committee. Bethesda, Maryland. September 30 - October 1.
- American Heart Association. San Diego, California. October 8-9.
- American Heart Association. Anaheim, California. November 16-19.
- NIH Grant Steering Committee. Anaheim, California. November 19-20.
- 1988 First International Symposium on Echocardiography and Doppler in Cardiac Surgery. Vienna, Austria. April 25-27.
- Western Thoracic Surgical Association. Waikolao, Hawaii. June 22-26.
- American College of Chest Physicians. New Orleans, Louisiana. October 28 - November 1.
- 1989 American College of Cardiology. Anaheim, California. March 19-23.
- Second International Symposium on Echocardiography and Doppler in Cardiac Surgery. Salzburg, Austria. May 1-3.
- Western Thoracic Surgical Association. Monterey, California. June 21-25.
- 1990 American College of Cardiology. New Orleans, Louisiana. March 18-22.
- Third International Symposium on Echocardiography and Doppler in Cardiac Surgery. Vienna, Austria. May 9-12.
- 1991 St. Jude Medical Asia-Pacific Symposium. Napa, California. February 14-17.
- American College of Cardiology. Atlanta, Georgia. March 3-7.
- Fourth International Symposium on Echocardiography and Doppler in Cardiac Surgery. Innsbruck, Austria. May 26-30.
- Symposium on Transplant Atherosclerosis. St. Louis, Missouri. October 24-27.
- American Heart Association. Anaheim, California. November 10-14.
- Second International Symposium on Circulatory Support. San Francisco, California. November 16-17.
- 1992 International Society for Heart and Lung Transplantation. 12th Annual Scientific Sessions. San Diego, California. April 1-4.

ATTENDANCE AT SCIENTIFIC MTGS AND NIH GRANT STEERING COMMITTEES (cont'd)

- Symposium on Fungal Infections in the Immunocompromised Host.
Los Angeles, California. September 5.
- 1993 American College of Cardiology. Anaheim, California. March 14-18.
- Second International Symposium on Heart Failure. Geneva, Switzerland. May 16-20.
- American Heart Association. Atlanta, Georgia. November 8-11.
- 1994 Western Association of Transplant Surgeons. Lahaina, Maui, Hawaii. March 14-15.
- Thermo Cardiosystems, Inc. Heartmate Left Ventricular Assist Device Training Program.
Texas Heart Institute. Houston, Texas. September 29-30.
- Cardiology Update, Cardiac Alliance. Carlsbad, California. October 7-9.
- 1995 Use of 2-D Echocardiography and Echo Doppler in the Peri-operative Period.
Marina del Rey, California. March 2-4.
- International Society for Heart and Lung Transplantation. 15th Annual Scientific Sessions.
San Francisco, California. April 5-8.
- American Heart Association. Anaheim, California. November 13-16.
- 1997 American College of Cardiology. Anaheim, California. March 14-18.
- 1998 First International Symposium on Intensive Cardiac Care. Jerusalem, Israel.
June 29 - July 2.
- UNOS Region 5 Scientific Meeting. Presentation of center-specific data, and discussion
of UNOS regulations. Los Angeles, CA. September 25.
- 1999 UNOS Region 5 Scientific Meeting. Presentation of center-specific data, and discussion
of proposed changes in organ allocation guidelines. Los Angeles, California. March 18.
- Transplantation in the 21st Century: A Symposium for Case Managers. Woodland Hills,
California. October 21.
- 2000 American College of Cardiology. Anaheim, California. March 12-15.
- UNOS Region 5 Scientific Meeting. Presentation of center-specific data, and discussion
of changes in UNOS organ allocation guidelines and proposed changes in UNOS Regions.
Los Angeles, California. March 17.
- State-of-the-Art Management of Heart Failure. Los Angeles, California. May 20.

ATTENDANCE AT SCIENTIFIC MTGS AND NIH GRANT STEERING COMMITTEES (cont'd)

- International Forum on Ischemic Mitral Regurgitation. Monterey, California.
October 13-14.
- 2001 International Society for Heart and Lung Transplantation. 21st Annual Scientific Sessions.
Vancouver, British Columbia. April 25-28.
- State-of-the-Art Management of Congestive Heart Failure. Newport Beach, California.
May 19.
- Heart of the Physician Conference. Colorado Springs, Colorado. November 7-11.
- American Heart Association. Anaheim, California. November 13-14.
- 2002 UNOS Region 5 Scientific Meeting. Las Vegas, Nevada. April 22.
- Third International Meeting on Intensive Cardiac Care. Tel-Aviv, Israel. June 24-27.
- 2003 International Society for Heart and Lung Transplantation. 23rd Annual Scientific Sessions.
Vienna, Austria. April 9-12.
- American Heart Association Second Asia Pacific Scientific Forum. Honolulu, Hawaii.
June 8-10.
- Third World Congress on Heart Disease. Washington, D.C. July 12-15.
- Controversies in Adult Cardiac Surgery – The Third in the Series. Santa Monica,
California. October 2-3.
- Thirteenth World Congress of the International Society of Cardio-Thoracic Surgeons. San
Diego, California. November 4.
- Heart of the Physician Conference. Colorado Springs, Colorado. November 12-16.
- 2004 Southern California Chapter of the American College of Surgeons. Santa Barbara,
California. January 16.
- UNOS Region 5 Scientific Meeting and Thoracic Organ Subcommittee Meeting. Las
Vegas, Nevada. April 30.
- American Heart Association Scientific Sessions. New Orleans, Louisiana. November 8-
10.
- 2005 Controversies in the Treatment of Cardiovascular Disease - The Fifth in the Series. Santa
Monica, California. October 7.
- American Heart Association Scientific Sessions. Dallas, Texas. November 12-16.

ATTENDANCE AT SCIENTIFIC MTGS AND NIH GRANT STEERING COMMITTEES (cont'd)

- 2006 American College of Cardiology Scientific Sessions, Atlanta, Georgia. March 11 - 14.
- International Society for Heart and Lung Transplantation, 26th Annual Meeting and Scientific Sessions. Madrid, Spain. April 5 - 8.
- Controversies and Advances in the Treatment of Cardiovascular Disease - The Sixth in the Series. Beverly Hills Hotel, Beverly Hills, California. October 5 - 6.
- Pain Management and End of Life Care Course. Cedars-Sinai Medical Center. Completed in December.
- 2007 International Society for Heart and Lung Transplantation, 27th Annual Meeting and Scientific Sessions. San Francisco, California. April 25 - 28.
- World Congress on Heart Disease. Vancouver, British Columbia, Canada. July 28 - 31.
- Controversies and Advances in the Treatment of Cardiovascular Disease - The Seventh in the Series. October 4 - 5.
- 2008 Treatment of Pre-Transplant Sensitized Patients. Consensus Conference, International Society for Heart and Lung Transplantation, Annual Meeting and Scientific Sessions. Boston, Massachusetts. April 8.
- UNOS (United Network for Organ Sharing) Membership and Professional Standards Committee (MPSC) Peer Review of heart transplant program in San Antonio, Texas. April 15-17.
- Controversies in the Treatment of Cardiovascular Disease - The Eighth in a Series. Beverly Hills, California. September 3-5.
- 2009 Controversies in the Treatment of Cardiovascular Disease - The Ninth in a Series. Beverly Hills, California. October 1-2.
- Cardiac Stem Cell Differentiation and Biopsy-derived Cardiac Regenerative Cells: clinical implications of basic research. Rome, Italy. October 14-16.
- 2010 American College of Cardiology Scientific Sessions, Atlanta, Georgia. March 14 - 16.
- Consensus Conference: Antibody Mediated Rejection in Heart Transplantation. Chicago, Illinois. April 20.
- International Society for Heart and Lung Transplantation, 30th Annual Meeting and Scientific Sessions. Chicago, Illinois. April 21 - 24.
- Heart Failure Society of America Board Review Course. Minneapolis, Minnesota. October 1 - 3.

ATTENDANCE AT SCIENTIFIC MTGS AND NIH GRANT STEERING COMMITTEES (cont'd)

Controversies and Advances in the Treatment of Cardiovascular Disease - The Tenth in the Series. Beverly Hills, California. October 7 - 8.

Heart Transplantation and Advanced Heart Failure: An Expert Review of Diagnosis and Treatment Options. Los Angeles, California. October 15 - 16.

American Board of Internal Medicine Examination in Advanced Heart Failure and Transplant Cardiology. Westlake, California. November 8.

2011 Society of Thoracic Surgeons Annual Scientific Meeting. San Diego, California. February 1.

INTERMACS (Interagency Registry for Mechanically Assisted Circulatory Support) Fifth Annual Meeting. San Diego, California. April 12.

International Society for Heart and Lung Transplantation. 31st Annual Scientific Sessions. San Diego, California. April 13 - 16.

Optimal Care and New Therapies for Advanced Heart Disease. Bakersfield, California, May 21; Newport Beach, California, September 17; and Las Vegas, Nevada, October 22.

Controversies and Advances in the Treatment of Cardiovascular Disease. The Eleventh in the Series. Beverly Hills, California. October 13-14.

2012 OneLegacy Board of Directors, Advisory Board, and Foundation Board Retreat. Laguna Beach, California. March 16-17, 2012.

International Society for Heart and Lung Transplantation. 32nd Annual Scientific Sessions. Prague, Czech Republic. April 18 - 21.

Optimal Care and New Therapies for Advanced Heart Disease. Ventura, California, May 12; Riverside, California, September 15.

Controversies and Advances in the Treatment of Cardiovascular Disease. The Twelfth in the Series. Beverly Hills, California. September 21-22.

2013 Success with Failure: An Advanced Heart Disease Symposium. Los Angeles, California. March 7.

International Society for Heart and Lung Transplantation. 33rd Annual Scientific Sessions. Montreal, Canada. April 24 - 27.

Optimal Care and New Therapies for Advanced Heart Disease. Long Beach, California. May 11.

ATTENDANCE AT SCIENTIFIC MTGS AND NIH GRANT STEERING COMMITTEES (cont'd)

- Experts in MCS Therapy: Current State of the Art. Los Angeles, California. November 2.
- American Heart Association Scientific Sessions. Dallas, Texas. November 16-20.
- Controversies & Advances in the Treatment of Cardiovascular Disease. The thirteenth in the series. Beverly Hills, California. November 21-22.
- 2014 International Society for Heart and Lung Transplantation. 34th Annual Scientific Sessions. San Diego, California. April 10 - 13.
- Controversies and Advances in the Treatment of Cardiovascular Disease. The fourteenth in the series. Beverly Hills, California. November 20-21.
- 2015 American College of Cardiology Scientific Sessions. San Diego, California. March 13-16.
- International Society for Heart and Lung Transplantation. 35th Annual Scientific Sessions. Nice, France. April 15 - 18.
- Consensus Conference on Donor Selection and Management. Philadelphia, Pennsylvania. May 1.
- American Transplant Congress. Philadelphia, Pennsylvania. May 2-6.
- Success with Failure. Long Beach, California. May 29.
- OneLegacy Board of Directors and Advisory Board Retreat. Laguna Niguel, California. October 2-3.
- A Global User's Guide to Mechanical Circulatory Support. Los Angeles, California. October 9-10.
- American Heart Association Scientific Sessions. Orlando, Florida. November 7-11.
- 2016 American Society of Transplantation – Cutting Edge of Transplantation: Resolving the Organ Shortage. Phoenix, Arizona. February 25-27.
- Heart Failure Summit – Partnering in HeartMate II Patient Care. Los Angeles, California. March 4-5.
- Overview of PA Pressure Guided Heart Failure Management. Santa Monica, California. April 23.

Consensus Conference on the Management of Antibodies in Heart Transplantation. Washington, DC. April 25.

Core Competencies in Mechanical Circulatory Support. Washington, DC. April 26.

International Society for Heart and Lung Transplantation 36th Annual Scientific Sessions. Washington, DC. April 26-30.

HeartWare Training Program. Los Angeles, California. July 15.

Impact of HLA and non-HLA antibodies in Solid Organ Transplant. Los Angeles, California. September 9.

Optimal Care and New Therapies for Advanced Heart Disease. Costa Mesa, California. October 29.

Controversies & Advances in the Treatment of Cardiovascular Disease. Beverly Hills, California. November 17-18.

2017 American Society of Transplantation - Cutting Edge of Transplantation: One Transplant for Life – Many Pathways to Success. Phoenix, Arizona. February 23-25.

Core Competencies in Mechanical Circulatory Support. San Diego, CA. April 4.

International Society for Heart and Lung Transplantation 37th Annual Scientific Sessions. Los Angeles, CA. April 5-8.

MEDICAL MISSIONS

- 1998 Serekunda, Banjul, The Gambia, West Africa. Medical clinic provided care to >1000 patients; taught CPR; gave Grand Rounds lectures. March 25 - April 5.
- 2000 Latrikunda and Chinchu Alaji, Banjul, The Gambia, West Africa. Medical clinic provided care to >2500 patients; taught CPR to schools and health college; gave Grand Rounds lectures (topics: Valvular Heart Disease, Echocardiography) at Royal Victoria Hospital. March 24 - April 2.
- 2001 Fajikunda, Banjul, The Gambia, West Africa. Medical clinic provided care to >2000 patients; gave Grand Rounds lecture at Royal Victoria Hospital. March 23 - April 1.
- 2002 Freetown, Sierra Leone, West Africa. Medical clinic provided care to >2500 patients. Visited amputee camp and Connaught Hospital. March 29 - April 5.
- 2003 Freetown, Ferry Junction, Sierra Leone, West Africa. Medical clinic provided care to >2500 patients. March 20-29.
- 2004 Freetown, Ferry Junction, and Kenema, Sierra Leone, West Africa. Medical clinic provided care to > 2500 patients. March 25 - April 3.
- 2005 Freetown, Ferry Junction, and Kenema, Sierra Leone, West Africa. Medical clinic provided care to > 3000 patients. March 27 - April 2.
- 2006 Kenema, Bonthe, and Lunsar, Sierra Leone, West Africa. Medical clinic provided care to > 3000 patients. March 23 - April 1.
- Banjul, The Gambia, West Africa. Medical clinic with 3 MD's and 1 NP provided care to >1400 patients. November 24 - December 2, 2006.
- 2007 Freetown, Kenema, Bo, and Lunsar, Sierra Leone, West Africa. Medical clinic provided care to > 3500 patients. March 23 - April 1.
- 2008 Lunsar and Jui, Sierra Leone, West Africa. Medical clinic provided care to > 3000 patients. March 20-30.
- Bujumbura, Burundi, East Africa. Medical clinic provided care to > 2000 patients. October 10-21.
- 2009 Mekeni and Kenema, Sierra Leone, West Africa. Medical clinic provided care to > 2500 patients. April 2-11.
- Libreville, Gabon. Medical care provided to President. May 1-4, 2009.
- 2010 Bo, Port Loco, and Lunsar, Sierra Leone, West Africa. Medical clinic provided care to >3000 patients. April 1-10.

MEDICAL MISSIONS (cont'd)

- 2011 Ouagadougou, Burkina Faso; Cotonou, Benin; and Freetown, Sierra Leone, West Africa. Medical Clinic provided care to >3500 patients. April 1-10.
- 2012 Tanji and Fajikunda, The Gambia, West Africa. Medical Clinic provided care to >1500 patients. March 28 – April 8.
- 2013 Tanji, The Gambia, and Bissau, Guinea-Bissau, West Africa. Medical Clinic provided care to >2000 patients. March 21 - 30.
- 2014 Tanji, The Gambia, and Bissau, Guinea-Bissau, West Africa. Medical Clinic provided care to >1500 patients. March 27 – April 7 (at beginning of Ebola outbreak).
- 2015 Mwanza, Tanzania, East Africa. Medical clinic provided care to >1250 patients. March 25 – April 5.
- 2016 Mwanza, Tanzania, East Africa. Medical clinic provided care to >1000 patients. March 25 – April 4.
- 2017